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GeneRAl intRoduCtion
epidemiology
Neuroendocrine tumors (NETs) are relatively rare tumors with an incidence of approxi-
mately 5 cases per 100,000 population per year (1-3). The incidence of NETs has been 
increasing over the decades. This might be related to an aging population, since these 
tumors tend to present at a relatively higher age. Also, increased awareness of physi-
cians for NETs and more sophisticated diagnostic imaging techniques for the detection 
of these tumors might have further contributed to this increase (1,4,5). Still, up to 70% 
of all NET patients present with metastases at diagnosis (4,6). These patients are usually 
treated in specialized centers, like European Neuroendocrine Tumor Society (ENETS) 
Centers of Excellence (CoE) (6,7). 
tumor origin
NETs originate from the diffuse neuroendocrine (NE) cell system (8). Although in many 
organs the physiological function of NE cells is yet unclear, in the gastrointestinal (GI) 
tract these cells are known to exert a regulatory function (8). 
NETs can arise throughout the whole body (1). About 70% of all NETs will develop in 
the gastroenteropancreatic (GEP) system and are named GEP NETs (1,3,9,10). In some 
patients with metastatic NETs, the primary tumor site is unknown. However, these occult 
primary tumors are relatively uncommon and account for 13% of all NETs (1).
tumor characteristics
GEP NETs originating from the various parts of the GI tract or the pancreas can manifest 
as different phenotypes and, therefore, can be considered as separate tumor entities 
(11,12). This is reflected by differences in tumor growth rates, metastatic patterns and 
secretory capacities (13). There is growing evidence that these heterogeneously pre-
senting endocrine tumor types differ in their clinical behavior as well (14-16).
Depending on their primary localization, GEP and lung NETs can be subdivided ac-
cording to their embryologic origin into: foregut, midgut, or hindgut NETs, as shown 
in Figure 1 (2,3). Foregut NETs originate from the: bronchus, stomach, duodenum, and 
pancreas. NETs from the midgut are localized in the lower jejunum, ileum, appendix and 
ascending colon. Hindgut NETs are derived from the transverse and descending colon 
and rectum (2,3). 
nomenclature 
GEP NETs are characterized by overproduction of metabolically active substances (hor-
mones and amines) causing clinical syndromes. Pancreatic NETs (panNETs) are generally 
named after the hormone which is secreted in excess and which causes the clinical 
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signs and symptoms. For example, a ‘PTHrP-oma’ is a NET which secretes parathyroid 
hormone-related peptide (PTHrP) in excess (17). 
In the past decades, NETs arising from the small intestine were called ‘carcinoids’. More 
than a century ago, the German pathologist Siegfried Oberndorfer named these tumors 
‘karzinoide’, or cancer-like, since these NETs generally have a more indolent growing 
pattern as compared to the more common GI adenocarcinomas (1,18). 
Figure 1 Origin and secretory capacity of primary neuroendocrine tumors
Neuroendocrine cells are found in several organs derived from the embryologic primitive gut. Foregut 
structures include: bronchus, stomach, fi rst part of the duodenum and pancreas. Midgut organs include 
the second portion of the duodenum and the right hemicolon. Hindgut derivatives stretch from transverse 
colon to rectum. Adapted from: https//www.netterimages.com.
Paraneoplastic clinical syndromes
Patients with midgut NETs may also suff er from the carcinoid syndrome (CS), especially 
when liver metastases are present. This is the most common and well known paraneo-
plastic clinical syndrome and includes symptoms of fl ushing, dyspnoea, abdominal pain 
as well as, diarrhea caused by tumoral production of hormones and peptides. Among 
these peptides, serotonin (5-HT) hypersecretion plays an important role (19,20) (Figure 
2). Approximately 50% of patients with CS also suff ers from shortness of breath on exer-
tion, peripheral edema, and fatigue as a result of right-sided heart failure caused by 
carcinoid heart disease (CHD) (19,21-24). 
Patients with CHD have characteristic endocardial fi brotic plaques on both mural and 
valvular endocardium with a localization mainly on the right side of the heart (25,26). 
Most aff ected is the tricuspid valve followed by the pulmonary valve (27). CHD heart 
valves are microscopically characterized by a proliferation of (myo)fi broblasts with 
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matrix-rich fi brous stroma, neovascularization and infl ammation (28,29). These changes 
can result into thickening and stiff ening and, consequently tricuspid valve regurgitation 
and, pulmonary valve stenosis (19,22,24,30). The exact underlying pathophysiological 
mechanism resulting into CHD is largely unknown. 
Figure 2 Carcinoid syndrome and symptoms
When neuroendocrine tumors metastasize to the liver, the biologically active 5-HT can pass directly and 
undegraded into the systemic circulation. The biological activity results in various symptoms in several or-
gan systems. Most common symptoms include fl ushing, dyspnoea, abdominal pain and diarrhea. Carcinoid 
heart disease can also develop. Adapted from: https//www.netterimages.com.
About 60-90% of all panNETs and 20% of the small intestinal NETs (siNETs) are non-
functioning, or non-syndromic (31-33). Non-functioning NETs are not associated with 
clinical syndromes and generally present late with locally advanced disease leading to 
tumor site-specifi c symptoms, or with distant metastases mainly to the lymph nodes, 
liver, or bone (13). 
PAthoPhySioloGy
Receptor expression
NETs can express a variety of receptor (sub)types on their cell surfaces. Two specifi c 
receptor types, namely somatostatin receptors (sst) and dopamine (DA) receptors, are 
abundantly expressed in normal, non-pathologic, human NE cells as well as in NETs (34). 
Sst are important therapeutic targets for the inhibition of hormonal secretion and cell 
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proliferation in GEP NETs. Sst and DA receptors share some structural and functional 
characteristics (35-37).
Somatostatin receptors (sst)
Somatostatin (SS) is a small peptide hormone that exerts a variety of inhibitory func-
tions on GI motility, exocrine secretion, hormone secretion, neurotransmission, immu-
nomodulation and cell proliferation in normal tissues and tumors (38,39). 
Two biologically active forms of SS exist: somatostatin-14 (SS-14), consisting of 14 
amino acids, and somatostatin-28 (SS-28), consisting of 28 amino acids (39-41). 
There are five different G protein-coupled somatostatin receptor subtypes, 
named sst1-5 (39). Sst2 exists in two alternative splicing forms, sst2a and sst2b (42-44). All 
sst subtypes can be expressed in variable amounts in NETs (45-55). Sst2 is predominantly 
expressed in about 90% of all siNETs and 80% of all panNETs, followed by sst1 and sst5, 
while sst3 is less often expressed and sst4 is almost absent (55-58). Undifferentiated grade 
3 GEP NETs and NECs express sst2 less frequently and in lower density as compared to 
well-differentiated grade 1-2 GEP NETs (59). 
After binding, SS can activate its receptors and activate guanine nucleotide-binding 
(G) proteins in downstream pathways resulting in the activation of potassium channels 
and inhibition of calcium channels and adenylate cyclase activity. Ultimately, this leads 
to inhibition of hormonal secretion and potentially also to control of cell proliferation 
(60-64). Sst signaling is presented in Figure 3.
All five sst subtypes bind somatostatin-14 and somatostatin-28 with high affinity (38). 
However, only sst2a, sst3 and sst5 display a high, low, and moderate affinity, respectively, 
towards the currently available synthetic octapeptide somatostatin analogs (SSAs) 
lanreotide and octreotide (38).
Sst expression, especially of sst2, is obligatory for successful treatment with SSAs, as 
well as radiolabeled SSAs.
Dopamine (DA) receptors 
Dopamine is a neurotransmitter in the central nervous system. It is a regulator of GI 
motility, cardiovascular and renal function, and in the endocrine system (65). Activities 
can be executed after binding of DA to its receptors on the cell surface, as demonstrated 
in Figure 4 (65). 
There are five different G protein-coupled DA receptors, e.g. dopamine receptor type 
1 (D1)–D5 (34). The presence of mainly D2 has been studied in GEP NET cells (55,66-68). 
After dopamine binding, D2 activates G proteins. These proteins can subsequently 
inhibit adenylyl cyclase activity, cyclic adenosine monophosphate (cAMP) and protein 
kinase A (PKA). In addition, G proteins can modulate actions of phospholipase C (PLC) 
and mitogen-activated protein kinases (MAPKs). Ultimately, these signal transduction 
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pathways can, in vitro, result in decreased gene expression and inhibition of growth and 
hormonal secretion in NET cells (34,42).
Figure 3 Somatostatin receptor signaling pathway
Somatostatin binds to sst receptor types and activates G proteins resulting in the inhibition of adenylyl 
cyclase activity, activation of potassium (K+) channels and inhibition of calcium (Ca2+) channels. This in turn 
results in eff ects on hormone secretion, apoptosis and cell growth. Adapted from: International Journal of 
Peptides 2013 2013 926295. 
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Figure 4 Dopamine receptor signaling pathway
D2 signaling after binding of dopamine. Via stimulation of G proteins, dopamine inhibits adenylyl cyclase 
activity and phosphatidylinositol metabolism, activates voltage-activated potassium (K+) and calcium 
(Ca2+) channels, and interferes with activities of phospholipase C (PLC) and the mitogen activated protein 
kinases (MAPKs). Subsequently, hormone secretion and gene expression are decreased. Adapted from: 
Neuropsychopharmacology 2014 39 156-168. 
Hybrid receptors 
Co-expression of sst and D2 has also been demonstrated in NETs (34,37,69). These cell 
surface receptors seem capable of heterodimerization, thereby generating so-called 
chimeric receptors or hybrid receptors with altered functional properties (35,70-72). 
Pathophysiologic pathways 
A variety of signaling pathways are involved in normal cell physiology and are crucial for 
activities like cell metabolism, proliferation, migration, diff erentiation and survival. How-
ever, these pathways are frequently deregulated in tumors (73-82). How exactly these 
diff erent pathways are involved in causing cancer, and more specifi c in NETs, is generally 
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unknown. Specifi c pathways that are known to be involved in the pathophysiology of 
GEP NETs are the insulin-like growth factor (IGF) pathway, the phosphatidylinositol 3-ki-
nase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and the RAS/RAF/
mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase (RAS/
RAF/MEK/ERK) or RAS/RAF/MEK/MAPK pathway (Figure 5).
Figure 5 IGF, PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathway
A simplifi ed representation of the IGF pathway, PI3K/AKT/mTOR pathway and the RAS/RAF/MEK/ERK path-
way. Adapted from: Biochemical Sciences 2011 36 320-328.
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Insulin-like growth factor (IGF) pathway
In the insulin-like growth factor (IGF) pathway, different polypeptide hormones or 
‘IGF-related factors’ participate. These include the ligands, e.g. insulin-like growth 
factor 1 (IGF1), IGF2 and insulin, the IGF receptors, e.g. IGF1R, IGF2R, and the insulin 
receptors (IRs), insulin receptor isoform-A (IR-A) and -B (IR-B). The IGF-binding proteins 
1-6 (IGFBP1-6) play an important role as well (73,74,83,84). The IGF1R and IR-A have 
predominantly mitogenic effects, IGF2R has scavenging functions, and IR-B is mainly 
involved in metabolic processes (73). 
IGFRs and IRs have been identified in vitro in GEP NETs (85-87). After binding to IGF1Rs, 
IR-As or hybrid receptors, IGFs can exert tumor-stimulating functions in an auto- and/
or paracrine way (83,84). Phosphorylation of these receptors activates downstream the 
insulin receptor substrate (IRS) 1-3 to the cell membrane, which subsequently activates 
both the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways (73).
PI3K/AKT/mTOR pathway 
Upon activation of receptor tyrosine kinases (RTKs) during receptor binding (e.g. IGF1R), 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) converts substrate phospha-
tidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-triphosphate 
(PIP3) (45,79). Furthermore, induction of AKT subsequently phosphorylates other 
downstream proteins, which results into the inactivation of the endogenous mTOR in-
hibitors, tuberous sclerosis complex 2 (TSC2) and proline-rich AKT substrate 40 (PRAS40) 
(79,88,89). Ultimately, this induces mTOR to modulate processes including cell metabo-
lism, proliferation, differentiation, survival, and motility (79). mTOR exists in two forms 
of protein complexes: mTORC1 and mTORC2 (79,90). Activation of AKT results mainly in 
mTORC1 complex induction. mTORC2 complex activates AKT through phosphorylation 
at Ser473 (89). It is suggested that this Ser473 plays a pivotal role in the resistance to tar-
geted therapy with selective mTORC1 inhibitors. The PI3K/AKT/mTOR pathway is closely 
linked and intracellular parallel located to the RAS/RAF/MEK/ERK pathway downstream 
of receptors (91).
RAS/RAF/MEK/ERK pathway
Growth factors can activate RTKs after receptor binding. This results in autophosphory-
lation. RAS-GDP is subsequently activated by adapter proteins GRB2 and SOS into RAS-
GTP. Subsequently, RAS recruits RAF to the membrane (92). The proteins PKC and PMA 
induce activation of RAF, MEK and ERK, respectively, in the signaling pathway cascade 
which can lead to altered gene expression (79). 
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diAGnoStiCS 
After the ENETS was founded in 2004 and the North American Neuroendocrine Tumor 
Society (NANETS) in 2006, expertise in the field of GEP and bronchial NETs was concen-
trated and this has resulted into the establishment of several clinical guidelines. Patients 
can be scheduled for standardized diagnostic procedures and can be selected for the 
most optimal treatment for their GEP NETs in highly specialized centers where tumor 
board discussions involving specialists from a wide variety in disciplines are taking place 
on a regular basis (93). For making the diagnosis of a GEP NET, pathology of tumor tissue, 
determination of biomarkers, and radiological and nuclear imaging are pivotal (93). 
microscopic examination on a biopsy specimen 
Tumor origin
First, the NE identity of the tumor has to be established, or confirmed. Generally, on a 
hematoxylin and eosin-stained tumor specimen, a tumor with neuroendocrine charac-
teristics can be recognized. It is recommended that the pathology diagnosis of a NET is 
supported by the demonstration of positive immunohistochemical staining for the NET 
markers chromogranin (Cg) and synaptophysin in tumor cells (94,95). 
Immunohistochemical tumor markers
1. Chromogranin (Cg)
Chromogranin (Cg) is a protein present in secretory granules in the cytoplasm of NE cells 
(93). Tumors co-secrete this protein with the amines and peptides that are present in the 
neurosecretory granules (96). 
2. Synaptophysin
Synaptophysin is an integral membrane protein of small clear vesicles, which can be 
demonstrated in all normal and NE tumor cells (93). Immunopositivity of this immuno-
histochemical marker is observed in most NETs (97,98).
3. Other immunohistochemical neuroendocrine markers
Although there are more NET markers, application of neuron-specific enolase, CD56 
and other NE markers are generally not routinely recommended because of the low 
specificity of the available antibodies (93). 
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macroscopic examination on a resection specimen 
ENETS TNM staging
Different macroscopic characteristics are used for the ENETS TNM staging (99,100). With 
this staging algorithm, information is collected on the primary tumor (T), the involve-
ment of regional lymph nodes (N) and the presence, or absence of distant metastases 
(M). This clinical information is essential for the decision on possible treatment modali-
ties as well as the prognosis of patients with NETs. 
Tumor grading
By convention, proliferative activity and differentiation of a NET has to be determined. 
Distinction between a well- and poorly-differentiated GEP NETs has to be made according 
to the World Health Organization (WHO) GEP NET classification guidelines (12). 
Proliferative activity can be assigned by counting mitoses per high-power field and/or 
by immunostaining for the proliferation marker Ki-67 antigen (using the MIB1 antibody), 
which is expressed in the nucleus (101). 
Tumor grading is associated with tumor aggressiveness and is based on the Ki-67 
proliferation index. The GEP NET WHO grading is subdivided into: WHO grade 1 (G1) 
(Ki-67 ≤2%), WHO G2 (Ki-67 3–20%) or WHO G3 (Ki-67 ≥20%) (99,100). WHO G1 and G2 
GEP NETs are considered as well-differentiated NETs that display diffuse and intense ex-
pression of the NE markers chromogranin A (CgA) and synaptophysin. WHO G3 GEP NETs 
are grouped together with poorly differentiated neuroendocrine carcinomas (NECs). The 
latter usually show only positive staining for synaptophysin, but not (or only little) for 
CgA. 
Other diagnostic options 
Optional for tumoral diagnostics is the performance of immunostaining for specific 
hormones, and sst2a. In the majority of tumor specimens of patients with G1 and G2 
NETs, sst2a expression is present. This also results in positive in vivo somatostatin receptor 
scintigraphy (SRS) using 111In-pentetreotide, or OctreoScan® (59).
Biochemical tumor markers
Circulating tumor markers, or biochemical markers, are measurable parameters in bio-
logical sources of the human body that provide helpful information in the diagnostic 
work-up and therapeutic evaluation of patients with tumors.
Plasma or serum 
1. Chromogranin A (CgA)
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Seven different forms of chromogranin can be found in the circulation. CgA is the most 
commonly used circulating tumor marker in patients with GEP and bronchial NETs (102). 
This tumor marker has an age-independent reference range for both sexes (103-105). 
Elevated levels of CgA are demonstrated in several other non-NET-related conditions 
(102,106-112). Therefore, CgA has a suboptimal sensitivity of 59% and specificity of 
68% (113). CgA can be secreted from both clinically functioning and non-functioning 
NETs, independent of their primary localization (102). CgA levels are often the highest in 
midgut NETs and non-functioning panNETs (102). The level of CgA correlates to tumor 
burden, WHO grading, and NET cell primary (102). Whereas elevated circulating levels 
of CgA correlate with prognosis in GEP NET patients (114,115), there is no information 
whether absence of CgA secretion is a favorable, or unfavorable prognostic factor in 
patients with stage IV GEP NETs. 
2. Neuron-specific enolase (NSE)
Neuron-specific enolase (NSE) is present in the cytoplasm and secreted by NE cells 
(17,116-118). Plasma NSE is elevated in 30-50% of patients with GEP NETs (113,118,119). 
It has shown 50% correlation with tumor size (113,118). Like CgA, this tumor marker also 
has an age-independent reference range for both males and females and can be used as 
circulating biomarker for both non-functioning and functioning NETs (103-105,120,121). 
NSE is generally considered as a marker for dedifferentiation in NETs (113). 
3.  Alternative tumor markers
The gut-brain peptide ghrelin is involved in different endocrine (growth hormone 
secretion, insulin secretion and glucose metabolism) and non-endocrine processes (ap-
petite, stimulation of food intake, GI motility and contribution to long term body-weight 
regulation) (122-128). Ghrelin can also be involved in neoplastic activities including cell 
proliferation, migration, invasion, inflammation, apoptosis, and angiogenesis (129-
131). About 50% of circulating ghrelin is acylated (132,133). NETs express ghrelin and 
its growth hormone secretagogue receptor GHSR1a (126,134,135). Most NETs secrete 
ghrelin, but hyperghrelinemia has been reported in only 11 patients with NETs until now 
(136-140). The function of ghrelin in GEP NETs is not known. In general, ghrelin plays an 
important role in the maintenance of the body mass index, so it can be postulated that 
this role is similar in NET patients with elevated ghrelin levels (127,141). Total plasma 
ghrelin has been studied as biomarker in GEP NET patients. However, these total plasma 
ghrelin levels were not discriminative between patients with GEP NETs and healthy 
controls (136).
Studies on prognostic markers for survival and predictive markers for tumor recurrence 
after surgery currently focus on circulating tumor cells and tumor DNA, thymidylate 
synthase expression and tumor-associated macrophages (142-144). Research is ongoing 
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in the field to develop more specific tumor markers in which innovative techniques are 
used including genomic profiling, epigenetics and microRNAs (145-147).
Traditional tumor markers are tumor products that are measured according to a 
single-analyte approach. Lately, a new tumor test has been launched according to a new 
approach: the ‘NETest’ (148-151). In this specific blood-based multi-analyte NET gene 
transcript assay with algorithm analyses, the expression of 51 different genes is tested, 
and seems to outperform single analyte tests in the detection and follow-up of NETs 
(148).
Urine 
1. Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA)
Serotonin and its metabolites are often secreted by NETs. Foregut NETs can secrete 
5-hydroxytryptophan (5-HTP), a precursor of serotonin. Especially midgut NETs, and 
to a lesser extent foregut and hindgut NETs, produce mainly 5-hydroxytryptamine (5-
HT) or serotonin. Generally, hindgut NETs do not secrete serotonin, or its metabolites. 
Foregut, midgut and hindgut NETs and their secretion products are shown in Figure 1 
(102,152,153). 
Serotonin regulates smooth muscle contraction, blood pressure and neurotransmis-
sion. It is produced and predominantly stored in NE cells of the GI tract (102). 5-hydroxy-
indoleacetic acid (5-HIAA) is the breakdown metabolite of serotonin and secreted in the 
urine. The 24-hours urinary collection of 5-HIAA is an established biomarker used in the 
diagnosis and follow-up of GEP and bronchial NET patients with the CS (102,154). For 
the CS, overall sensitivity for urinary 5-HIAA measurements is about 70% and specificity 
90% (152,155). In some patients with non-metastatic NETs or CS, urinary 5-HIAA levels 
can also be within the reference range (156). 
imaging
Radiological imaging
The choice for a specific imaging method depends on tumor-related aspects. These 
include the primary tumor localization, tumor spread to local structures, relation of the 
tumor to adjacent organ structures, presence of regional and distant metastases and, 
detection of therapy effects and/or recurrent disease (13). 
Computer tomography (CT), magnetic resonance imaging (MRI), ultrasound (US), and 
endoscopic ultrasound (EUS) are the mostly used imaging modalities (13). Detection 
rates of the CT and MRI scan are comparable for the visualization of panNETs, liver me-
tastases and extrahepatic metastases. Preferentially, NET lesions in the abdomen and 
chest should be visualized by CT (13).
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For both CT and MRI, ‘Response Evaluation Criteria In Solid Tumors’ (RECIST) criteria 
are generally used to evaluate tumors in clinical trials. 
EUS is currently the imaging modality of choice for small non-metastatic panNETs.
Nuclear imaging 
Somatostatin receptor scintigraphy (SRS) using OctreoScan® is a nuclear imaging 
modality in which mainly somatostatin receptor subtype 2 (sst2), and to a lesser extent 
also sst3 and sst5 expression on tumor cells is visualized in vivo with the commercially 
available radiopeptide 111In-pentetreotide (157). This technique was first introduced 
using [123I-Tyr3]octreotide (158). Using OctreoScan® and single photon emission com-
puted tomography (SPECT), more than 75% of all GEP NETs and/or their metastases can 
be detected (159). However, sst expression is not entirely specific for this tumor entity 
and, therefore, an OctreoScan® can also be positive in other tumors or conditions (159). 
The reasons to perform an OctreoScan® in patients, suspected or diagnosed with a 
NET, are the detection and staging of a NET and its metastases, the selection of patients 
who are eligible for peptide receptor radiotherapy (PPRT), to evaluate effects of PRRT, or 
the detection of disease recurrence. 
Recently, new imaging options as positron emission tomography (PET) and PET-CT 
with 68Ga-labeled SSAs (like 68Gallium-DOTA-TOC PET/CT), but also 18F-DOPA SPECT and 
11C-5-HTP SPECT have been introduced to further optimize the sensitivity and specificity 
to detect NETs (160). Future developments involve the development of somatostatin 
receptor antagonist-coupled isotopes and radiolabeled ligands for other receptors, like 
the cholecystokinin (CCK), gastrin and bombesin receptors.
tReAtment
tumor resection
Surgery with a complete resection of the primary NET and, if present, metastases is the 
only curative option for patients with a NET. Debulking surgery should be considered 
in patients with uncontrolled hormonal syndromes and patients with non-functioning 
tumors who experience symptoms which are related to tumor mass (161). 
Prior to surgery, patients with the CS should be evaluated for perioperative treatments 
to prevent a life-threatening carcinoid crisis (45).
interventions
Interventions such as selective (chemo)embolization, radioembolization, radiofre-
quency ablation, or microwave ablation of metastases can be applied at any time during 
the disease course in GEP NET patients with liver-dominant metastatic disease (162).
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medical therapy in advanced disease
Molecular targeted therapies 
Targeted therapies are commonly used in G1-2 patients with metastasized GEP NETs 
in order to control tumor growth and symptoms of hormonal hypersecretion and to 
improve quality of live. 
1. Somatostatin analogs (SSAs)
The two biologically active forms of SS, SS-14 and SS-28, cannot be used in daily clinical 
practice because of their short half-life in the circulation (39,163). 
Octreotide was the first stable synthetic SSA that was synthesized (164). Hereafter, 
another SSA, lanreotide with similar affinity and activity profiles was developed (163). 
Octreotide and lanreotide have binding preferences to sst2, sst3 and sst5 (38,39,62). 
The main indications for using SSAs in NET patients are the control of hormone-related 
symptoms in functioning NETs and tumor growth control (38,165). SSAs can inhibit 
hormone release that cause the clinical syndromes and, thereby, reduce symptoms and 
improve quality of life in selected patients, especially those with vasoactive intestinal 
peptide (VIP)-secreting panNETs (VIPomas) and patients with siNETs and CS (165-168). 
Octreotide LAR has been shown to significantly prolong time to tumor progression 
(TTP) compared with placebo in patients with (non-)functional metastatic midgut NETs 
(168). Treatment with lanreotide autogel in patients with metastatic G1-2 GI and pan-
NETs is also associated with significantly prolonged progression-free survival (PFS) (169). 
Long-acting SSAs are able to induce a relief of symptoms, accompanied by a reduction 
in the tumor markers 5-HIAA and CgA in 30–70% of GI NETs patients. Although most 
patients experience a rapid relieve of symptoms, a loss of response of inhibition of hor-
mone secretion can occur after continuous treatment of octreotide LAR and lanreotide 
autogel within weeks to months (20,169,170).
Patients with GEP NETs that escape from medical treatment by developing tachyphy-
laxis and/or resistance will eventually develop progressive disease (63,171). Tachyphy-
laxis is a rapidly decreasing response to a drug following continuous administration. The 
processes which underlie this rebound phenomenon are poorly understood. Mecha-
nisms that are potentially involved in SSA tachyphylaxis are receptor phosphorylation, G 
protein uncoupling, receptor internalization, and degradation (63,171). 
1a. Pasireotide 
Pasireotide is a new SSA with high affinity for all sst except sst4 (172,173). In contrast with 
octreotide LAR, no tachyphylaxis was observed with pasireotide LAR (173-175). 
In a small phase II trial, short-acting pasireotide was effective at controlling symptoms 
in 27% of patients with metastatic NETs and CS inadequately controlled with octreotide 
LAR (176). Treatment with long-acting pasireotide LAR regretfully did no show such 
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an advantage. Pasireotide LAR, therefore, shows no superiority over octreotide LAR in 
patients with syndromic GI NETs. 
1b. Telotristat etiprate 
Recently, the drug telotristat etiprate has been developed. This oral serotonin syn-
thesis inhibitor blocks tryptophan hydroxylase activity which is involved in serotonin 
synthesis (39). It will be positioned as supportive treatment for patients with signs and 
symptoms caused by hyperserotonemia like severe secretory diarrhea which is refrac-
tory to long-acting SSAs (39). In phase II studies in patients with the CS and diarrhea, 
this drug induced a 30% reduction in bowel movements in 28% of subjects co-treated 
with long-acting SSAs. This clinical response was also accompanied by a more than 50% 
reduction of urinary 5-HIAA excretion in 56% of the patients (177,178). Results of phase 
III placebo-controlled double blind trials with this drug in patients with CS and diarrhea 
refractory to SSAs have been reported at international meetings (39). 
2. Chimeric molecules
A dopamine-somatostatin chimeric molecule, also named ‘dopastatin’, acts on both sst 
and D2. Regretfully, with chronic administration, the dopamine-somatostatin chime-
ric molecule BIM-23A760 which binds preferentially to sst2, sst5 and D2 was found to 
produce a metabolite which interfered with the activity of the parent compound (179). 
In the future, new dopamine-somatostatin chimeric molecules which are differently 
metabolized and which retain their activity might be expected.
Protein kinase inhibitors
3a. Mammalian target of rapamycin (mTOR)C1 inhibitors 
Everolimus and rapamycin belong to the group of orally active mammalian target of 
rapamycin (mTOR) inhibitors (180). This everolimus is a tyrosine kinase inhibitor that 
specifically inhibits mTORC1 and modulates metabolic processes and signaling through 
growth factors, like IGF1, downstream of their cognate receptors (180). In panNET cell 
lines, mTOR inhibitors decreased cell growth (181-183). In addition, everolimus inhibits 
tumor growth, both in vitro and in vivo (184,185)
Everolimus is registered for the treatment of patients with progressive well-differen-
tiated G1-2 panNETs (180,185-187) and will probably be registered for the treatment of 
patients with progressive well-differentiated G1-2 siNETs. 
3b. Sunitinib
Sunitinib malate is a multitargeted tyrosine kinase inhibitor that blocks protein tyrosine 
kinases including vascular endothelial growth factor receptors 1 (VEGFR1)-3, platelet-
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derived growth factor receptors alpha (PDGFRα) and beta (PDGFRβ), stem cell factor 
receptor (Kit), Flt-3, and colony-stimulating factor 1 receptor (CSF1R) (188). These kinases 
play an important role in angiogenesis (189). VEGF and their receptors are abundantly 
expressed in panNETs (190-194). In patients with unresectable, advanced metastatic 
panNETs, treatment with sunitinib prolonged PFS as compared with placebo (195). 
3c. Linsitinib (OSI-906)
Recently, the dual IGF1R/IR tyrosine kinase inhibitor linsitinib (OSI-906) has been 
developed (196). In vitro, linsitinib has shown antiproliferative effects in several cell lines 
(196-200). Since both IGF1R and IR are important targets for therapy in NETs, dual inhibi-
tion could be a potentially novel therapy for patients with NETs. No clinical trials with 
OSI-906 in patients with NETs have been initiated yet.
Peptide receptor radiotherapy (PRRT)
Peptide receptor radiotherapy (PRRT) involves the use of radiolabeled SSAs in the treat-
ment for patients with G1-2, inoperable or metastasized NETs (159). Nowadays, the most 
commonly used radiolabeled SSA is 177Lu-DOTAtate (201). 
In general, tumor response rates and PFS of PRRT with 177Lu-DOTAtate are favorable 
as compared to alternative treatment modalities.  In a study in more than 500 GEP 
NET patients who underwent PRRT with 177Lu-DOTAtate, complete tumor response 
(disappearance of all target lesions) was observed in 2%, partial response (decrease in 
tumor size >30%) was observed in 28% and minor response (decrease in tumor size 
>25%–<50%) was observed in 16% of patients with metastatic inoperable GEP NETs 
(202). Median TTP was 40 months and median OS was 46 months (202). 
Interferon (IFN)
In the past, interferon  alpha (IFNα) appeared a promising treatment modality in 
the management  of functioning midgut NETs. Interferon alpha (IFNα) binds to IFNα 
receptors, which are expressed on NET cells. After binding to its specific receptors, 
IFNα can reduce tumor cell proliferation via cell cycle blockage of the G1-S phase. This 
biotherapeutical also exerts immunomodulation and inhibition of angiogenesis (203). 
IFNα reduces hormone secretion and symptoms in about 60% of the patients with GI 
NETs (203,204). Bevacizumab is a monoclonal antibody that blocks angiogenesis by 
inhibiting vascular endothelial growth factor A (VEGF-A). In a recently published phase 
III trial, octreotide LAR combined with either IFNα, or bevacizumab showed comparable 
antitumor effects in patients with advanced small intestinal NETs (205). Two prospec-
tive randomized trials conducted in patients with stage IV GEP NETs have shown that 
SSAs, IFNα or their combination have comparable antiproliferative effects when used 
after prior disease progression (206,207). Interferon beta (IFNβ), seems more potent as 
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compared to IFNα in inhibiting cell proliferation of GEP NET cells in vitro. However, no in 
vivo data exist on the use of this drug in GEP NET patients (204,208,209). 
Systemic chemotherapy
Chemotherapy is recommended in patients with poorly differentiated (G3) NETs and 
NECs of any site and, in progressive and/or extended panNETs (210,211). 
Patients with panNETs are usually treated with combinations of streptozotocin (STZ) 
with 5-fluorouracil (5-FU), or doxorubicin with STZ (211). These combinations resulted 
in objective tumor response rates of about 40% (212,213). Temozolomide, alone or in 
combination with capecitabine, may be considered as an alternative therapeutic regi-
men (32). Patients with metastatic grade 3 GI, or bronchial NETs are generally treated 
with a combination of cisplatinum with etoposide (212). 
AimS oF the theSiS
Despite the many advances in the GEP NET field reported above, there is still an unmet 
need for:
1) improvement of the diagnostic work-up and follow-up of GEP NET patients using 
sensitive and specific tumor markers and,
2) identifying new biotherapeutical options by modulating pathological pathways in 
panNET cells. 
We have aimed to answer the following research questions in the present thesis:
Chapter 2: What is the role of serum NSE as a biomarker for tumor progression and 
survival in GEP NET patients? 
Chapter 3:  What is the clinical importance of true non-secretion of CgA as prognostic 
factor in patients with ENETS TNM stage IV GEP NETs? 
Chapter 4:  Are fasting AG and UAG potential novel biomarkers in patients with GEP 
NETs? Is there a relationship between fasting AG, UAG and AG/UAG ratios 
and biochemical and clinical parameters in GEP NET patients? 
Chapter 5:  Is there a relationship between serum CgA, the Ki-67 proliferation index in 
tumor samples and the expression of IGF-related genes in GEP NET tissues 
in relation to 5-year survival of GEP NET patients? 
Chapter 6: What is the sst2a-positivity in GEP NET samples of PRRT-treated patients? Is 
there a relationship between best GEP NET response to PRRT and tumoral 
sst2a immunohistochemistry? 
Chapter 7: Are panNET cell lines useful as a model for the study of the IGF pathway in 
 GEP NETs? 
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 Do panNET cells produce growth factors that stimulate IR-As and can SSAs 
and/or DAs influence the production of these growth factors?
Chapter 8:  What is the effect of linsitinib alone, or in combination with the mTOR 
inhibitors everolimus and rapamycin, on cell migration and proliferation 
of panNET cells?
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letteR to the editoR
Serum neuron-specific enolase (NSE) is considered a tumor marker in patients with 
gastroenteropancreatic neuroendocrine tumors (GEP NETs) (1). It is elevated in 30-50% 
of GEP NET patients and correlates with tumor size (2,3). NSE has a sensitivity of 38% 
and specificity of 73% for GEP NET detection (2). The prognostic role of serum NSE as a 
biomarker for GEP NETs patients’ survival is poorly studied (4). 
We retrospectively studied 592 patients with sporadic (non-familial) ENETS TNM 
stage IV GEP NETs. Median follow-up was 58.7 months (25th-75th percentile: 34.02-92.98). 
Serum NSE was measured at first consultation, using enzyme immunoassay (NSE Cobas 
E602, Roche Diagnostics, Mannheim, Germany). 
Cut-off values for serum NSE were: NSE ≤1× ULN (≤16.2 µg/L),  NSE 1-3× ULN (16.2-
48.6 µg/L) and  NSE >3× ULN (48.6 µg/L). 
Primary outcome was overall survival, calculated from date of diagnosis to date of 
death by any cause, or date of last follow-up. Using statistical software R version 3.1.3 
‘survival’ package, overall survival was estimated with the Kaplan-Meier method. Hazard 
ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox proportional 
hazards models including age at diagnosis, OctreoScan® (SRS) positivity (Krenning scale 
≥2 in all lesions), primary tumor site, sex and bone metastases. 
Two hundred forty-two (41%) of GEP NET patients had an elevated NSE (>1× ULN). 
NSE >3× ULN were seen in pancreatic NETs.
Median overall survival (mOS) across all groups was 103.9 months (95% CI 92.8-137.1). 
mOS was 161.8 months in the NSE ≤1× ULN group (95% CI 130.7-not reached [NR]) and 
72.5 months in the NSE 1-3× ULN group (95% CI 60.2-108.6; Cox proportional hazard-
adjusted HR versus NSE ≤1× ULN: 1.96 [1.45-2.63], P<0.001). In the NSE >3× ULN group, 
mOS was 27.8 months (95% CI 15.2-44.7; HR versus NSE ≤1× ULN: 6.15 [4.36-8.69], 
P<0.001) (Figure 1). Significant contributors to our model included: age at diagnosis 
(HR 1.03 [1.02-1.04], P<0.001) and SRS positivity (HR 0.48 [0.28-0.83], P<0.001). 
The ENETS/WHO grading system using Ki-67 staining was introduced in 2010 (5). 
Therefore, we used SRS positivity as a surrogate marker for ENETS/WHO tumor grading, 
since SRS positive GEP NETs are generally well-differentiated, ENETS/WHO grade 1-2 
tumors. However, the assumption that all SRS positive patients could have ENETS/WHO 
grade 1-2 tumors could be considered a limitation of this study. We therefore studied 
the subpopulation of 367 patients with known ENETS/WHO 2010 grading (62% of all 
patients). In this population, the same Cox proportional hazard model with ENETS/
WHO grade as an additional parameter was applied and showed that higher ENETS/
WHO grade significantly contributed (P<0.001) to the model, but that NSE remained 
independently associated with overall survival (P<0.001). Multivariate analysis data are 
shown (Supplementary table 1, available at Annals of Oncology online).
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This study demonstrates that NSE is a biomarker for overall survival in ENETS TNM 
stage IV GEP NET patients. Our study cohort had a median follow-up of almost 5 years 
and a mOS of over 8.5 years across all groups. Elevated NSE was found in over 40% of 
patients, confirming published data (2,3). Elevated serum NSE indicates a more aggres-
sive disease course and determination of NSE at first consultation could, therefore, have 
prognostic implications. 
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Figure 1 Kaplan-Meier estimate of overall survival in NSE <1× ULN (continuous line), NSE 1–3× ULN (dotted 
line) and NSE >3× ULN (dashed line) level groups.
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Supplementary table 1 Multivariate analysis model with hazard ratios (HRs) estimated through Cox pro-
portional hazards model.  P-values determined with Wald test for HR in Cox-proportional hazards regres-
sion 95% CI. Primary tumor site ‘Other’ includes: neuroendocrine tumors of unknown origin, stomach, duo-
denum and colorectal neuroendocrine tumors.
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ABStRACt
introduction: Chromogranin A (CgA) is a widely used biomarker for the work-up of gas-
troenteropancreatic neuroendocrine tumors (GEP NETs), correlating with tumor volume 
and biological activity. During diagnosis and follow-up we found patients with elevated 
CgA levels and patients without elevated CgA levels (=‘true non-secretors’).
objectives: We assessed, in a tertiary referral center, whether true non-secretion of CgA 
is an unfavorable prognostic factor in patients with stage IV GEP NETs. 
methods: In total, 692 consecutive patients were evaluated. After exclusion of patients 
with concomitant proton pump inhibitors, 616 and 524 patients were included for 
analysis of baseline and follow-up CgA, respectively. Cut-off values for baseline and 
follow-up CgA groups were: normal (reference range [RR]), intermediate (≤2× upper 
limit of normal [ULN]), high (2-10× ULN) and very high (>10× ULN). Overall survival (OS) 
was estimated with Kaplan-Meier methods.
Results: Of the 692 evaluated patients, median follow-up was 61.3 months (25th–75th 
percentile: 35.7–97.5) and median OS was 104.6 months (95% CI: 94.4-136.5). OS was sig-
nificantly shorter in patients with high baseline CgA (median 103.9 versus 222.4 months, 
P<0.01) and very high baseline CgA versus RR (56.2 versus 222.4 months, P<0.0001). For 
follow-up CgA, OS was only significant shorter in the very high follow-up CgA versus RR 
(62.9 months versus not reached). This effect remained in multivariate analysis with Cox 
proportional hazard models. 
Conclusions: True non-secretion of CgA has shown to be a favorable biomarker for OS in 
patients with stage IV GEP NETs, both at first referral as well as during follow-up.
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intRoduCtion
Chromogranin A (CgA), a member of the granin family, is an acidic glycoprotein with 
439 amino acids which is present in the secretory dense core granules of most neuro-
endocrine cells (1). Immunohistochemistry for CgA is widely used and considered to be 
the most valuable tissue-based biomarker in the diagnosis of neuroendocrine tumors 
(NETs) (2). Elevated levels of serum or plasma CgA can be found in various types of 
NETs, including gastrointestinal tract NETs, (non-)functioning pancreatic NETs, paragan-
gliomas, pheochromocytomas, medullary thyroid carcinomas, pituitary and parathyroid 
adenomas and in some patients with small-cell lung cancer (3,4). Furthermore CgA has 
shown to be the best available general serum tumor marker for the work-up of gastro-
enteropancreatic NETs (GEP NETs) (3,5). A recent meta-analysis demonstrated that the 
sensitivity and specificity of elevated serum levels of CgA in the diagnosis of patients 
with NETs are 0.73 and 0.95 respectively (6). 
The highest levels of CgA have been found in patients with metastatic small intestine NETs 
and non-functioning pancreatic NETs (3,7). Depending on the extent of the disease, serum 
CgA is elevated in >60% of patients. CgA levels may correlate with tumor volume, presence 
of metastases and biological activity in the tumors, but care should be taken in measuring 
CgA and interpreting the results. Somatostatin analogs (SSAs) are known to affect blood 
levels of CgA by blocking the production and release of CgA in addition to affecting tumor 
burden. Falsely elevated levels of CgA have also been reported in patients using proton 
pump inhibitors (PPIs) or histamine H2 blockers, in patients with renal or liver failure, and in 
those with chronic atrophic gastritis type A or inflammatory bowel disease (7-9). 
Both functionally active NETs and non-functioning NETs can co-secrete CgA with 
amines and peptides that are present in their neurosecretory granules (3,7). During 
diagnosis and follow-up we found patients with metastatic GEP NETs that secrete CgA 
resulting in elevated circulating CgA levels and patients with metastatic GEP NETs 
without elevated CgA levels. The latter we have called ‘true non-secretors’. The reason 
why some patients with well-differentiated metastatic GEP NETs do not show elevated 
circulating CgA levels is not known. It is well known that poorly differentiated neuroen-
docrine carcinomas (NECs) lose their expression of CgA (2). On the other hand expres-
sion of CgA in non-endocrine tumors is considered a poor prognostic factor (10). In our 
study in neuroendocrine tumor patients, we postulated that these non-secretors would 
have a poorer prognosis because we considered the lack of secretion of any substance 
from a GEP NET to be a sign of further dedifferentiation. 
Since the prognostic value of CgA in patients with metastatic NETs has not been 
confirmed to date (3,5), this study, conducted in a large single-center cohort, aimed to 
determine whether true non-secretion of CgA is an unfavorable prognostic factor in 
patients with metastatic, ENETS/AJCC TNM stage IV (11-13) GEP NETs. Finally, we investi-
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gated whether there were any significant differences in patient and tumor characteristics 
between ‘true non-secretors’ and patients with CgA secreting GEP NETs.
PAtientS And methodS
Patients
In this retrospective case study, all patients with metastatic, ENETS/AJCC TNM stage 
IV (11-13) GEP NETs, diagnosed between 1 January 1993 and 31 December 2012 were 
identified from the Erasmus MC NET database and included. 
TNM stage IV indicates the presence of metastases at any distant anatomical site 
(including non-regional lymph nodes) (11-13). The date of diagnosis was defined as the 
date at which tumor tissue was collected during biopsy or surgery. Follow-up time was 
determined from the date of diagnosis to the date of death or the last follow-up for 
survivors. Patients diagnosed with the multiple endocrine neoplasia syndrome type 1 
(MEN1) were excluded. In addition, to prevent influence of PPIs on CgA levels, patients 
with concomitant PPI use at the time of CgA measurement were excluded. Information 
on age, sex, location of primary tumor, OctreoScan® (SRS) positivity, presence, or ab-
sence of bone metastasis and concomitant use of PPIs was collected. 
definitions CgA groups
Patient groups were defined by first CgA level at referral or diagnosis (baseline CgA) and 
highest CgA level measured during follow-up (follow-up CgA). All serum CgA measure-
ments were performed in the Erasmus MC, using an ELISA (CisBio Bioassays, Codolet, 
Franassay; upper limit of normal [ULN] <94 µg/L). 
Four patient groups were defined by both baseline CgA and follow-up CgA levels. Cut-
off values for serum CgA were: normal baseline CgA or follow-up CgA (reference range, 
<94 µg/L), intermediate baseline CgA or follow-up CgA (≤2× ULN, 94-188 µg/L), high 
baseline CgA or follow-up CgA (2-10× ULN, 188-940 µg/L) and for very high baseline or 
follow-up CgA (>10× ULN, >940 µg/L). 
Primary outcome was overall survival, calculated from date of diagnosis to date of 
death by any cause, or date of last follow-up.
Statistical analysis
Continuous data were described as the mean and standard deviation (SD) and were 
compared by ANOVA tests. Categorical data were described as counts and percentages 
and were compared by χ2 tests. Overall survival was estimated with the Kaplan-Meier 
method. The hazard ratios (HRs) were estimated using a Cox proportional hazards model. 
HRs and 95% confidence intervals (CIs) were also calculated. The proportional hazard 
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assumption (Schoenfeld residuals) was always satisfied. Data analysis was performed 
using statistical software R version 3.1.3 and is based on the survival-package. A two-
sided P-value of <0.05 was considered statistically significant.  
ReSultS
Patient inclusion and stratification
In total, after exclusion of 19 MEN1 patients, 692 consecutive patients were evaluated with 
a median follow-up of 61.3 months (25th–75th percentile: 35.7–97.5 months) and a median 
overall survival (mOS) of 104.6 months (95% CI: 94.4-136.5). After exclusion of patients 
with concomitant PPI use, 616 and 524 patients were included for analysis of baseline and 
follow-up CgA, respectively. Of these patients, 492 (79.9%) had an elevated baseline CgA 
level (>1× ULN) and 465 (88.7%) had an elevated follow-up CgA level (>1× ULN). Other 
clinical conditions which might have caused elevations in CgA were excluded.
Patient characteristics of the different groups for baseline CgA and follow-up CgA 
measurements can be found in table 1. Highly significant differences were found for 
only two parameters: age at diagnosis for both baseline CgA and follow-up CgA measure-
ment, and bone metastasis differed only significantly for follow-up CgA measurement. 
Baseline CgA and survival
Median time between histological diagnosis of the GEP NET and measurement of 
baseline CgA was 3.2 months (25th–75th percentile: 0.9–17.4 months). With regard to the 
measurement of baseline CgA, survival analysis without concomitant PPI use (N=616) 
showed a mOS of 222.4 months in the normal baseline CgA group (95% CI: 141.0-not 
reached [NR]), and 213.0 months in the intermediate baseline CgA group (95% CI: 114.2-
NR; Cox-adjusted HR versus normal CgA: 1.26 [0.79-1.99], P=0.33). Subsequently, mOS 
was 103.9 months in the high baseline CgA group (95% CI: 90.8-144.8; HR versus normal 
CgA: 1.92 [1.29-2.88], P<0.01) and 56.2 months in the very high baseline CgA group (95% 
CI: 49.08-65.7; HR versus normal CgA: 3.58 [2.44-5.26], P<0.0001) (Figure 1). Using a Cox 
proportional hazard model, age at diagnosis (HR 1.02 [1.01-1.03], P<0.0001), bone me-
tastasis (HR 1.33 [1.03-1.72], P<0.05), SRS positivity (HR 0.30 [0.18-0.53], P<0.0001) and 
unknown/other origin of tumor (HR 1.58 [1.18-2.12], P<0.01) had a statistical significance, 
while sex did not contribute significantly to the model. In subanalysis, only including the 
351 patients with known ENETS/WHO grading, the same Cox proportional hazard model 
with ENETS/WHO grade as an additional parameter was applied and showed that ENETS/
WHO grade 3 significantly contributed (HR versus ENETS/WHO grade 1: 5.02 [2.92-8.65], 
P<0.0001) to the model. However, very high CgA remained independently associated 
with overall survival (HR versus normal CgA: 3.54 [2.06-6.10], P<0.0001).
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Follow-up CgA and survival
Follow-up CgA measurement during the course of the disease was used to define four 
groups: low, intermediate, high and very high follow-up CgA groups. Median time be-
tween histological diagnosis of the GEP NET and measurement of follow-up CgA was 
18.6 months (25th–75th percentile: 3.9–52.1).
In the patients without concomitant PPI use (N=524), mOS was not reached in the 
normal follow-up CgA group, while mOS in the intermediate follow-up CgA group was 
222.4 months (95% CI: 163.5-NR; HR versus normal: 1.58 [0.77-3.24], P=0.21). In the high 
and very high follow-up CgA group, mOS was 147.6 months (95% CI: 127.8-NR; HR versus 
normal: 1.55 [0.80-3.02], P=0.20) and 67.3 months (95% CI: 59.3-83.4; HR versus normal: 
3.70 [1.98-6.91], P<0.001), respectively (Figure 2). Additional significant contributors to 
the used Cox proportional hazard model included: bone metastasis (HR 1.41 [1.06-1.87], 
P<0.05), SRS positivity (HR 0.33 [0.17-0.621], P<0.0001) and unknown/other origin of 
tumor (HR 1.60 [1.17-2.19], P<0.01), while sex did not contribute significantly. In sub-
table 1 Characteristics at baseline of patient groups based upon baseline chromogranin A (CgA) measure-
ment and follow-up CgA measurement. Differences are tested by ANOVA for age and through χ2 for all 
other variables. 
 CgA=chromogranin A, ULN=upper limit of normal, SRS=OctreoScan®
SiNETs=small intestine neuroendocrine tumors, PanNETs=pancreatic neuroendocrine tumors 
Primary tumor site “Other” includes: neuroendocrine tumors of unknown origin, neuroendocrine tumors of 
stomach, duodenum and colorectal.
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analysis, only including the 302 patients with known ENETS/WHO grading, the same Cox 
proportional hazard model with ENETS/WHO grade as an additional parameter was ap-
plied and showed that ENETS/WHO grade 3 signifi cantly contributed (HR versus ENETS/
WHO grade 1: 4.19 [2.29-7.64], P<0.0001) to the model. In this extended model, very 
high CgA remained independently associated with overall survival (HR versus normal 
CgA: 2.99 [1.40-6.40], P<0.005).
diSCuSSion
This single-center retrospective study demonstrates that, contrary to our expectations, 
true non-secretion of CgA is not an unfavorable prognostic factor for patients with 
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Figure 1 Kaplan-Meier estimate of overall survival in normal (<1× ULN, ---), intermediate (1-2× ULN,  ), 
high (2-10× ULN,  ) and very high (>10× ULN,   ) baseline serum chromogranin A (CgA) level groups 
(N=616).  
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ENETS/AJCC TNM stage IV GEP NETs, both when measured at fi rst diagnosis as well as 
when measured at follow-up. Both serum baseline CgA and follow-up CgA levels show a 
positive correlation with overall survival.
The selected timeframe of 20 years for inclusion in this study was based upon the fi rst 
availability of the most commonly used imaging techniques and treatment modalities 
in our institution. This included the introduction of somatostatin receptor imaging with 
the OctreoScan®, peptide receptor radiotherapy (PRRT) (14) and SSAs (15). Any possible 
bias caused by evolving imaging and treatment protocols has therefore been minimized. 
Patients in our research population, referred to our hospital for PRRT, mostly have 
metastatic disease. For CgA measurements in patients with metastatic disease specifi ci-
ties of 100% have been reported (16-19). 
 Figure 2 Kaplan-Meier estimate of overall survival in normal (<1× ULN, ---), intermediate (1-2× ULN, ), 
high (2-10× ULN,  ) and very high (>10× ULN,  ) follow-up chromogranin A (CgA) level groups (N=524). 
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Bone metastases in our cohort only influenced follow-up CgA levels, likely because 
bone metastases were not yet present at the time of diagnosis. Patients who live longer 
are more likely to develop bone metastases during the course of their disease. This 
is reflected by the relatively high frequency of bone metastases in our patients with 
normal CgA levels. 
A recent meta-analysis demonstrated that CgA is an efficient biomarker for the diag-
nosis of NETs with a sensitivity of 73% and specificity of 95%, indicating that serum CgA 
might be helpful in the clinical management and follow-up of NETs (6). Another study 
by Yao and colleagues evaluated the prognostic value of CgA in patients with pancreatic 
NETs treated with everolimus. They confirmed the prognostic importance of baseline 
levels of CgA by multivariate analysis, hereby identifying CgA as an independent pre-
dictor of overall survival (9). In line with this study we confirm a significant difference 
in OS between true non-secretors (2) and different elevated levels of CgA secretion by 
not only pancreatic NETs, but also by small intestinal and other NETs and, therefore, 
determination of CgA at first consultation can be used for predicting prognosis in all 
types of GEP NETs. Up until the present study the prognostic value of CgA in patients 
with GEP NET had not been confirmed (3).
An elevated CgA level at baseline was found in over 80% of the patients, which is in 
accordance with earlier published data (3,9,20,21). 
Current ENETS guidelines state that where possible, PPIs should be interrupted, 
leaving a clearance of at least three half-lives, prior to CgA plasma sampling (3). The 
potential weakness of CgA as a biomarker is that the use of PPIs can frequently cause a 
significant elevation in CgA levels (7,8). Since PPIs are now widely available in drugstores 
without a doctor’s prescription, the value of future studies will likely be affected. 
By selecting strict cut-off values to divide the patients in four groups, both at first 
measurement as highest measurement during follow-up, the impact of relatively small 
increases in CgA could be studied. Our study demonstrates that patients in high and 
very high CgA groups clearly have a worse prognosis when compared with those in 
the normal CgA group. Hence, an increase in CgA indicates a more aggressive disease 
course. The determination of CgA at first consultation can be used for predicting the 
prognosis. Also, CgA during the course of the disease provides additional information 
on tumor aggressiveness. The earlier hypothesis that GEP NETs tumors may lose CgA 
expression to incomplete or partial endocrine differentiation is hereby refuted.
For our data collection we did not include information on tumor grading, because Ki-
67 staining on tumor samples was not routinely used for the diagnostic work-up during 
the entire follow-up period. After all, the ENETS/WHO grading system was introduced 
in 2010 and our inclusion of patients dates back to 1993 (12,13). We therefore used 
SRS positivity as a surrogate marker for tumor grading, since SRS-positive GEP NETs are 
generally well-differentiated, ENETS-WHO grade 1-2 tumors (22,23). 
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However, the assumption that all SRS-positive could have ENETS/WHO grade 1-2 
tumors could be considered a limitation of this study. We therefore studied the sub-
population of patients with known ENETS/WHO 2010 grading and demonstrated that 
CgA remains associated with survival.
In conclusion, true non-secretion of CgA has been proven to be an independent 
biomarker for overall survival in patients with stage IV well-moderately differentiated 
GEP NETs, both at first referral as well as perhaps more evident at follow-up. 
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ABStRACt 
introduction: To date, the value of fasting plasma acylated ghrelin (AG) and unacylated 
ghrelin (UAG) as potential novel biomarkers in patients with neuroendocrine tumors 
(NETs) is unknown. 
objectives: Of this study: are to 1) compare fasting AG and UAG levels between non-
obese, non-diabetic NET patients (N=28) and age- (±3 years) and sex-matched non-
obese, non-diabetic controls (N=28); and 2) study the relationship between AG, UAG, 
and AG/UAG ratios and biochemical (chromogranin A [CgA] and neuron-specific enolase 
[NSE] levels) and clinical parameters (age at diagnosis, sex, primary tumor location, 
carcinoid syndrome, ENETS TNM classification, Ki-67 proliferation index, grading, prior 
incomplete surgery) in NET patients. 
methods: Fasting venous blood samples (N=56) were collected and directly stabilized 
with 4-(2-aminoethyl) benzenesulphonyl fluoride hydrochloride after withdrawal. Plas-
ma AG and UAG levels were determined by ELISA. Expression of ghrelin was examined in 
tumor tissue by immunohistochemistry. 
Results: There were no significant differences between NET patients and controls in 
AG (median: 62.5 pg/mL, IQR: 33.1–112.8 versus median: 57.2 pg/mL, IQR: 26.7–128.3, 
P=0.66) and UAG in levels (median: 76.6 pg/mL, IQR: 35.23–121.7 versus median: 64.9, 
IQR: 27.5–93.1, P=0.44). 
Conclusions: No significant correlations were between AG, UAG, and AG/UAG ratios 
versus biochemical and clinical parameters in NET patients with the exception of age at 
diagnosis (AG: ρ=–0.47, P=0.012; AG/UAG ratio: ρ=–0.50, P=0.007) and baseline chromo-
granin A levels (AG/UAG ratio: ρ=–0.44, P=0.019). In our view, fasting plasma acylated 
and unacylated ghrelin appear to have no value as diagnostic biomarkers in the clinical 
follow-up of patients with NETs.
AG and UAG in NETs 69
 4
intRoduCtion   
Ghrelin is a gut-brain hormone that is produced predominantly by gastric X/A-like neu-
roendocrine cells (1,2). Ghrelin exists in two forms: acylated ghrelin (AG) and unacylated 
ghrelin (UAG). About 50% of circulating ghrelin is in the acylated form (3,4) and exerts its 
functions through the growth hormone secretagogue receptor type 1a (GHSR1a) (5,6). 
Acylation of ghrelin, which is required for its ability to activate the GHSR1a in vivo, is per-
formed by the enzyme ghrelin O-acyltransferase (GOAT) (5,7,8). UAG does not activate 
the GHSR1a at physiological concentrations (5,9). Therefore, UAG has been considered 
as an inactive degradation product of ghrelin (2,10). However, as recently reported, UAG 
could also act as a separate hormone in several physiological and pathophysiological 
conditions, independent from AG (9).
AG seems to be involved in different endocrine and non-endocrine processes (2,11-
16). Neoplastic effects of ghrelin have been reported as well including: cell proliferation, 
cell migration, cell invasion, inflammation, apoptosis, and angiogenesis (17-19). 
Neuroendocrine tumors (NETs) are rare tumors characterized by the hypersecretion of 
several bioamines and peptides (20,21). NETs can also express ghrelin and its receptors 
(14,22). Although most NETs release ghrelin, hyperghrelinemia has been reported in 
only 11 patients with NETs (23-27).
The function of ghrelin in NETs is not well understood. It has been suggested that 
ghrelin could be responsible for the striking maintenance of body mass index (BMI) 
that can be observed in NET patients (15,28). Although total serum ghrelin levels in 
NET patients were reported to be positively correlated with tumor burden (29), total 
plasma ghrelin seems not to be a useful biomarker since total plasma ghrelin levels did 
not discriminate between patients with NETs and healthy controls (23). Currently, there 
are no data on the clinical usefulness of the two isoforms of ghrelin, AG and UAG, as 
potential biomarkers in patients with NETs. Examining the relationship between these 
two isoforms has relevance, since it is becoming clearer that levels of ghrelin acylation 
are regulated and not constant (4). For example, the ratio of AG/UAG has been found to 
be linked with metabolic status (30,31). 
Therefore, the aims of this study are to 1) compare fasting AG and UAG levels between 
non-obese, non-diabetic NET patients (N=28) and age- (±3 years) and sex-matched non-
obese, non-diabetic controls (N=28); and 2) study the relationship between AG, UAG, 
and AG/UAG ratios and biochemical (chromogranin A [CgA] and neuron-specific enolase 
[NSE] levels) and clinical parameters (age at diagnosis, sex, primary tumor location, 
carcinoid syndrome, ENETS TNM classification (32,33), Ki-67 proliferation index, grading, 
prior incomplete surgery) in NET patients. 
70 Chapter 4
SuBjeCtS And methodS 
net patients 
Between March 2014 and March 2015, 28 Caucasian, non-obese, non-diabetic patients 
who were referred with a newly diagnosed neuroendocrine tumor were recruited. The 
diagnosis of a NET was based on biochemical, histological and clinical parameters. The 
primary NETs were originating from the small intestine, pancreas, stomach, lung, or had 
an unknown origin. 
Patients were eligible for the study if they were medical treatment naive, were not 
obese, and had neither metabolic syndrome nor diabetes mellitus. Prior surgery with 
incomplete removal of the NET was permitted for inclusion into the study.
All NET patients gave written informed consent before inclusion in this study, which 
was approved by the Medical Ethics Committee of the Erasmus University MC in Rot-
terdam. 
Controls
All patients with NETs were sex- and age-matched to 28 healthy Caucasian, non-obese, 
non-diabetic controls (within a range of ±3 years of age). Patients were paired with 
age-matched controls since a study in men found an age-dependent decline in AG 
concentrations (34). Controls were healthy volunteers from Erasmus MC, Rotterdam. All 
controls were recruited prospectively between January 2015 and March 2015.
Exclusion criteria for the controls were the following: past or existent malignancies; 
endocrine disorders including diabetes mellitus, acromegaly, Cushing syndrome; 
metabolic syndrome; any active use of glucocorticoids; active inflammatory or infec-
tious disease; past gastric surgery, kidney, or liver function abnormalities; epilepsy; and 
psychiatric and eating disorders.
Controls gave their written informed consent before inclusion into the study.
materials
Vacutainers were obtained from Becton Dickinson (Breda, Netherlands; cat# 367899; 
6 mL K2 EDTA). 4-(2-aminoethyl) benzenesulphonyl fluoride hydrochloride (Pefabloc, 
SC AEBSF) was purchased from Roche Applied Science (cat# 11429876001; Almere, 
Netherlands). Stock solutions of AEBSF were prepared in distilled water to give a final 
concentration of 200 mg/mL AEBSF.
Human AG and UAG are determined by a double-antibody sandwich technique. 
The enzyme immunoassay (EIA) kits were obtained from Bertin Pharma (Montigny-le-
Bretonneux, France; A05106 and A05119, respectively).
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Blood collection, AeBSF treatment, and storage
Overnight fasting venous blood samples for the measurement of plasma AG and plasma 
UAG were withdrawn and collected in EDTA tubes. One 6 mL EDTA tube per patient or 
control was collected. 
Immediately after withdrawal, AEBSF (dilution 1:100) was directly added to all blood 
samples to prevent des-acylation of AG (3,35). Whole blood was carefully mixed by in-
version and stored on water ice (4°C) until centrifugation at 2,500 g at 4°C for 5 minutes. 
Plasma of these venous blood samples was then rapidly aliquoted, four 1.5 mL Eppen-
dorf tubes with 300 mL each. All plasma samples were stored at –80°C until the assay 
was performed. AEBSF was stored for a maximum of 1 month after dilution.
Acylated and unacylated ghrelin eiAs 
After thawning on ice, plasma samples of all NET patients (N=28) and sex- and age-
matched controls (N=28) were centrifuged for 1 minute at 1,500 g, 4°C and kept on ice 
before transferring to the assay plates. All samples were measured in duplicate (50 µL/
well) according to the manufacturer’s protocol (3).
A cubic polynomial fitting was used to determine concentrations from the calibra-
tion curves. This resulted in r2 values >0.99 in the majority of the assays. The intra-assay 
percent coefficient of variation (%CVs) for AG was 5.8 and for UAG 1.8. Interassay %CVs 
for AG was 14.7 and for UAG 17.3.
immunohistochemistry 
Protein expression of total ghrelin was investigated in a small intestine NET tissue 
sample of one patient. Normal stomach tissue was used as a positive control. Mounted 
sections were deparaffinized, blocked for endogenous peroxidase activity, and rinsed 
with water. Following antigen retrieval, sections were incubated overnight at 4°C with 
the antiacylated ghrelin antiserum (N-terminal antibody [#404,4-4]; dilution 1:2,000), 
which was kindly provided by Professor Hiroshi Hosoda. Next, sections were incubated 
with Brightvision poly-HRP-Anti Ms/Rb/Rt IgG kit (Immunologic, Duiven, The Nether-
lands), and the peroxidase activity was developed with 0.07% 3,3-diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Finally, 
sections were counterstained with hematoxylin. 
Clinical and tumor characteristics
Clinical data of NET patients, including age at diagnosis, sex, primary tumor location, 
carcinoid syndrome, baseline serum CgA levels, baseline serum NSE levels, ENETS TNM 
classification, Ki-67 proliferation index, grading, and prior incomplete surgery, were col-
lected from patient’s medical records.  
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Statistical analysis
Analyses were performed using SPSS software (version 21 for Windows; SPSS) and 
GraphPad Prism® version 6.04 (GraphPad Software). Comparisons between NET patients 
and controls were analyzed by Wilcoxon signed-ranks tests, Mann-Whitney U tests, and 
Fisher’s exact tests. Correlation analyses were done using Spearman’s rank correlation 
test. The results are expressed as median±interquartile range (IQR). P-values of <0.05 
were considered to be statistically significant. 
ReSultS
Characteristics of the NET patients and their tumors are summarized in table 1. 
Patients with NETs were matched with their controls by age and sex. Patients had a 
median age of 57.5 years (IQR: 50.3–66.5) and controls 58.0 years (IQR: 50.0–64.0). 
Plasma AG and UAG levels in NET patients (N=28) and their sex- and age-matched 
controls (N=28) are shown (Figure 1). Levels of plasma AG (Figure 1A) and plasma UAG 
(Figure 1B) showed a wide range in both patients and controls. Healthy controls had 
‘reference levels’ of AG that ranged from 10 to 273 pg/mL and plasma UAG levels of 
8–331 pg/mL. 
Median plasma AG levels in NET patients and controls were 62.5 (IQR: 33.1–112.8) and 
57.2 (IQR: 26.7–128.3, P=0.66), respectively (Figure 1A). Median plasma UAG levels in 
NET patients and controls were 76.6 (IQR: 35.2–121.7) and 64.9 (IQR: 27.5–93.1, P=0.44), 
respectively (Figure 1B). The highest observed AG level of 973.2 pg/mL and highest UAG 
level of 311.2 pg/mL were observed in the same patient with a small intestine NET. 
The AG/UAG ratios in NET patients and the control population are provided (Figure 
1C). The median AG/UAG ratios in NET patients were 1.1 (IQR: 0.7–1.6), which were not 
significantly different from the median AG/UAG ratios in controls (1.0, IQR: 0.7–2.0, 
P=0.86). 
Figure 2A shows the primary tumor localization in NET patients and the distribution 
of plasma AG. Plasma UAG levels are shown in Figure 2B, and AG/UAG ratio in Figure 2C. 
All data are expressed as median±interquartile range (IQR). 
In Figure 3A, tumor grading in NET patients and the distribution of plasma AG is 
shown. Plasma UAG levels and tumor grading are shown in Figure 3B, and the AG/UAG 
ratio in Figure 3C. All data are expressed as median±interquartile range (IQR). 
There were no significant differences in plasma AG levels (P=0.60), plasma UAG levels 
(P=0.55), and AG/UAG ratio (P=0.53) between NET patients who did not undergo surgery 
and those who did undergo surgery with incomplete tumor removal.
We found no statistically significant correlations in NET patients between plasma AG, 
UAG, and AG/UAG ratios versus biochemical and clinical parameters with the exception 
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of AG and AG/UAG ratio versus age at diagnosis (ρ=–0.47, P=0.012; P=0.46; ρ=–0.50, 
P=0.007) and AG/AUG/ratio versus baseline CgA levels (P=0.88, P=0.15; ρ=–0.44, 
P=0.019): sex (P=0.46, P=0.41, P=0.41), primary tumor location (P=0.41, P=0.38, P=0.19), 
carcinoid syndrome (P=0.46, P=0.41, P=0.41), baseline serum NSE levels (P=0.47, P=0.36, 
P=0.10), ENETS TNM classification (P=0.39, P=0.39, P=0.39), Ki-67 proliferation index 
table 1 Patient and tumor characteristics (N=28). Data are expressed as median±interquartile range (IQR).
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Figure 1 Plasma acylated ghrelin (AG), plasma unacylated ghrelin (UAG), and acylated ghrelin/
unacylated ghrelin (AG/UAG) ratio in Caucasian, non-obese, non-diabetic NET patients (N=28) versus 
sex- and age-matched healthy Caucasian, non-obese, non-diabetic controls (N=28). Data are expressed as 
median±interquartile range (IQR).
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Figure 2 Primary tumor localization in patients with neuroendocrine tumors (NETs), and the distribution 
of plasma acylated ghrelin (AG), plasma unacylated ghrelin (UAG), and acylated ghrelin/unacylated ghrelin 
(AG/UAG) ratio. Data are expressed as median±interquartile range (IQR).
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Figure 3 Plasma acylated ghrelin (AG) and plasma unacylated ghrelin (UAG) in Caucasian, non-obese, 
non-diabetic NET patients (N=28) distributed according to tumor grading. Data are expressed as 
median±interquartile range (IQR).
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(P=0.92, P=0.99, P=0.65), grading (P=0.40, P=0.40, P=0.86), prior incomplete surgery 
(P=0.47, P=0.41, P=0.42). 
Immunohistochemistry was performed on a small intestine NET tissue sample of the 
patient with the highest plasma AG and UAG levels. Staining showed no immunoreac-
tive NET cells for ghrelin (Figure 4).
            
        
 
A B 
 C D 
Figure 4 Immunohistochemistry: section of normal stomach tissue (panel A, magnification 10×), immuno-
histochemical staining of ghrelin on normal stomach tissue (panel B, magnification 10×), section of small 
intestine NET tissue (panel C, magnification 20×), and immunohistochemical staining of ghrelin small intes-
tine NET tissue (panel D, magnification 20×). The scale bar is set on 1 mm.
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diSCuSSion
This is the first study in which we measured fasting plasma acylated and unacylated 
ghrelin levels in a series of Caucasian, non-obese, non-diabetic NET patients and healthy 
sex- and age-matched Caucasian, non-obese, non-diabetic controls, using a sensitive 
assay. 
Recently, we published the results of a non-interventional study in which we com-
pared two different, commercially available, ELISA formats of AG and UAG in venous 
plasma stabilized or not with 4-(2-aminoethyl) benzenesulphonyl fluoride (AEBSF) and 
stored for 0-6 months at -20°C or -80°C (3). We observed that when measured in AEBSF-
stabilized plasma, the AG/UAG ratio is markedly higher than previously described and 
that UAG is a physiological component of the circulation. This highlights the importance 
of immediately stabilizing blood samples on collection for determination of both AG and 
UAG concentrations and provides a valuable tool for their measurement in physiological 
and interventional studies (3). 
Trivedi and co-workers (36) showed that AEBSF may inhibit acetylcholinesterase 
(AChE) activity from the kits and thus may change AG levels. However, this problem of 
AEBSF suppressing AChE activity is circumvented using the applied processing method 
and Bertin Pharma EIA kits described by Delhanty and co-workers (3). Therefore, it is 
unlikely that because of technical issues, AG and UAG overlap and have almost the same 
reference range in both controls and NET groups.
Using a AEBSF-stabilized assay, our results are of interest as we found no significant 
differences in plasma AG levels and plasma UAG levels between NET patients and their 
matched controls. Therefore, we are quite certain that fasting plasma AG and UAG levels 
are no suitable diagnostic biomarkers in patients with NETs. Although the study was 
performed with a relatively small group of NET patients, we suspect that lack of power 
does not play a major role in our study.
We have also shown in this paper that incorrect processing of blood samples leads to 
raised UAG levels likely through conversion of AG to UAG. Also, we get roughly similar 
low levels of AG and UAG, and AG/UAG ratios to that described by Tong and co-workers 
(37) using a different two-site sandwich ELISA that does not use AChE as an indicator.
We observed in our series of NET patients significant negative correlations of AG and 
the AG/UAG ratio versus age at diagnosis. These data are in accordance with the obser-
vation of an age-dependent decline of AG concentrations found in men by Nass and 
co-workers. Additionally, we detected in NET patients a significant negative correlation 
of the AG/AUG ratio versus baseline CgA levels. However, these AG/UAG ratios were not 
significantly different between patients and controls. Our hypothesis is that AG/UAG 
ratios reflect a favorable metabolic status for NETs. AG/UAG ratio were not significantly 
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different between users of proton pump inhibitors (PPIs) and patients not taking PPIs 
(P=0.42). 
Healthy controls had ‘reference levels’ of AG that ranged from 10 to 273 pg/mL and 
plasma UAG levels of 8–331 pg/mL. This is not an unusual finding in fasted subjects. For 
example, Liu and co-workers (4) find a range of 43-366 pg/mL for AG in four volunteers 
using a similar method of blood sample stabilization. 
In one NET patient, the fasting plasma AG and UAG levels of 973.2 pg/mL and 311.2 
pg/mL, respectively, exceeded the control ’reference values’ of plasma AG and plasma 
UAG. 
This particular 37-year-old male patient is the first case report of hyperghrelinemia 
associated by a small intestinal NET. He has a stage IIA, grade 2 NET that was found 
accidently after a short period of abdominal pain and fever. At the time of referral, he 
had no other clinical symptoms. Laboratory examination showed a normal baseline CgA 
level and normal 24-hours urinary 5-hydroxyindoleacetic acid  (5-HIAA) excretion, but 
an elevated baseline NSE level (21.1 µg/L, maximum reference value: 16.2 µg/L). IHC 
on his small intestinal NET biopsy showed no immunoreactivity for ghrelin, however. 
This finding suggests that the NET does not seem to be directly responsible for the 
hyperghrelinemia. Although immunohistochemical staining on a non-representative 
incidentally ghrelin-negative tumor area from a tumor with ghrelin in other areas could 
not be excluded.
In the literature, only 11 NET patients with elevated total and/or acylated  ghrelin 
levels have been described (23-27). Of these patients, only one patient had clinical 
symptoms of hypersecretion of vasoactive products by the NET. This particular patient 
was especially suffering from diarrhea, tiredness, and anemia, and he developed diabe-
tes mellitus as well. 
According to the authors, these symptoms were caused by the patient’s ghrelinoma. 
However, overproduction of other more common hormones including gastrin, glucagon, 
vasoactive intestinal peptide, and 5-hydroxyindoleacetic acid, which could explain the 
signs and symptoms were not excluded. Therefore, we could not confirm that ghrelin 
overproduction is of clinical importance and a ‘ghrelinoma syndrome’ probably does not 
exist. This is based on our finding that plasma AG and UAG levels are not significantly 
different between sex- and age-matched healthy individuals and NET patients. In ad-
dition, we found no significant correlations between plasma AG and UAG levels versus 
biochemical and clinical parameters. We suggest that the elevated AG and UAG levels 
in the particular NET patient were caused by non-tumoral-related processes in which 
ghrelin plays a role. 
In conclusion, we observed that, using a sensitive AEBSF-stabilized ghrelin assay, 
fasting plasma AG and UAG are useless as clinical diagnostic biomarkers in patients with 
a NET. 
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ABStRACt
introduction: Chromogranin A (CgA) and the Ki-67 proliferation index are considered as 
important biochemical and pathological markers for clinical behavior of gastroentero-
pancreatic neuroendocrine tumors (GEP NETs), respectively. The IGF system has been 
suggested as an important regulator of GEP NET proliferation and differentiation. A pos-
sible relationship between serum CgA (sCgA), Ki-67 proliferation index, and expression 
of IGF-related genes in patients with GEP NETs has not been demonstrated yet. 
objectives: This study investigates the relationship between sCgA, the Ki-67 prolifera-
tion index, and the expression of IGF-related genes in GEP NET tissues and their relation 
with 5-year survival. 
methods: Tumor and blood samples from 22 GEP NET patients were studied. Tumoral 
mRNA expression of IGF-related genes (IGFs: IGF1, IGF2; IGF receptors: IGF1R, IGF2R; 
insulin receptors: subtype A [IR-A] and B [IR-B]; IGF-binding proteins [IGFBPs]: IGFBP1, 
IGFBP2, IGFBP3 and IGFBP6) was measured using quantitative RT-PCR. Ki-67 prolifera-
tion index was determined using immunohistochemistry. 
Results: sCgA was measured with ELISA. Five-year survival in patients with non-elevated 
sCgA (N=11) was 91 versus 46% in patients with elevated sCgA (N=11) (P=0.006). IR-A 
mRNA expression was significantly higher in tumors obtained from patients with 
elevated sCgA than in those from patients with non-elevated sCgA (6.42±2.08 versus 
2.60±0.40; P=0.04). 
Conclusions:  This data suggests that sCgA correlates well with 5-year survival of GEP 
NET patients, and that IR-A mRNA expression correlates well with tumor mass in GEP 
NET patients. 
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intRoduCtion 
Gastroenteropancreatic neuroendocrine tumors (GEP NETs) are rare and heterogeneous 
tumors which may vary according to their biological, functional and clinical behavior 
(1). Chromogranin A (CgA) and the Ki-67 proliferation index are considered as important 
biochemical and pathological markers, respectively, for GEP NET clinical behavior. The 
insulin-like growth factor (IGF) system has been suggested as an important regulator 
of GEP NET proliferation and differentiation (2). Up to present, a possible relationship 
between serum CgA (sCgA), the cellular expression of the Ki-67 protein, and the IGF-
related genes has not been studied in GEP NETs. 
Deregulation of the IGF system, a complex network involved in cell growth and 
metabolic functions in normal tissues and tumors, plays an important role in the patho-
physiology of GEP NETs (2). The IGF system consists of different IGF-related genes: two 
ligands (IGF1 and IGF2), two IGF receptors (IGF1R and IGF2R), two insulin receptors (IR-A 
and IR-B), and six IGF-binding proteins (IGFBPs). Upon binding to the IGF1R and IR-A, 
IGFs predominantly generate mitogenic effects. Binding to IR-B predominantly exerts 
metabolic effects (3,4). Almost all IGFs are bound to one of the six high-affinity IGFBPs 
which all differ with regard to their IGF inhibiting and potentiating actions (4-7). The 
functions of IGFBP1, IGFBP2, IGFBP3, and IGFBP6 have been well-characterized (6). 
The Ki-67 proliferation index is generally used for grading of NETs (8-10). The ENETS/
AJCC/WHO 2010 grading system consists of three categories: Grade 1 (G1)=Ki-67 pro-
liferation index ≤2%, G2=Ki-67 proliferation index 3-20%, and G3=Ki-67 proliferation 
index >20% (8,9,11,12). This grading system has been shown to have relevant prognos-
tic consequences and has been used for decision making with regard to therapeutic 
options in GEP NET patients (13,14).
Another important characteristic of GEP NETs is the presence of the CgA protein. CgA 
is co-secreted by GEP NET cells in the bloodstream with other hormones or peptides 
(15). CgA is the best available circulating parameter in the follow-up of tumor mass in 
GEP NET patients (16). 
The main aim of our research was to investigate relationships between sCgA levels 
in GEP NET patients, cellular Ki-67 proliferation index, and the mRNA expression of IGF-
related genes in their GEP NET tissues and to correlate this with their 5-year survival.
SuBjeCtS And methodS 
Patients with a GeP net and tissue samples
A total of 22 GEP NET tissue samples from 22 non-consecutive GEP NET patients were 
collected before the start of any non-surgical therapy. The diagnosis of GEP NET was 
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based on clinical, biochemical, radiological, and histopathological characteristics. After 
tumor excision or biopsy, these tissue samples were immediately frozen in liquid nitro-
gen and stored at –80°C. The other tissues were obtained from the Erasmus MC Tissue 
Bank. These specimens were stored according to a standard procedure (17). 
All patients gave written informed consent before inclusion in the studies, which were 
approved by the Medical Ethics Committee of the Erasmus MC, Rotterdam. 
Biochemical parameters
Blood samples for the determination of sCgA were obtained at the time of diagnosis of 
the GEP NET (baseline). The sCgA levels were measured using a commercially available 
ELISA method (CIS Bio International, Gif-sur-Yvette cedex, France; upper limit of normal 
[ULN] 94 µg/L). 
‘Non-elevated’ sCgA was defined as ≤2× the ULN (≤188 µg/L), and ‘elevated’ sCgA was 
defined as >2× ULN (>188 µg/L). These definitions were based on a previous publication 
and were selected to maximally exclude other confounding factors which might have 
caused (slight) elevations of sCgA (18).
Ki-67 immunohistochemical staining
Immunohistochemical analysis for Ki-67 was performed on 4 μm thick paraffin-embed-
ded tissue sections according to the standardized and optimized benchmark procedure 
(Benchmark Ultra, Ventana, Tucson, AZ, USA). Pretreatment was performed with CC1 
buffer for 64 minutes at 97°C. Primary monoclonal mouse antibodies against Ki-67 
(clone MIB1, 1:200 dilution; DAKO, Glostrup, Denmark) were incubated for 32 minutes 
at 36°C, and were detected by a high-sensitive detection kit (UltraView Universal DAB 
Detection kit).
The Ki-67 proliferation index in GEP NET samples was expressed as the percentage 
of Ki-67 immunopositive NET cells. The counting procedure was performed by three 
experienced investigators according to the published guidelines (8,9,12).
In addition, all GEP NET tissue samples were classified according to the ENETS/AJCC/
WHO 2010 grading system: Grade 1 (G1)=Ki-67 proliferation index ≤2%, G2=Ki-67 
proliferation index 3-20%, and G3=Ki-67 proliferation index >20% (8,9).
Real-time quantitative PCR
For mRNA expression experiments, total RNA of GEP NET tissues was isolated with the 
ready-to-use High Pure RNA Isolation Kit (Roche Diagnostics). The cDNA synthesis and 
real-time quantitative PCR (RT qPCR) were performed according to previously published 
methods (19). Sequences and concentrations of primer-probe sets for all above-men-
tioned genes are listed in the Supplementary table 1, see section on supplementary 
data given at the end of this article. The relative expression of IGF-related genes was 
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calculated using the comparative threshold method, , after efficiency correction of 
target and reference gene transcripts (HPRT) (20,21).
Statistical analysis
Data were analyzed using SPSS software (version 17 for Windows; SPSS, Inc.). Com-
parative statistical evaluations were performed by Mann-Whitney U tests. Correlation 
analysis was accomplished using Spearman’s rank correlation tests. Survival rates were 
calculated using the Kaplan-Meier method, and groups were compared using the 
log-rank test. Kaplan-Meier curves were plotted using overall survival data. The mRNA 
expression data are reported as mean±SEM. 
ReSultS
Patient characteristics
Patient characteristics are shown in table 1. Fifty percent of the patients had non-elevated 
sCgA levels (N=11) and the others had elevated sCgA (N=11) with median values of 121 
and 894 µg/L respectively. As compared to the elevated sCgA group, there were more fe-
male patients in the non-elevated sCgA group, these patients were younger, their primary 
tumor origins were less often in the small intestine and less distant metastases were found.
table 1 Characteristics of 22 GEP NET patients
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tumor characteristics
In the non-elevated sCgA group, there were four G1 and six G2 patients and, there was 
one G3 patient. In the elevated sCgA group there were eight G1 and three G2 patients 
(table 2).
In the non-elevated sCgA group, four patients were classified as ENETS stage IIIB and 
the other seven patients were classified as ENETS stage IV. In the elevated sCgA group, 
two patients were classified as ENETS stage IIIB and the other nine patients were classi-
fied as ENETS stage IV.
table 2 GEP NET tissue characteristics
 
 
 
 
 
Five-year survival of GeP net patients
In Figure 1, the 5-year survival of 22 GEP NET patients categorized according to non-
elevated and elevated sCgA is shown. There was a significant shorter 5-year survival in 
the elevated sCgA group as compared to the non-elevated sCgA group (46 versus 91%; 
P=0.006). 
In the elevated and non-elevated sCgA groups, no statistical significant correlations 
could be found between the mRNA expression levels of the different IGF-related genes 
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and 5-year survival. Also, no statistical signifi cant correlation could be demonstrated 
between the Ki-67 proliferation index and the 5-year survival in these two groups (data 
not shown). 
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Figure 1 Five-year survival in 22 gastroenteropancreatic neuroendocrine tumor (GEP NET) patients divided 
according to those with non-elevated sCgA (≤2× ULN, N=11, solid line) versus elevated (>2× ULN, N=11, 
dashed line; P=0.006) sCgA.
tumoral mRnA expression of iGF-related genes in GeP net samples
In table 3, the tumoral mRNA expression levels of IGF-related genes in the non-elevated 
and elevated sCgA groups are shown. There was a signifi cant higher tumoral mRNA 
expression for IR-A in the elevated sCgA group compared with the non-elevated sCgA 
group (2.60±0.40 versus 6.42±2.08, P=0.04). 
Correlation between iGF-related genes and Ki-67 proliferation index
No statistical signifi cant relationship between the Ki-67 proliferation index and mRNA 
expression of IGF-related genes could be demonstrated (data not shown). 
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diSCuSSion
To our knowledge, this is the first study in which the relationship between sCgA levels, 
the tumoral Ki-67 proliferation index, and the tumoral expression of IGF-related genes 
has been evaluated in GEP NET patients.
Survival analysis showed a significantly shorter 5-year survival in patients with 
elevated sCgA levels compared with those with non-elevated sCgA levels. sCgA levels 
generally correlate well with tumor mass. These findings have already been confirmed 
by other groups (22,23). 
In the elevated and non-elevated sCgA groups, no statistical significant correlations 
could be found between the mRNA expression levels of the different IGF-related genes 
and 5-year survival. Also, no statistical significant correlation could be demonstrated 
between the Ki-67 proliferation index and the 5-year survival in these two groups. 
However, other studies have shown a significant shorter survival in grade 3 GEP NET 
patients (Ki-67 index >20%) (24,25). A possible explanation for our discrepant results 
could be the very small sample size of these heterogeneous tumor entities and the short 
follow-up. 
Our study showed significant higher tumoral mRNA expression of the insulin recep-
tor A (IR-A) in GEP NET patients with elevated sCgA compared with those patients with 
non-elevated sCgA. Increased expression of the IR-A, a mitogenic variant of the IR, is also 
table 3 Tumoral mRNA expression levels of different IGF-related genes in GEP NET tissue samples of pa-
tients with non-elevated and elevated sCgA levels
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found in tumors arising in the colon, breast, thyroid, prostate, and fibrous tissues (26-32). 
Until present, these findings have not been reported for GEP NETs. 
As sCgA levels correlate well with tumor bulk, our data therefore suggest that tumor 
mass correlates to tumoral IR-A expression in patients with GEP NETs. 
No significant difference in tumoral mRNA expression levels was observed for all other 
IGF-related genes between patients with non-elevated versus patients with elevated 
sCgA. Although we have no obvious explanation for these findings, we suggest that IR-A 
expression has predominantly tumor-stimulating functions in more advanced tumors in 
contrast to other IGF-related genes, which are involved in the pathophysiology of GEP 
NETs regardless of the tumor stage.
In conclusion, our study could not demonstrate a relationship between IGF-related 
genes and the Ki-67 proliferation index in GEP NET tissues. We could confirm previous 
observations supporting a negative correlation between sCgA levels and 5-year survival. 
We could not demonstrate a relationship between the tumoral Ki-67 proliferation index 
and sCgA. However, our study results showed a relation between cellular IR-A mRNA 
expression and tumor mass. 
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Supplementary table 1 Overview with the used sequences of forward and reverse primers and, probes 
for IGF-related genes. Concentrations (nmol/L) used for primer-probe sets and, efficiencies are also listed.
 
Abbreviations: Conc=used concentration (nmol/L), EFs=efficiency factors
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ABStRACt
introduction: It is unknown whether tumoral somatostatin receptor subtype 2a (sst2a) 
immunohistochemistry (IHC) has additional value compared to somatostatin receptor 
scintigraphy (SRS) uptake using OctreoScan® in predicting response to peptide recep-
tor radiotherapy using 177Lu-octreotate (PRRT) in patients with gastroenteropancreatic 
neuroendocrine tumors (GEP NETs). 
objectives: Of this study were 1) to establish the percentage of sst2a immunopositivity 
in GEP NET samples of PRRT-treated patients, 2) to determine the relationship between 
best GEP NET response using RECIST 1.0 criteria 1 year after PRRT and tumoral sst2a 
IHC, and 3) to compare characteristics of patients with sst2a IHC-negative and -positive 
tumors. 
methods: All 73 consecutive patients were selected for PRRT based on a positive SRS. 
Radiological response was scored according to RECIST 1.0 criteria. Sst2a status was de-
tected on tumor samples by IHC. 
Results: In total, 93% of GEP NET samples showed sst2a IHC-positivity. No statistically 
significant relationship was observed between in vitro sst2a expression and in vivo best 
GEP NET response 1 year after PRRT (P=0.47). Sex, primary tumor site, disease stage, 
ENETS TNM classification, Ki-67 index, highest serum chromogranin A level, and highest 
neuron-specific enolase level were not significantly different between patients with 
negative and positive sst2a tumoral IHC with the exception of age at diagnosis (P=0.007). 
Conclusions: Sst2a IHC on tumor samples has no additional value compared to SRS 
uptake using OctreoScan® in predicting tumor response after PRRT.
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intRoduCtion 
The majority of gastroenteropancreatic neuroendocrine tumors (GEP NETs) express 
somatostatin (sst) receptor subtypes. The somatostatin receptor subtype 2a (sst2a) is the 
most common receptor subtype in GEP NETs and is expressed in about 90% of these 
tumors (1-4). Sst2a can be used both as a diagnostic and as a therapeutic target in pa-
tients with GEP NETs. Although sst2a can be visualized in vivo by sst receptor scintigraphy 
(SRS) using 111In-pentetreotide scintigraphy (OctreoScan®) and in vitro on tumor samples 
using immunohistochemistry (IHC), there is no consensus on how best to identify sst2a 
expression on GEP NETs (5). 
Peptide receptor radiotherapy with 177Lu-octreotate (PRRT) is increasingly used for the 
palliative treatment of inoperable or metastasized GEP NETs expressing sst2a (6-8). Prior 
to PRRT, uptake on the OctreoScan®, equal or higher than the liver uptake as judged from 
planar images (defined as Krenning scale 2-4), is generally required (9). Of all GEP NET 
patients who receive PRRT, about 80% achieved a partial response or stable disease (9). 
The rest of these patients developed progressive disease following PRRT (9). Therefore, it 
would be helpful if it was possible to determine which patients with GEP NETs will have 
a beneficial response prior to PRRT. 
A strong and positive association between SRS uptake and in vitro sst receptor IHC 
in tumor samples was demonstrated in several studies (10-12). However, the potential 
superiority of IHC in demonstrating tumoral sst2a expression compared to SRS uptake 
in predicting GEP NET response to PRRT has not been studied. Since IHC studies have 
shown that sst2a expression could be demonstrated in approximately 50% of GEP NETs 
which were not visualized by SRS, sst2a IHC could potentially have an advantage (5). 
Therefore, we 1) established the percentage of sst2a immunopositivity in GEP NET 
samples of patients who had been treated to PRRT, 2) studied the relationship between 
the best GEP NET response at 1 year after PRRT and tumoral sst2a expression, and 3) 
compared 8 characteristics of GEP NET patients with negative and positive sst2a IHC in 
tumors: sex, age at diagnosis, primary tumor site, disease stage, ENETS TNM classification 
(13,14), Ki-67 index, highest serum chromogranin A level, and highest neuron-specific 
enolase level. 
The purpose of this study was to investigate the additional value of tumoral sst2a 
expression using IHC in tumor samples compared to SRS uptake in predicting best GEP 
NET response to PRRT after 1 year. 
102 Chapter 6
mAteRiAlS And methodS 
Patients with GeP nets 
We retrospectively recruited 73 GEP NET cases from our Erasmus MC NET database. All 
these patients were selected for PRRT based on the fact that they all had a positive SRS 
and Krenning scale 2-4 uptake. Patients were eligible if they had undergone a baseline 
CT scan and at least 2 follow-up CT scans at 6 six weeks and 3 or 12 months after 4 com-
pleted treatment cycles with PRRT. In addition, their tumoral sst2a status was determined 
on GEP NET tissue samples, which were obtained prior to PRRT. 
All GEP NET patients treated at the Erasmus MC, Rotterdam, gave written informed 
consent before inclusion in the PRRT study, which was approved by the Medical Ethics 
Committee of the Erasmus MC, Rotterdam. 
tumoral sst2a expression 
Formalin-fixed paraffin-embedded sections of 4 μm were cut and immunostained with 
primary rabbit monoclonal antibody directed against sst2a according to the protocol 
provided by the manufacturer (Bio-Trend, clone SS-8000-RM, dilution 1:25, CC1 buffer, 
BenchMark Ultra strainers; Ventana Medical Systems, Tucson, Ariz., USA) for 64 minutes 
at 97°C. IHC was uniformly performed on all GEP NET samples obtained in the Erasmus 
MC, Rotterdam, between March 2000 and July 2013. 
GEP NET tissue samples were obtained by surgical resection (N=36) or tumor biopsy 
(N=37). Normal human pancreatic tissues served as positive controls. Two investigators 
independently determined the immunoreactivity score (IRS) of the IHC stainings and 
were blinded to the tumor response results. The tumor samples were scored according 
to an intensity score (+1=weak staining; +2=intermediate staining; +3=strong staining) 
and proportion score (0=no positivity; +1=less than 1/3 tumor cell positivity; +2=1/3 to 
2/3 tumor cell positivity; and +3=more than 2/3 tumor cell positivity). The sum of both 
scores was between 0 and 6 (15). 
tumor response 
‘Best GEP NET response at 1 year’ was defined as the best tumor response that was con-
firmed at a second follow-up CT scan. This best GEP NET response was determined on 2 
and, if available, on 3 CT scans that were evaluated at 6 weeks and 3 and/or 12 months 
after the fourth completed cycle of PRRT. 
Target lesions were measured according to RECIST version 1.0 (16). Two trained inves-
tigators independently measured tumor response and scored all GEP NET responses; 
they were blinded to the IHC results. Discrepancies were resolved by a consensus review 
with a third expert.
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definition
SRS using Octreoscan® is a nuclear imaging method in which tumoral sst2a expression is 
visualized using 111In-pentetreotide scintigraphy. 
Statistical analysis 
Analyses were done with non-parametric tests using SPSS software (version 21 for 
Windows; SPSS Inc., Chicago, Ill., USA) and GraphPad Prism® version 6.04 (GraphPad 
Software, San Diego, Calif., USA). Comparative statistical evaluations between groups 
were done by one-way ANOVA, Fisher’s exact tests, and independent-samples t tests. 
Overall survival was calculated using the Kaplan-Meier method, and groups were com-
pared with the log-rank test. Univariate analysis was performed to study the relationship 
between the different patient characteristics and progressive disease. We judged values 
as significant at a P-value <0.05.  
ReSultS 
Sixty-eight patients (93%) with GEP NETs had positive sst2a IHC in their tumor samples. In 
the tumor samples from the remaining 5 patients (7%), sst2a IHC was negative. 
The best GEP NET responses at 1 year after the last PRRT cycle are shown in table 1 
for patients with positive and negative sst2a IHC in their tumor samples. No significant 
relationship was observed between the in vitro sst2a expression and the in vivo best GEP 
NET response 1 year after PRRT (P=0.47). For all GEP NETs and tumor samples, the best 
tumor response 1 year after PRRT and the corresponding IRS of tumoral sst2a expression 
were determined (table 2). 
table 1 Best GEP NET response 1 year after PRRT of patients with positive and negative sst2a immunohisto-
chemical tumor expression
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In Figure 1, IRS’ with the corresponding best GEP NET responses are illustrated. There 
was no significant difference between IRS and best GEP NET response 1 year after PRRT 
(P=0.14). The mean IRS of tumoral sst2a expression for patients with partial response, 
stable disease, and progressive disease was 5±0.5, 3.9±0.2 and 3.7±0.9, respectively. 
PR SD PD
0
2
4
6
IR
S
Figure 1 IRS’ with corresponding best GEP NET response. Data are expressed as means±SEM. PR=partial 
response; SD=stable disease; PD=progressive disease.
There was no statistically significant difference in overall survival between patients 
with positive and negative sst2a IHC in their tumor samples (P=0.91; Figure 2). Patient 
and tumor characteristics including sex, age at diagnosis, primary tumor site, disease 
stage, ENETS TNM classification, Ki-67 index, highest serum CgA level, and highest NSE 
level were compared between patients with sst2a IHC-positive and -negative tumors. 
Patients with negative sst2a IHC in their tumor samples had a significantly lower age at 
diagnosis (P=0.007) as compared to patients with positive sst2a IHC. However, there were 
table 2 Best GEP NET response 1 year after PRRT and corresponding IRS’ of sst2a IHC on tumor samples (N 
= 73)
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no statistically significant differences for the other characteristics between patients with 
positive and negative sst2a IHC. These results are shown in table 3. 
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Figure 2 Overall survival of 73 patients with GEP NETs.
Five of 68 patients (7%) with positive sst2a IHC in their tumor samples and 1 of 5 patients 
(20%) with negative sst2a IHC in their tumor samples developed progressive disease. 
These percentages were not significantly different (P=0.27). The only characteristic 
which significantly predicted progressive disease after PRRT in our study group was an 
advanced disease stage (P=0.0001). 
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diSCuSSion 
We investigated whether there is an additional value of tumoral sst2a IHC in tumor 
samples compared to SRS uptake in predicting GEP NET response to PRRT. Sst2a im-
munopositivity was demonstrated in 93% of the tumor samples from GEP NET patients 
treated with PRRT. These data are in accordance with earlier published data (5). It was 
previously shown that 93% of the GEP NET patients with positive SRS had sst2a or sst5 
expression in their tumors. However, 7% of the tumors which could be visualized using 
table 3 Characteristics of GEP NET patients (N=73)
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SRS had no sst2a expression using IHC (5). No statistically significant relationship was 
observed between tumoral sst2a expression using IHC and best GEP NET response to 
PRRT at 1 year. In addition, there was no significant association between sst2a expression 
using IHC and overall survival in our patient group. However, in other studies, positive 
sst2 expression using IHC was associated with improved overall survival in patients with 
GEP NETs (17,18). Apparently, tumoral sst2a expression is an independent predictor for 
survival but has no greater value than SRS in predicting GEP NET response to PRRT. 
In our study, 5 patients (7%) received PRRT based on sufficient uptake on SRS but had 
negative sst2a IHC in their tumor samples. Other research groups have also found that 
both methods have a high concordance rate in demonstrating sst2a expression (5,19-21). 
Therefore, in countries with no accessibility to an OctreoScan®, IHC could be a useful 
method for the demonstration of tumoral sst2a expression prior to PRRT. 
Our group of 5 patients (7%) with sst2a-negative IHC in their tumor samples all had in 
common that the tumor samples were tissue biopsies. In about half (N=36) of the pa-
tients with positive sst2a IHC, these studies were performed on tumor biopsies. However, 
there could be a sampling error using biopsies from sst2a-negative lesions in a patient 
presenting with both sst2a-positive and -negative lesions. Alternatively, there could be 
a sampling problem using biopsies from non-representative incidentally sst2a-negative 
tumor areas from tumors with abundant sst2a expression in other areas. 
Possible pitfalls in assessing sst2a IHC in vitro could be the reliability of the sst2a anti-
body, a suboptimal IHC procedure, and cross-activity with other antigens. In addition, 
tumoral sst2a receptor levels in the whole tumor were based on IHC performed in only a 
slice of tumor tissue. 
In a study in medullary thyroid carcinoma patients, no correlation could be demon-
strated between tumoral sst expression on IHC and patients’ age. In this series, about a 
half of the medullary thyroid carcinoma samples displayed sst2-positive IHC (22). Another 
study showed no significant difference in median age between GEP NET patients with 
low versus high tumor uptake on SRS (23). Although we found a significantly lower age 
at diagnosis in patients with a negative tumoral sst2a expression, this might be explained 
by the low number of patients in this group. Therefore, we believe that this observation 
was a chance finding and has no clinical significance. 
In only one publication, GEP NET patients with sst2-positive tumors on SRS who were 
treated with PRRT were subdivided into two subgroups: those with progressive disease 
versus those with no progressive disease (24). In this study, the only parameter which 
was significantly different between these two patient groups was baseline tumor pro-
gression. Unfortunately, this parameter was not investigated in our study. 
In three different studies, the percentages of NETs that were sst2a negative on SRS and 
sst2a positive on IHC on tumor samples (sst2a: IHC+/SRS–) varied between 12 and 33%. 
The percentages NETs that were sst2a positive on SRS but sst2a negative on IHC on tumor 
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samples (sst2a: IHC–/SRS+) varied between 0 and 15% (10,25,26). Other sst receptor 
subtypes than sst2 showed no significant relationship between IHC on tumor samples 
and in vivo SRS uptake on Octreoscan® (10,25,26). Since these receptor subtypes are less 
frequently expressed on GEP NETs as compared to sst2a, we focused only on sst2a IHC in 
our study (1-4).
About 10% of all SRS' for the localization and staging of GEP NETs can show false-
positive uptake, mostly in non-tumor-related areas (27). Potential sources for this false-
positive uptake on SRS are: thyroid disease, breast disease, granulomatous lung disease, 
inflammatory diseases like respiratory infections, recent operation sites, lymphomas, 
meningiomas, paragangliomas, and accessory spleens (28-32). None of these causes 
could explain SRS positivity in our 5 patients with negative tumoral sst2a IHC. 
The radioligands pentetreotide and octreotate, which are used for the Octreoscan® 
and PRRT, respectively, have the highest binding affinity for sst2a but also bind with 
lower affinity to sst3 and sst5 (33). Theoretically, it is possible that SRS visualized sst3 and/
or sst5 in the patients with negative tumoral sst2a IHC. 
In conclusion, we have shown that the assessment of tumoral sst2a expression using 
IHC has no additional value compared to SRS using OctreoScan® in predicting the in 
vivo GEP NET response to PRRT. Ninety-three percent of our GEP NET patients with a 
positive SRS and Krenning scale 2-4 uptake prior to PRRT had a positive sst2a tumor 
sample staining on IHC. We, therefore, suggest that if there is no accessibility to the 
OctreoScan®, sst2a IHC in a tumor sample is also a suitable investigational tool for the 
selection of suitable patients for PRRT.
Further research is needed to investigate other potential markers that can predict best 
GEP NET response to PRRT. 
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ABStRACt 
introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) express 
insulin-like growth factor (IGF)-related factors (IGF1, IGF2; insulin receptor [IR]-A, IR-B; 
IGF-binding protein [IGFBP]1–3) as well as somatostatin (sst) and dopamine receptor 
type 2 (D2). 
objectives: To 1) compare mRNA expression of IGF-related factors in human pancreatic 
NET (panNET) cell lines with that in human GEP NETs to evaluate the usefulness of these 
cells as a model for studying the IGF system in GEP NETs, 2) determine whether panNET 
cells produce growth factors that activate IR-A, and 3) investigate whether somatosta-
tin analogs (SSAs) and/or dopamine agonists (DAs) influence the production of these 
growth factors. 
methods: In panNET cells (BON1 and QGP1) and GEP NETs, mRNA expression of IGF-
related factors was measured by quantitative real-time PCR. Effects of the SSAs octreo-
tide and pasireotide (PAS), the DA cabergoline (CAB), and the dopastatin BIM-23A760 
(all 100 nM) were evaluated at the IGF2 mRNA and protein level (by ELISA) and regarding 
IR-A bioactivity (by kinase receptor activation assay) in panNET cells. 
Results: PanNET cells and GEP NETs had comparable expression profiles of IGF-related 
factors. Especially in BON1 cells, IGF2 and IR-A were most highly expressed. PAS+CAB 
inhibited IGF2 (–29.5±4.9%, P<0.01) and IGFBP3 (–20.0±4.0%, P<0.01) mRNA expres-
sion in BON1 cells. In BON1 cells, IGF2 protein secretion was significantly inhibited with 
BIM-23A760 (–23.7±3.8%). BON1- but not QGP1-conditioned medium stimulated IR-A 
bioactivity. In BON1 cells, IR-A bioactivity was inhibited by BIM-23A760 and PAS+CAB 
(–37.8±2.1% and –30.9±4.1%, respectively, P<0.0001). 
Conclusions: 1) The BON1 cell line is a representative model for studying the IGF system 
in GEP NETs, 2) BON1 cells produce growth factors (IGF2) activating IR-A, and 3) com-
bined sst and D2 targeting with PAS+CAB and BIM-23A760 suppresses IGF2-induced IR-A 
activation.
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intRoduCtion 
The insulin-like growth factor (IGF) system is considered to play an important role in 
gastroenteropancreatic neuroendocrine tumors (GEP NETs) (1-3). The IGF system is 
involved in cell metabolism, growth, differentiation and survival (4-6). Known proteins 
that are part of this IGF system include IGF1 and IGF2, IGF receptor 1 (IGF1R), IGF2R, 
insulin receptors (IR) isoform A (IR-A) and B (IR-B), and IGF-binding proteins 1, 2 and 3 
(IGFBP1-3). 
The tumor promoting role of IGF1, IGF2, and the IGF1R in cancer has previously been 
explored (7-9). IGFs can also exert their effects after binding to IR-A and IR-B. IR-A has 
mainly mitogenic effects and IR-B is involved in metabolic activities (7,9). We have 
recently shown that, compared to IGF1R and IR-B, IR-A was the most predominantly ex-
pressed receptor in GEP NETs (10). In addition, we have shown that BON1 pancreatic NET 
(panNET) cells produce growth factors (IGF2) that stimulate the IGF1R in an autocrine/
paracrine manner (11). To the best of our knowledge, the functional role of IR-A has not 
been studied in this respect. 
GEP NET cells also express somatostatin receptors (sst) and dopamine type 2 receptors 
(D2), which are known to inhibit the secretion of many factors/hormones (12-14). Sst and 
D2 are highly, but variably, expressed in most GEP NETs, and their expression may depend 
on the stage of tumor dedifferentiation (12-14). Of the sst, sst2a is the most abundantly 
expressed subtype. Somatostatin analogs (SSA) such as octreotide (OCT) and lanreotide, 
which act primarily via sst2, are used in the treatment of GEP NETs and were previously 
shown to control symptoms related to the overproduction of hormones and bioactive 
substances, and more recently to control tumor progression as well (15,16).  
In theory, targeting sst and/or D2 could result in lowering of the production of factors 
that interact with IR-A. Heterodimerization of sst and D2 can result in receptors with an 
enhanced functional activity (17,18). As such, the combination of single-receptor ligands 
as dopamine agonists (DAs) and SSAs, and also somatostatin-dopamine (SS-DA) chimeric 
compounds, could have synergistic effects by targeting these co-expressed receptors in 
GEP NETs. Beneficial effects of chimeric compounds and multiligand SSAs were already 
shown in a subgroup of patients with NETs and growth hormone/prolactin-secreting 
pituitary adenomas (19-22). In one study, antiproliferative effects were observed in the 
small intestine NET (siNET) cell line KRJ1 after incubation with multiligand SSAs but not 
with SS-DA, because KRJ1 cells lack D2 expression (23).
To the best of our knowledge, there are no studies in GEP NET cells in which the effect 
of targeting sst and D2 on the production of IGF-related factors has been evaluated. The 
main aims of our study were: 1) to compare the expression of the IGF system in human 
panNET cells (BON1 and QGP1) and a series of GEP NET tissues, and to investigate in 
which aspect the human panNET cell models reflect the human IGF system in GEP NETs; 
116 Chapter 7
2) to evaluate whether panNET cells produce growth factors that are able to activate 
IR-A, and 3) to investigate whether SSAs and/or DAs can influence the production of 
these growth factors.
mAteRiAlS And methodS 
Cell lines and culture conditions
For functional experiments, we used the human panNET cell lines BON1 and QGP1. The 
BON1 cell line that was established from a lymph node metastasis of a human functional 
panNET (24) and was a kind gift of Dr. C.M. Townsend (The University of Texas Medical 
Branch, Galveston, Tex., USA). The QGP1 cell line, which was derived from a pancreatic is-
let cell carcinoma, was obtained from the Japanese Collection of Research Bioresources 
(JCRB) Cell Bank (25).
In kinase receptor activity (KIRA) bioassays, we utilized the human embryonic kidney 
(HEK) cell-line Flip-in™-293 from Invitrogen (Breda, The Netherlands), which was stably 
transfected with plasmids (pNTK2) containing a cDNA insert of the human IR-A gene, 
using Fugene® transfection reagens according to manufacturer’s protocol (26). The IR-A 
plasmid was kindly provided by Axel Ullrich (Martinsried, Germany). 
Cell lines were routinely cultured in 75 cm2 cell culture flasks from Corning (Amster-
dam, The Netherlands). BON1 cells were cultured in culture medium consisting of a 
1:1 mixture of DMEM and F-12K medium, supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, 0.5 mg/L fungizone, and 2 mM L-glutamin. QGP1 cells were 
cultured in RPMI 1640 culture medium enriched with 10% FBS and 100 U/mL penicillin. 
HEK IR-A cells were grown in DMEM containing 10% FBS, 100 U/mL penicillin, 100 µg/L 
streptomycin, and 500 µg/mL geneticin from Invitrogen. 
The cell lines were passaged weekly by trypsinization with trypsin/EDTA (0.05%/0.53 
mM) and resuspended in medium. Trypan blue staining was used to assess cell viability, 
which always exceeded 95%. Before plating, cells were counted microscopically in a 
standard hemocytometer. Periodically, cells were confirmed as free of Mycoplasma. The 
cell culture conditions in the incubator were kept at a humidified atmosphere of 5% CO2 
at 37°C.
Cell experiments for mRnA expression and iR-A bioactivity (KiRA assay)
For all mRNA expression and IR-A bioactivity experiments, both panNET cell lines were 
seeded at a density of 100,000 cells/well in 12-multiwell culture plates (Corning). After 
48 and 72 hours, the media were refreshed with serum-free medium. 
In order to test whether growth factors produced by panNET cells could influence 
tyrosine kinase activity of IR-A, 72-hours conditioned medium of BON1 cells and QGP1 
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cells was collected. Since QGP1-conditioned medium showed no tyrosine kinase IR-A 
bioactivity, we did not further evaluate the effects of SSA/DA on this cell line. Therefore, 
all further experiments were performed with BON1 cells only. 
BON1 cells were incubated for 72 hours without or with SSAs and/or DAs at a concen-
tration of 100 nM. After 72 hours of incubation, supernatant of the cells was collected, 
stored at -20°C, and later used for IR-A bioassays. The same control and treated BON1 
cells were used for total RNA isolation. The samples were stored at –20°C until analysis. 
The ability of BON1-secreted factors to stimulate IR-A phosphorylation was measured 
using an in-house IR-A KIRA assay according to a previously published method (27). 
Bioactivity was expressed relative to a standard curve of insulin. The treatment groups 
were tested in quadruplicate.
test substances
Regarding SSAs, we tested OCT (Novartis Pharma AG, Basel, Switzerland) and the multi-
receptor-binding SSA pasireotide (PAS), also known as SOM230 (28). PAS was a gift from 
Novartis. The DA used was cabergoline (CAB; Pharmacia-Pfizer, New York, N.Y., USA). 
The SS-DA chimeric compound BIM-23A760 was provided by Biomeasure Inc./IPSEN 
(Milford, Mass., USA). Cells were treated with either single drugs or with drug combina-
tions, namely OCT+CAB and PAS+CAB. The sst and D2 binding affinities of all compounds 
are listed in online Supplementary table 1 (for all online supplementary material, see 
www.karger.com/doi/10.1159/000444280) (22,28-33). Stock solutions of SSAs were 
prepared in 0.01 M acetic acid and 0.1% bovine serum albumin. CAB was dissolved in 
70% ethanol. All stock solutions were aliquoted at concentrations of 10-4 M and stored at 
-20°C. For each experiment, fresh working solutions were diluted in serum-free medium. 
GeP net tissues
The diagnosis of a GEP NET was based on both clinical parameters and histology. Sam-
ples of GEP NETs were immediately frozen after surgery in liquid nitrogen and stored 
at –80°C until further analysis. Tissues obtained from the Erasmus MC (MC) Tissue Bank 
were stored according to a standardized protocol (34). Approval from the Medical Ethi-
cal Committee of the Erasmus MC, as well as informed consent to use the tumor tissues 
for research purposes, was obtained. 
Quantitative real-time PCR
Total RNA of  panNET cells and GEP NET samples was isolated to determine mRNA ex-
pression of the IGF-related factors according to the manufacturer’s protocol with a High 
Pure Isolation Kit (Roche Diagnostics, The Netherlands). 
Poly A+ mRNA isolation for detection of sst and D2 mRNA in panNET cells was per-
formed according to a previously used method (35). Sequences and concentrations of 
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the primes and probes that were used have been described previously (10). The synthe-
sis of cDNA and quantitative real-time PCR was conducted as previously described (36). 
The used primer probe sets of all IGF-related factors, including their sequences and 
concentrations, have been previously published (10). Relative mRNA expression of IGF-
related factors was calculated using the comparative threshold method after efficiency 
correction of target and reference gene (HPRT) transcripts (37,38). The tested com-
pounds did not significantly change expression of HPRT after 72 hours of incubation 
(data not shown).
iGF2 protein assay 
To test whether inhibition of IR-A activation could be clarified by modulation of IGF2 
secretion, we used a ‘two-step’ sandwich-type immunoassay with a Non-Extraction IGF-
II Enzyme-Linked Immunosorbent Assay Kit (DSL Germany GMBH-Benelux, Assendelft, 
The Netherlands). The assay was performed according to the protocol supplied by the 
manufacturer. Intra- and interassay coefficients of variability were 5.2 and 6.9%, respec-
tively. 
iGF2 immunohistochemistry
Expression of the IGF2 protein in GEP NET tissues was measured by immunohistochemis-
try (IHC) using a polyclonal goat antibody (1:500; Santa Cruz Biotechnology, Dallas, Tex., 
USA) as described previously (36). The immunoreactivity of IGF2-stained GEP NET tissues 
was interpreted in a semiquantitative manner and expressed as an immunoreactivity 
score (IRS) between 0 and 6 (39). The IGF2 staining and IRS counting procedure were 
done by 2 independent researchers, and any discrepancy was resolved by a consensus 
review. 
Statistical analysis 
For statistical analysis, GraphPad Prism® version 6.04 (GraphPad Software, San Diego, 
Calif., USA) was used. Comparative statistical evaluations between groups were accom-
plished with unpaired t tests and one-way ANOVA followed by Tukey’s tests for multiple 
post hoc comparisons. Correlation analysis was performed using Spearman’s rank corre-
lation tests. Each drug condition of an experiment was tested in quadruplicate, with the 
exception of the IGF2 ELISA, which was done in triplicate. All experiments were carried 
out at least 2 times and gave comparable results. Outliers were excluded by Grubbs’ test 
with the GraphPad QuickCalcs outlier calculator. Data are reported as means±SEM. In all 
analyses, a two-sided P-value of P<0.05 (*P<0.05, **P<0.01) was considered statistically 
significant.
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ReSultS
levels of mRnA expression of sst and d2 in pannet cells
Figure 1A shows mRNA levels of sst and D2 in BON1 cells. The sst subtypes were ex-
pressed in the following order: sst5>sst1>sst2>sst3 (0.57±0.093, 0.47±0.058, 0.081±0.011, 
and 0.036±0.0065). D2 mRNA expression levels were 0.27±0.011. Of all receptors, sst5 was 
expressed most highly.  
In QGP1 cells, the order of expression was the same as in the BON1 cells, but the ex-
pression of sst3 was not detectable sst5: 0.05±0.02; sst1: 0.038±0.022; sst2: 0.005±0; sst3: 
not detectable). D2 in the most highly expressed receptor in QGP1 cells, and is expressed 
at the same level as in BON1 cells (0.16±0.08) (Figure 1B). 
mRnA expression of iGF-related factors in pannet cells
mRNA expression levels of the IGF-related factors were measured in BON1 (Figure 1C) 
and QGP1 cells (Figure 1d). The results are expressed as relative expression (normalized 
to HPRT). In BON1 cells, IGF2 was expressed at the highest level (292.8±34.60). BON1 
cells expressed statistically significant higher mRNA levels of IGF2 than of IGF1 (P<0.01). 
Of the IGF-related receptors, IR-A had the highest mRNA expression level (0.27±0.016). 
IR-A was significantly more highly expressed (14.3-fold) than IR-B (0.27±0.016 versus 
0.019±0.0016, P<0.01). In addition, IR-A was expressed at a higher level (1.2-fold) than 
IGF1R (0.27±0.016 versus 0.22±0.0093, P<0.05). No statistically significant difference of 
mRNA expression levels was observed between the IR-A and IGF2R (0.27±0.016 versus 
0.24±0.019, P>0.05) or between IGF1R and IGF2R (0.22±0.0093 versus 0.24±0.019, 
P>0.05). With respect to IGFBPs, IGFBP2 (0.76±0.034) was expressed at the highest level, 
followed by IGFBP3 (0.35±0.023) and IGFBP1 (0.023±0.0019). 
IGF-related factors were expressed in a relatively comparable pattern in QGP1 cells, 
but their expression levels were considerably lower than in BON1 cells. PanNET IGF2 
(292.8±34.60 versus 0.26±0.15, P=0.01) and IR-A (0.27±0.016 versus 0.064±0.005, 
P=0.0003) were significantly more highly expressed in BON1 cells than in QGP1 cells. In 
addition, in QGP1 cells there was no detectable expression of IGFBP1 and IGFBP3. 
mRnA expression of iGF-related factors in GeP net tissues
The mRNA expression levels of IGF-related factors were investigated in primary human 
GEP NETs originating from the small intestine (N=18; Figure 2A: IGF-related receptors, 
Figure 2C: IGF-related proteins) and pancreas (N=7; Figure 2B: IGF-related receptors, 
Figure 2d: IGF-related proteins).
Expression data on a subset of these GEP NETs were previously reported (10). All genes 
were expressed in highly variable amounts. Of the IGFs, IGF2 was most highly expressed 
(siNET: 3.60±1.31; panNET: 1.05±0.56). IGF2 was expressed at a higher level than IGF1 
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(siNET: 3.60±1.31 versus 0.71±0.20; panNET: 1.05±0.56 versus 0.35±0.25). IR-A was the 
most prominently expressed IGF-related receptor in this series of GEP NET tissues; it 
was expressed at a higher level than IR-B (siNET: 4.34±0.69 versus 1.50±0.42; panNET: 
1.87±0.41 versus 0.47±0.18) and IGF1R as well (siNET: 0.34±0.11; panNET: 0.12±0.06) 
(Figure 2A, B). Although the expression levels varied, overall siNETs and panNETs 
showed mRNA expression patterns of IGF-related factors comparable to those of the 
panNET cell lines. Results of logarithmic gene expression levels are shown.
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Figure 1 mRNA expression profiles of sst and D2 (A, B) and IGF-related factors (C, D) in BON1 (A, C) and QGP1 
cells (B, D), expressed as relative expression normalized to HPRT. For all samples: N=2. ND=Not detectable.
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Receptor bioactivity after stimulation with serum-free conditioned Bon1 
cell medium 
Conditioned medium of BON1 cells stimulated IR-A bioactivity, whereas control, uncon-
ditioned medium did not (Figure 3A). Conditioned medium of QGP1 cells did not show 
any detectable bioactivity of IR-A (data not shown). 
In the IR-A KIRA assay, the strongest inhibition of BON1 conditioned medium-induced 
IR-A bioactivity was observed after treatment for 72 hours with the SS-DA chimera 
BIM-23A760 (-37.8±2.1%, P<0.0001). Other compounds or combinations of compounds 
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Figure 2 mRNA expression patterns of IGF-related receptors (A, B) and proteins (C, D) in siNETs (A, C; N=18) 
and panNETs (B, D; N=7), expressed as log relative expression normalized to HPRT. Horizontal bars represent 
means.
122 Chapter 7
(all tested at 100 nM) that induced a statistically significant decrease in conditioned 
medium-induced IR-A bioactivity were: PAS+CAB (-30.9±4.1%, P<0.0001), OCT+CAB 
(-26.5±2.1%, P<0.01), CAB (-24.1±3.4%, P<0.05), and PAS (-19.4±2.6%, P<0.05). No statis-
tically significant differences in IR-A bioactivity were observed after treatment with OCT 
(-8.0±6.1%). Data, expressed as percentage change from baseline of IR-A activation, are 
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Figure 3 A IR-A bioactivity of unconditioned BON1 cell medium (UM) and supernatant of conditioned 
BON1 cell medium (CM). ND=Not detectable. B IR-A bioactivity after treatment with single or combinations 
of compounds (all at concentrations of 100 nM), expressed as percentage change from baseline. *P<0.05, 
**** P<0.0001 versus control.
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shown in Figure 3B. None of the compounds had a direct effect on IR-A phosphoryla-
tion (data not shown), indicating that the effects involved inhibition of the secretion of 
growth factors produced by BON1 cells. Under the conditions that we used, concentra-
tions of IGF2 between 0.25 and 0.5 nM induced an IR-A activation comparable to that of 
BON1 conditioned medium (data not shown).
mRnA levels of iGF-related factors after treatment with SSAs and dAs
First, mRNA levels of IGF-related factors were measured after 6, 24, and 72 hours of treat-
ment. After 72 hours, the mRNA data showed the most significant changes. Therefore, all 
experiments were accomplished at that time point. A significant decrease in IGF2 mRNA 
was observed after treatment with PAS+CAB (-29.5±4.9%, P<0.01). The results are shown 
in Figure 4. IGFBP3 expression as well was significantly decreased after treatment with 
PAS+CAB (-20.0±4.0%, P<0.01; data not shown). No other statistically significant effects 
on mRNA were found for the remaining IGF-related factors. None of the other drugs or 
combinations were able to modulate mRNA expression levels.
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Figure 4 Change in mRNA expression of IGF2 after 72 hours of treatment with single or combinations of 
compounds in BON1 cells. **P<0.01 versus control.
iGF2 eliSA
Total IGF2 protein levels were quantitatively measured in conditioned medium of BON1 
cells. A significant decrease in IGF2 protein levels was observed after 72 hours of incuba-
tion with BIM-23A760 (-23.7±3.8%). Inhibitory but statistically non-significant effects 
were observed with the other compounds (OCT: -12.5±5.3%; CAB: -12.1±4.8%; PAS+CAB: 
-9.8±8.2%; PAS: -12.0±3.3%; OCT+CAB: -5.7±12.4%). The results are shown in Figure 5.
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iGF2 immunohistochemistry 
IGF2 IHC was determined in 25 tissue samples of siNETs (N=18) and panNETs (N=7) in 
order to examine IGF2 protein expression. Most of the tumors expressed a significant 
amount of IGF2 protein, although its expression was variable. The intensity and propor-
tion of the IGF2 IHC staining were heterogeneous in most of the GEP NET tissues. In 
online Supplementary table 2, the IGF2 mRNA and protein expression levels of both 
siNETs and panNETs are listed. No significant correlation was observed between IGF2 
mRNA and IGF2 protein in siNETs (ρ=0.17, P=0.49) and panNETs (ρ=0.44, P=0.33), ex-
pressed as IGF2 IRS. Figure 6 shows exemplary photomicrographs of staining of IGF2 in 
GEP NET samples with a IRS of 2, 4 and 6, respectively. There was no statistically signifi-
cant association between the proliferation marker Ki-67 and IGF2 IRS in siNETs (ρ=–0.09, 
P=0.79) and panNETs (ρ=0.89, P=0.11). 
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Figure 5 Change in IGF2 protein secretion in BON1 cells after 72 hours of treatment with single or combina-
tions of compounds. **P<0.01 versus control.
diSCuSSion
To the best of our knowledge, this is the first study having gathered evidence that the 
human BON1 cell line is a model that reflects in many respects the typical characteristics 
of the IGF system in human GEP NETs. We showed that especially IGF2 and IR-A are 
expressed at high levels in our series of GEP NETs as well as in the BON1 cell model. In 
addition, we demonstrated that SSAs and DAs modulate the secretion of growth factors 
(e.g. IGF2) produced by BON1 cells that are capable of activating IR-A. 
We measured mRNA levels of IGF-related factors (IGF1, IGF2, IGF1R, IGF2R, IR-A, IR-B, 
and IGFBP1-3) in both panNET cell lines and GEP NETs. In earlier publications, the expres-
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sion of these genes has been studied in human NETs (2,10). However, the quantitative 
expression of factors of the IGF system, and modulation of the expression of these 
growth factors (both at the mRNA and the protein level, during treatment with SSAs, 
DAs, or their combinations), have not been studied so far.
Overall, BON1 and QGP1 cells displayed an expression pattern of IGF-related factors 
which was relatively comparable to that of GEP NETs, both siNETs and panNETs. How-
ever, BON1 cells did not express detectable levels of IGF1, and QGP1 cells did not express 
detectable levels of IGF1, IGFBP1, and IGFBP3. In BON1 cells, IGF2 mRNA levels were 
expressed 1,000-fold more highly, and IR-A levels 5-fold more highly, than in QGP1 cells. 
These relatively low mRNA expression levels of IGF2 (and IR-A) in QGP1 cells may explain 
the absence of effects on conditioned medium of QGP1 on IR-A bioactivity. Therefore, 
the QGP1 cell line appears not a suitable model for investigating whether SSAs and/or 
DAs can modulate the production of these growth factors. On the other hand, both cell 
lines are panNET cell lines, and the difference between the cell lines might reflect the 
heterogeneity is this tumor group. 
In both BON1 and QGP1 cells, we observed higher mRNA expression levels for sst1 
than for sst2. The siNET cell line KRJ1 demonstrated equal mRNA expression levels for 
  
Figure 6 Exemplary cases of IGF2 IRS of GEP NET tissues. A–F siNETs (N=18). G–I panNETs (N=7). A, D, G HE. 
B, E, H IGF2. C, F, I Negative controls.
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sst1 and sst2 (3). In most studies where the quantitative mRNA expression levels of sst 
were studied, sst2 was more highly expressed than sst1 (40-44). In general, there is a 
predominant expression of  sst1  and  sst2 mRNA  in NETs, with a highly variable mRNA 
expression levels (40,45). We suggest that these differential findings again represent the 
heterogeneity of these tumors. No sst/DA mRNA expression levels were determined in 
our series of GEP NETs, since expression profiles of these receptors have already been 
extensively investigated (40,42). 
For all experiments, we used the concentration of 100 nM of OCT, PAS, CAB, and/or 
BIM-23A760. With this supraphysiological concentration, we expected to observe ef-
fects that could answer our primary research question, i.e. to investigate whether the 
different SSAs and/or DAs used were able to activate sst subtypes and D2 resulting in 
a maximal biological response. At such a concentration, it is not fully possible to make 
statements about the specific involvement of individual sst subtypes in this context.
In a previous study, modulation of the IGF2/IGF1R autocrine loop was demonstrated 
in BON1 cells using neutralizing IGF2 antibodies (27). To assess IGF2-mediated activity 
of the IR-A, we used an IR-A KIRA bioassay developed in-house. In the current study, 
we focused on IR-A bioactivity, as stimulation of IR-A by IGF2 may play a role in signal 
transduction in tumorgenesis (7,9). With the IR-A bioassay, we found that stimulation 
of phosphorylation of tyrosine residues of the IR-A by conditioned medium of BON1 
cells was as potent as a stimulation of 167 pM recombinant human insulin. As indicated 
above, a significant IR-A bioactivity of conditioned medium of QGP1 cells was not ob-
served. This may be explained by the reduced IGF2 mRNA expression in QGP1 cells, 
which  was approximately 1,000-fold lower than in BON1 cells. 
Since BON1 cells only produce IGF2 but not IGF1, the most likely explanation for the 
observed IR-A activation in BON1 cells is the production of IGF2. After 72 hours of incu-
bation, BON1 cells treated with PAS+CAB showed a significant decrease in IGF2 mRNA, 
while no effects were observed on mRNA expression after incubation with any of the 
other components. PAS and CAB monotherapy had less effect on mRNA expression. 
There was only a borderline reduction in IGF2 mRNA after treatment with BIM-23A760. 
Although sst1 was the most highly expressed sst1 subtype in our BON1 cell line, a 
72-hours incubation of BON1 cells with BIM-23926 (sst1 analog) did not result in a statis-
tically significant change in IGF2 mRNA expression compared to untreated BON1 cells 
(+113.80±19.31%, P=0.52) (unpublished data). Apparently, targeting sst1 is not effective 
in modulating IGF2 mRNA levels. Overall, these results suggest that the sst subtypes 2 
and 5 and D2 may play a role in modulating IGF2 mRNA levels.
BIM-23A760 treatment resulted in a significant decrease in secreted IGF2, while no 
effect was seen after any of the other treatments. Treatment with PAS+CAB or BIM-
23A760 induced a significant decrease in IR-A bioactivity. In the IR-A KIRA bioassay, all 
compounds or combinations, except OCT, were able to suppress the activation of IR-A. 
SSA and DA effects on IGF2-induced IR-A activation in panNET cells 127
 7
This result indicates that BON1 conditioned medium-induced IR-A activation can be 
modified by the (combined) activation of D2 and sst subtypes 2 and 5. The absence of an 
effect of OCT may be explained by the very low sst2 expression in BON1 cells.
While IGF2 expression has previously been demonstrated in GEP NET tissue at the 
mRNA level, there are no large studies that have evaluated IGF2 protein expression. In 
order to study whether IGF2 is also highly expressed in GEP NET tissues, we performed 
IHC. The GEP NET tumors also expressed IGF2 protein at a significant but variable level. 
Protein expression of sst has already previously been examined in GEP NET cells (46). 
No significant correlations were observed by IHC between IGF2 mRNA expression and 
IGF2 protein positivity in GEP NET tissues. Nonetheless, our study suggests that IGF2 is 
expressed at significant levels in almost all GEP NETs. No significant association between 
IGF2 IRS and Ki-67 index was found as well, which may be explained by the small sample 
size of our GEP NET series.
Although the BON1 and QGP1 cell lines are both originating from panNETs, discrepan-
cies in results of experiments between the panNET cell lines indicate that these cell lines 
represent two different tumor subtypes, namely tumors with a low IGF2 production and 
panNETs with high levels of IGF2 secretion. 
In conclusion, the human BON1 panNET cell line, and to a lesser extent the QGP1 cell 
line, appears to be a suitable model for studying the role of the IGF system in human 
panNETs. Of all the IGF-related factors, IGF2 and IR-A seem the most important players 
in human BON1 panNET cells and human GEP NETs. We found that most GEP NET tissues 
express IGF2 protein as well. In our hands, therapies with the combination of PAS+CAB or 
with the SS-DA chimeric compound BIM-23A760, which act through D2 and sst subtypes 
2 and 5, showed especially inhibitory effects on autocrine/paracrine (IGF2)-induced IR-A 
activation. Our study suggests that combinations of SSAs and DAs and/or chimeric SS-
DA ligands are treatment options showing promise for the treatment of GEP NETs, and 
they should be in the focus of future research.
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Supplementary table 1 Human somatostatin receptor (sst) and dopamine receptor subtype 2 (D2) binding 
affinities of octreotide, pasireotide, cabergoline and BIM-23A760 (nM).
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Supplementary table 2 Insulin-like growth factor 2 (IGF2) mRNA levels (relative expression, normalized 
to HPRT) and corresponding IGF2 immunoreactivity score (IRS) in gastroenteropancreatic neuroendocrine 
tumors (GEP NETs, N=25) of which are small intestine (siNET, N=18) and pancreatic NETs (panNETs, N=7). 
ND=Not detectable.

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
  8
diff erential eff ects of linsitinib and 
mtoR inhibitors on cell migration 
and proliferation of pancreatic 
neuroendocrine tumor cells
Roxanne C.S. van Adrichem1, Peter M. van Koetsveld1, Richard A. Feelders1, Timon 
Vandamme1,2, Wouter W. de Herder1, Leo J. Hofl and1
1Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The 
Netherlands 
2Department of Oncology, University of Antwerp, Belgium 
Manuscript in preparation
136 Chapter 8
ABStRACt
introduction: Effects of dual insulin-like growth factor 1 receptor (IGF1R)/insulin re-
ceptor (IR) kinase inhibitor linsitinib (LIN) and mammalian target of rapamycin (mTOR) 
inhibitors on cell proliferation and migration in pancreatic neuroendocrine tumors 
(panNETs) are unknown. 
objectives: 1) To study whether LIN (100 nM) and/or mTOR inhibitors everolimus (EVE 
10 nM) and sirolimus (SIR 10 nM) can modulate panNET cell (BON1, QGP1) prolifera-
tion and migration and, 2) to investigate the underlying mechanism to exert panNET 
cell migration and proliferation via selective blockade of the PI3K/AKT/mTOR and RAS/
RAF/MEK/ERK pathways with AKT1/2/3 inhibitor AZD5363 (AZ) and MEK1/2 inhibitor 
PD0325901 (PD).
methods: Scratch assays were used to measure cell migration. DNA measurements were 
used as a measure of cell proliferation. Statistical analyses were performed by one-way 
ANOVA and Tukey’s multiple comparison tests.
Results: Significant inhibition of panNET cell migration was observed after an 8-hours 
incubation with LIN (P<0.0001), not with mTOR inhibitors (P>0.05) in both panNET cell 
lines. Significant additive effects on panNET proliferation were observed after a 7-days 
incubation with LIN or EVE versus LIN+EVE and LIN+SIR, in QGP1 only (P<0.0001). AZ 
(100 nM) and PD (10 nM) significantly inhibited, also additive, migration (P<0.0001) but 
not proliferation in both cell lines. 
Conclusions: 1) Linsitinib plus mTOR inhibition differentially affects cell migration and 
proliferation in panNETs cells. 2) Cross-talk between the PI3K/AKT/mTOR and RAS/RAF/
MEK/ERK pathways is essential to accomplish panNET cell migration and proliferation. 
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intRoduCtion
Pancreatic neuroendocrine tumors (panNETs) are historically considered to be relatively 
rare neoplasms. However, their incidence and prevalence is increasing (1). About half 
of the patients with panNETs present with liver metastases at initial examination or 
during the disease course (1,2). The development of metastases in panNETs is a complex 
process in which different steps are involved including cell proliferation and migra-
tion (3). Activation of growth factors such as the insulin-like growth factor 1 receptor 
(IGF1R) and/or insulin receptor (IR) may play a key role in proliferative and migratory 
processes. This activation results into downstream induction of the phosphatidylinositol 
3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and the RAS/
RAF/Mitogen-activated protein kinase/ERK kinase/extracellular-signal-regulated kinase 
(RAS/RAF/MEK/ERK) pathway (4-8). However, the exact contribution of these signaling 
pathways to the development of metastases remains unclear.
Nowadays, a commonly used first-line therapy for patients with progressive or 
symptomatic well- and moderately differentiated unresectable, locally advanced and 
metastasized panNETs is the mammalian target of rapamycin (mTOR) inhibitor evero-
limus (9,10). However, panNETs frequently escape everolimus therapy and patients will 
consequently develop progressive disease (11-13). 
Recently, a potential role for the dual IGF1R/IR tyrosine kinase inhibitor linsitinib or 
‘OSI-906’ has been established (14). Linsitinib has shown antiproliferative effects in vitro 
in different cell lines (14-18). In clinical trials, linsitinib has been used for several types of 
cancer (19-21). Currently, only one phase III trial on adrenocortical carcinomas has been 
completed but showed no significant increase in overall survival (19). However, prelimi-
nary data showed promising results with regard to tumor response and tolerability in 
advanced solid tumors and linsitinib might be a potential new drug for treatment of 
panNETs (14,20,21). To the best of our knowledge, effects of linsitinib, alone or com-
bined with mTOR inhibitors, on panNET cell proliferation and migration have not been 
studied so far. 
Co-targeting the PI3K/AKT/mTOR pathway and RAS/RAF/MEK/ERK pathway has 
already shown antiproliferative effects in castration-resistant prostate cancer and, 
head and neck squamous cell carcinomas tumors (22,23). Combined everolimus with 
a tyrosine kinase inhibitor (TKI) has demonstrated antitumor effects in neuroendocrine 
tumors (NETs) as well (24). Since mTOR inhibitors have already proven their antiprolifera-
tive effects on panNET, we conducted a study to examine whether the dual IGF1R/IR 
kinase inhibitor linisitinib has additive or synergistic effects when combined with the 
mTOR inhibitors everolimus and sirolimus in panNET cells.
Further aims of our study were: 1) to assess whether the dual IGF1R/IR kinase inhibitor 
linsitinib and/or mTOR inhibitors everolimus and rapamycin can modulate panNET cell 
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proliferation and cell migration in the human panNET cell lines BON1 and QGP1 and 2) 
to investigate the underlying mechanism of the effects of linsitinib and mTOR inhibitors 
on proliferation and panNET cell migration by selective blocking of the PI3K/AKT/mTOR 
pathway and RAS/RAF/MEK/ERK pathway, in both panNET cell lines, with the AKT1/2/3 
inhibitor AZD5363 and MEK1/2 inhibitor PD0325901.
mAteRiAlS And methodS
Cell lines and culture conditions
We used two human panNET cell lines for our experiments: BON1 and QGP1. The BON1 
cell line was a kind gift of Dr. C.M. Townsend (The University of Texas Medical Branch, 
Galveston, USA). QGP1 cells, originating from a pancreatic islet cell carcinoma, were ob-
tained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. Identity 
of both cell lines was confirmed using short tandem repeat profiling (25). PanNET cell 
lines were routinely cultured in 75 cm2 cell culture flasks from Corning (Amsterdam, The 
Netherlands). BON1 cells were cultivated in culture medium consisting of a 1:1 mixture 
of DMEM and F-12K medium, supplemented with 10% fetal bovine serum (FBS), 100 U/
mL penicillin, 0.5 mg/L fungizone, and 2 mmol/L L-glutamin. QGP1 cells were grown in 
RPMI 1640 culture medium containing 10% FBS and 100 U/mL penicillin from Invitrogen 
(Breda, The Netherlands). 
Both cell lines were harvested weekly by trypsinization with trypsin (0.05%)-EDTA (0.53 
mM) and resuspended in culture medium. Trypan blue staining was used to measure cell 
viability and always exceeded 95%. Cells were counted microscopically in a standard 
hemocytometer. Cell culture conditions in the incubator were kept at a humidified 
atmosphere of 5% CO2 at 37°C. 
In all experiments, seeded cells were plated in 10% FBS-enriched culture medium. 
After three days, this culture medium was replaced by FBS-free culture medium with 
0.1% bovine serum albumin (BSA). Subsequently, all experiments were performed under 
these serum-free culture conditions.
drugs and reagents
To test modulation of cell migration and cell proliferation in panNET cell lines, we 
used two groups of compounds including the IGF1R/IR tyrosine kinase inhibitor (TKI) 
linsitinib (LIN), also known as ‘OSI-906’, and the mTOR inhibitors everolimus (EVE) and 
sirolimus (SIR) (all from LC Laboratories Inc., Woburn, MA, USA). Both panNET cell lines 
were also treated with the drug combinations linisitinib+everolimus (LIN+EVE) and 
linisitinib+sirolimus (LIN+SIR) to investigate additive drug effects. 
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Stock solutions of the IGF1R/IR TKI and mTOR inhibitors were prepared in 40% 
dimethylsulfoxide (DMSO), aliquoted at concentrations of 1 mM and stored at -20°C. 
For each experiment, fresh working solutions were diluted in 40% of DMSO to (supra)
pharmacological concentrations. 
Tested concentrations were: LIN 1 nM and 100 nM, EVE 10 nM and SIR 10 nM. 
Both panNET cell lines were also incubated with the phase II AKT1/2/3 inhibitor 
AZD5363 (AZ; Selleckchem, Huissen, The Netherlands) and phase II MEK 1/2 inhibitor 
PD0325901 (PD; Pharmacia Pfizer, New York, USA). In combination experiments IC50 
concentrations of AZ (100 nM) and PD (10 nM) were used according to manufacturer’s 
data (26,27).
Scratch assays 
Scratch assays or ‘wound healing’ assays were used as model system in order to study 
panNET cell migration under conditions that more accurately mimic steps of the 
metastatic pathway. The in vitro cell migration was measured by a previously described 
scratch assay method with some modifications (28). 
PanNET cells were seeded in 12-multiwell plates coated with poly-L-lysin (final con-
centration 10 µg/mL), respectively 700,000 cells per well and 1,300.000 cells per well for 
BON1 and QGP1 cells in 10% FBS-enriched culture medium. This culture medium was 
refreshed after 2 days. After 3 days, cells formed a uniform monolayer throughout the 
whole well. A sterile plastic 0-200 µL pipet tip was used to generate a homogeneous 
scratch in the shape of a cross in the cell monolayer. Peeled off cells were removed with 
three washes in FBS-free medium with 0.1% BSA. Subsequently, panNET cells were incu-
bated for 8 hours with the test compounds in FBS-free culture medium with 0.1% BSA.
Cells that migrated into these scratched areas were evaluated on pictures made 
by camera (Canon PowerShot A640, zoom operation ×1.0) under light microscopy 
(Carl Zeiss 42616, magnification 5×). The scratch widths were measured with ImageJ 
Software (version 1.46j, National Institute of Health, USA). The ability of cells to migrate 
was measured after 8 hours. Scratch widths (mean at t=8 hours – mean t=0 hours) were 
compared to corresponding areas in control cells incubated with vehicle DMSO (final 
concentration 0.4%).
Cell proliferation assay
Effects of drugs were tested following 7 days of incubation. PanNET cells were plated in 
24-multiwell culture plates in FBS-containing medium at 6,000 (BON1) cells and 20,000 
(QGP1) cells per well, respectively. After 3 days, medium was refreshed and cells were in-
cubated with the compounds in medium with 0.1% BSA for 3 days. After 3 days, medium 
and compounds were refreshed and cells were incubated for 4 additional days. Controls 
received vehicle only (0.4% DMSO). After 7 days, cells were collected for DNA measure-
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ment. Measurements of total DNA content were determined with the bisbenzimide 
fluorescent dye (Hoechst 33258; Sigma-Aldrich, Zwijndrecht, The Netherlands) as previ-
ously described (29). 
Statistical analysis 
Data were analysed using SPSS software (version 17 for Windows; SPSS Inc., Chicago, 
Illinois) and GraphPad Prism Software (version 7.01; San Diego, California, USA). Com-
parative statistical evaluations between groups were done by one-way ANOVA, two-way 
ANOVA and Tukey’s multiple comparison tests. Result were considered significant when 
P<0.05*, P<0.01**, P<0.001*** and P<0.0001****. Migration assays were performed three 
times and each assay was done in triplicate. Proliferation tests were done three times 
and each experiment executed in quadruplicate. 
ReSultS
Pannet cell migration: dose-dependent effects of lin, eVe and SiR 
All compounds were tested in the concentrations: 1 nM, 10 nM, 100 nM and 1,000 nM. 
LIN showed dose-dependent effects in both panNET cell lines. Statistically significant 
inhibition of BON1 and QGP1 cell migration was already observed with LIN 1 nM and 
LIN 10 nM, respectively (Figure 1A and 1B). Both mTOR inhibitors had no statistically 
significant effect on panNET cell migration.
 LIN 1 nM and 100 nM are the concentrations to obtain 50% (IC50) and maximal reduc-
tion in QGP1 cell migration respectively with LIN. In BON1 cells we tested with the same 
concentrations for comparability. 
dose-dependent effects of lin, eVe and SiR on pannet cell proliferation
In both cell lines, cell proliferation was strongly and significantly inhibited after treat-
ment with both mTOR inhibitors (Figure 1C and 1d). These inhibitory effects on the 
panNET cell lines were dose-dependent and, stronger in higher pharmacological con-
centrations. However, only in higher pharmacological concentrations, LIN inhibited cell 
proliferation in BON1 cells as well, but not in QGP1 cells. 
Additive effects on pannet cell proliferation and migration
Effects of LIN (100 nM) and EVE/SIR monotherapy (10 nM), as well as additive effects of 
LIN+EVE and LIN+SIR were compared on panNET cell proliferation and migration. Re-
sults are shown in Figure 2A-d. No significant additive effects on panNET cell migration 
were observed with LIN versus LIN+EVE and LIN+SIR in BON1 cells (Figure 2A) and QGP1 
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cells (Figure 2B). An 8 hours-incubation of LIN 1 nM versus LIN 1 nM+EVE 10 nM and LIN 
1 nM+SIR 10 nM resulted in comparable result (data not shown). 
For BON1 cells, no additive antiproliferative effects of combination therapy were 
observed compared to LIN or mTOR monotherapy (Figure 2C). Compared to LIN mono-
therapy (100 nM) and EVE (10 nM) alone, the combination of LIN 100 nM+EVE 10 nM 
and LIN 100 nM+SIR 10 nM resulted in a statistically significant additive reduction in 
proliferation in QGP1 cells (Figure 2d). 
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Figure 1 Dose-dependent effects for linsitinib (LIN), everolimus (EVE) and sirolimus (SIR) on pancreatic neu-
roendocrine tumor (panNET) cell migration (8-hours incubation) and proliferation (7 days of incubation): A 
BON1 cell migration, B QGP1 cell migration, C BON1 cell proliferation, D QGP1 cell proliferation. Results are 
significant when: P<0.01**, and P<0.0001****. 
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Figure 2 Partial additive effects of linsitinib (LIN, 100 nM) plus mammalian target of rapamycin (mTOR) in-
hibitors everolimus (EVE, 10 nM) and sirolimus (SIR, 10 nM) in panNET cells: A BON1 cell migration, B QGP1 
cell migration, C BON1 cell proliferation and, D QGP1 cell proliferation. Significant results: P<0.001***, and 
P<0.0001****.
effects of AZd5363 on pannet cell proliferation and migration
In order to understand the underlying mechanism of LIN and the mTOR inhibitors EVE 
and SIR to exert their differential effects on panNET cell migration and proliferation, we 
treated BON1 and QGP1 cells with AKT1/2/3 inhibitor AZD5363 (AZ) and MEK1/2 inhibi-
tor PD0325901 (PD). Results are displayed in Figure 3. 
AZ treatment resulted in a dose-dependent, statistically significant, inhibition of 
panNET cell migration. The strongest significant effects were observed with the highest 
tested pharmacological concentration (Figure 3A: BON1 cells, Figure 3B: QGP1 cells). 
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No significant inhibition on BON1 cell migration was observed with AZ 1 nM, but this 
concentration stills inhibits QGP1 cell migration.
No statistically significant inhibition on proliferation was observed after incubation 
with AZ on BON1 (Figure 3C) and QGP1 cells (Figure 3d). AZ, however, showed a 
growth-stimulating trend. 
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Figure 3 Effect of the AKT1/2/3 inhibitor AZ5363 (AZ) on panNET cells: A BON1 cell migration, B QGP1 cell 
migration, C BON1 cell proliferation and D QGP1 cell proliferation. Significant are P-values: P<0.05*, P<0.01**, 
and P<0.0001****.
effects of Pd0325901 on pannet cell proliferation and migration
In both cell lines, there was a significant dose-dependent inhibition of cell migration. 
(Figure 4A: BON1, Figure 4B: QGP1). In the QGP1 cell line, but not in the BON1 cells, 
migration was significantly inhibited already at 0.1 nM. 
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A strong and statistically significant dose-dependent inhibition of cell proliferation 
was also observed after treatment with PD in both cell lines (Figure 4C: BON1, Figure 
4d: QGP1).
Additive effects of AZ and Pd on pannet cell migration and proliferation
In both panNET cell lines, incubation with AZ (100 nM)+PD (10 nM) resulted in a statisti-
cally significant and, additive inhibition of migration compared to AZ or PD monotherapy 
(BON1: Figure 5A and QGP1: Figure 5B). 
Effects of AZ (100 nM)+PD (10 nM) are shown on BON1 cell (Figure 5C) and QGP1 cell 
proliferation in Figure 5d. AZ monotherapy (100 nM) has no significant effect on pan-
NET cell proliferation. Addition of AZ (100 nM) to PD (10 nM) has no additional effect to 
the already strong inhibition of PD on panNET cell proliferation in BON1 and QGP1 cells.
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Figure 4 Effects of the MEK1/2 inhibitor PD0325901 (PD) on panNET cells: A BON1 cell migration, B QGP1 
cell migration, C BON1 cell proliferation and D QGP1 cell proliferation. Result were considered significant 
when P<0.05*, P<0.01**, P<0.001*** and P<0.0001****.
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Figure 5 Partial additive effects of AKT1/2/3 inhibitor AZ5363 (AZ, 100 nM) and MEK1/2 inhibitor PD0325901 
(PD, 10 nM) on panNET cells: A BON1 cell migration, B QGP1 cell migration, C BON1 cell proliferation and D 
QGP1 cell proliferation. Significant are P-values: P<0.05*, P<0.001*** and P<0.0001****.
diSCuSSion
Cell proliferation and cell migration are important processes involved in tumor progres-
sion and development of metastases (3). The mTOR inhibitor EVE, which is used in the 
treatment of patients with progressive and/or symptomatic well- and moderately dif-
ferentiated unresectable and metastasized panNETs, has shown significant antiprolifera-
tive effects on panNET cell lines and NET tissues (4,30,31). Additionally, in the RADIANT-3 
trial tumor shrinkage was observed in 64% of the patients treated with EVE as compared 
to 21% of patients in the placebo group (32). Modulation of cell migration with EVE had 
been investigated in some studies, however, both inhibitory and absence of inhibitory 
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effects were observed in cell lines (33-36). One study, performed in bronchial NET cells, 
showed a decrease of cell migration after three days of treatment with EVE (24). In our 
opinion, after such a timeframe, effects of cell proliferation could be involved as well. 
Therefore, in our experiments, migration effects were studied during an 8-hours incuba-
tion period. To date, the other tested mTOR inhibitor SIR has not been studied in clinical 
trials for the treatment of panNET patients.
Cell proliferation and migration can also be modulated via upstream inhibition of 
mTOR by IGF1R/IR TKIs like LIN. One study investigated effects of an IGF1R/IR TKI on 
cell proliferation, but not cell migration, in a bronchial NET cell line (37). Therefore, this 
is the first study in which we examined the ability of the dual IGF1R/IR TKI LIN and the 
mTOR inhibitors EVE and SIR to modulate both panNET cell proliferation and migration 
as processes of tumor progression. Migration was studied using in vitro scratch assays. 
In these scratch assays, or ‘wound healing assays’, a scratch was created in panNET cell 
monolayers in order to measure cell migration. Since cell migration is one step in the 
complex processes of developing metastases, this model system could provide impor-
tant information with regard to tumor progression.
We tested mTOR inhibitors using a concentration of 10 nM that can be reached in the 
circulation and which is well-tolerated in patients (38,39). In our study, we observed a 
potent inhibition of panNET cell proliferation after treatment with mTOR inhibitors in this 
concentration. However, mTOR inhibitors had, even in suprapharmacological concentra-
tions no effect on cell migration. LIN showed clear differential effects, with inhibition of 
panNET cell migration already after low-dose treatment and, in relatively higher doses 
inhibition of cell proliferation in both panNET cell lines. Combination therapy of LIN and 
an mTOR inhibitor might therefore modulate panNET progression with dual inhibition 
of cell migration and proliferation. This drug combination that differentially modulates 
different signalling pathways,  might be a potential new therapeutic option for patients 
with well- to moderately differentiated metastasized panNET. 
In vitro studies showed that LIN completely blocks the phosphorylation and activa-
tion of the IGF1R at IC50 0.024 µM and the IR at IC50 0.039 µM. Antitumor activity was 
seen with EC50 ranging from 0.02-0.81 µM (14). In a phase I trial, the oral administration 
of 150 mg LIN twice daily resulted into antitumor activity in patients with advanced 
solid tumors, which correlates with maximal plasma concentrations ranging between 
1.71-3.11 µM. These concentrations exceed the minimum predicted concentrations for 
antitumor activity of 0.021 µM (21). The above-mentioned concentrations for antitumor 
activity correspond well with results in our study of LIN 10-100 nM. With concentrations 
of LIN 100 nM, statistically significant inhibitory effects were observed on both panNET 
cell migration and proliferation. In addition, in our experiments these relatively low 
concentrations of LIN already induced migration inhibitory effects. Therefore, lower 
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dosages of LIN may be equally effective in vivo with potentially less side effects. This 
needs, however, further investigation (19). 
In our experiments, we demonstrated in BON1 cells that LIN in lower pharmacological 
concentrations inhibited panNET cell migration and in higher concentrations also cell 
proliferation. These effects on proliferation were not observed in QGP1 cells. On the 
other hand, in QGP1 cells, combined treatment of LIN with an mTOR inhibitor resulted 
in significant additive inhibitory effects on proliferation. This was not observed in BON1 
cells. These different effects of LIN combined with mTOR inhibitors on both cell lines 
might reflect the heterogeneous behavior of these panNET cells. 
The PI3K/AKT/mTOR pathway plays an important role in the pathophysiology of 
panNET cell proliferation and migration (4,5,32,40-42). mTOR inhibitors target the 
mTOR complex 1 (mTORC1), not mTORC2, which results in a negative feedback loop to 
maintain PI3K activity and upregulate AKT (8,13). The mTORC2 is involved in cell migra-
tion (8,13,40). The influence of RAS/RAF/MEK/ERK pathway has not been studied for 
panNET cell migration, only for cell proliferation (4,43). In a single study, the RAS/RAF/
MEK/ERK pathway was shown to be involved in melanoma cell migration (44). Therefore, 
our hypothesis was that the PI3K/AKT/mTOR pathway is preferentially involved in cell 
proliferation and that the RAS/RAF/MEK/ERK pathway is predominantly associated with 
cell migration. In order to test this pathway selectivity, we conducted experiments with 
an AKT1/2/3 inhibitor (AZ) and MEK1/2 inhibitor (PD). 
PD seems to modulate both cell migration and cell proliferation, and we observed 
that the migration system is much more sensitive to AZ, as compared to the prolifera-
tion system, which is almost not affected. Although PD was used to investigate pathway 
selectivity, MEK 1/2 is a potentially interesting target that could modulate both panNET 
cell migration and proliferation. 
Upstream inhibition could be compensated via intracellular downstream activation of 
the PI3K/AKT/mTOR pathway and thereby escape from cell proliferation. Probably cross-
talk between signalling pathways plays a key role in this process. In our experiments, 
we demonstrated no effect on panNET cell proliferation with AZ, but cell proliferation 
might be modulated via interaction of AKT with other pathways than the RAS/RAF/MEK/
ERK pathway. 
In conclusion, we demonstrate that mTOR inhibitor monotherapy inhibits at low phar-
macological concentrations panNET cell proliferation, but not migration. In contrast, 
LIN modulates in low pharmacological concentrations both panNET cell migration and 
in higher pharmacological concentrations cell proliferation. Therefore, we suggest that 
combination therapy of LIN plus mTOR inhibitors EVE or SIR, both in a low dose, could 
effectively influence panNET cell migration and proliferation as important processes of 
tumor progression. 
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GeneRAl diSCuSSion
Gastroenteropancreatic neuroendocrine tumors (GeP nets)
Since its foundation, the European Neuroendocrine Tumor Society (ENETS) and the 
North American Neuroendocrine Tumor Society (NANETS) have put effort to standardize 
diagnostic work-up and treatments in patients with gastroenteropancreatic neuroen-
docrine tumors (GEP NETs) and these will undergo continuous renewal on the basis of 
evolving insights (1). 
The main aims of this thesis were to: 1) improve the diagnostic work-up and follow-up 
of GEP NET patients using sensitive and specific tumor markers and, 2) to identify new 
biotherapeutical options by modulating pathological pathways in pancreatic NET (pan-
NET) cells. 
The importance of the findings in the studies that are described in this thesis and their 
implications for the current and future diagnostic work-up and treatment of patients 
with GEP NETs are discussed below.
Biomarkers
Currently used circulating biomarkers like serum chromogranin A (CgA) and neuron-
specific enolase (NSE) have major limitations because of a relative lack of sensitivity, 
specificity and predictive capacity in the diagnosis of GEP NET patients (2-4). Immuno-
histochemical markers in tumor cell specimens have these restrictions to a certain extent 
as well. New biomarkers for these patients are needed to provide better diagnostic and 
prognostic information. The prognostic value of the two most frequently used single-
analyte serological biomarkers NSE and CgA was further investigated. 
First, we have studied serum NSE as an independent predictor for overall survival (OS) 
in patients with GEP NETs (Chapter 2). We have demonstrated that NSE is a predictive 
biomarker for OS independent of the primary GEP NET. Although less than half of the 
GEP NET patients have elevated NSE levels, in those patients with elevated NSE levels, 
any increase of NSE above reference levels is indicative of a poor prognosis. Thereby, 
only a single NSE measurement can already provide prognostic information.
Second, in Chapter 3 we have investigated the prognostic role of serum CgA levels 
in patients with stage IV GEP NETs. In this study, we have clearly demonstrated that 
patients in the high and very high CgA groups have a worse prognosis than patients in 
the normal CgA group. Therefore, as with NSE, strongly elevated CgA levels in GEP NET 
patients are also indicative for a poor prognosis. It is know that some GEP NET tumor 
cells do not express Cg as a manifestation of tumor dedifferentiation. In contrast we have 
demonstrated that patients with stage IV GEP NETs with circulating CgA levels within 
the reference range did have a better prognosis as compared to those patients with 
elevated CgA levels. It would be of interest to further investigate the clinical implications 
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of this finding, e.g. whether and how patients with a CgA-secreting GEP NET should be 
treated differently as compared to patients having a non-CgA secreting NET. It has also 
been shown that serum CgA and NSE can produce additional prognostic information 
when both are considered in combination. GEP NET patients with combined elevated 
serum CgA and NSE had a shorter median progression-free survival (PFS) than those 
with combined normal levels (5). Future research is needed to investigate whether the 
addition of more single-analyte circulating tumor markers to these two biomarkers 
can lead to the development of a diagnostic multi-analyte test with superior metrics. 
Recently, the specific in vitro multi-analyte NETest® with algorithm analyses has been 
launched. This test is further discussed in ‘Future perspectives in diagnostics’.
In this thesis we have also aimed at identifying potential new single-analyte 
biomarkers. In Chapter 4, we have studied whether fasting plasma acylated (AG) and 
plasma unacylated ghrelin (UAG) could be new useful biomarkers in GEP NET patients. 
However, we could not find significant differences in fasting plasma AG and UAG levels 
between GEP NET patients and their sex- and age-matched controls. Therefore, fasting 
plasma AG and UAG do not seem suitable diagnostic biomarkers in patients with GEP 
NETs. 
In order to test whether combined use of single-analyte serological and immunohis-
tochemical markers could offer additional prognostic information, we have studied in 
Chapter 5 the relationship between serum CgA, the Ki-67 proliferation index and the 
expression of insulin-like growth factor (IGF)-related genes in GEP NET tissues and their 
relation with patient survival. We found significant higher tumoral mRNA expression 
of insulin receptor isoform A (IR-A) in GEP NET patients with elevated serum CgA as 
compared to those with non-elevated serum CgA levels. As serum CgA levels correlate 
well with tumor mass, our data suggest that tumor mass correlates with tumoral IR-A ex-
pression in patients with GEP NETs. Whether tumoral IR-A could be used as a prognostic 
tumor marker for patients with GEP NETs has not been investigated yet and would be an 
interesting future research focus. In vivo research might provide information on whether 
the dual IGF1 receptor (IGF1R)/IR tyrosine kinase inhibitor (TKI) linsitinib, or a more 
specific IR-A TKI, are potential therapeutic tools to modulate tumoral IR-A and clinical 
symptoms in those patients with CgA-producing GEP NETs expressing high IR-A levels. 
The somatostatin receptor subtype 2a (sst2a) is a commonly expressed receptor in 
GEP NETs. As shown in Chapter 6, we found that tumoral sst2a expression using im-
munohistochemistry on tumor samples had no significant additional value compared 
to somatostatin receptor scintigraphy (SRS) using 111In-pentetreotide (OctreoScan®) 
in predicting the in vivo GEP NET response to peptide receptor therapy (PRRT) using 
177Lu-DOTAtate. Although there was no additional value of immunohistochemical sst2a 
expression in GEP NET tissues in this selected study population, tumoral sst2a and its 
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clinical relevance as an independent prognostic predictor were recently demonstrated 
by another research group (6).
The studies in this thesis on currently available serological and immunohistochemical 
single-analyte biomarkers and/or their combinations have revealed new prognostic 
insights with clinically relevant information. 
Future perspectives in diagnostics
NETest® 
The recently commercially available multi-analyte NETest®  is significantly more sensi-
tive and specific (>93%) than single-analyte assays which are used for the diagnostic 
work-up and follow-up of patients with GEP NETs (7). This test affords information on 
tumor behavior, treatment and their effectiveness (7-10). For this non-invasive blood 
test, expression data of 51 genes are combined with clinical parameters of patients 
from whom blood samples are analyzed. Gene expression of genomic clusters (sst-ome, 
proliferome, growth factor signalome, metabolome, secretome, epigenome, plurome, 
apoptome) is captured in a NET score. This NET score is calculated from four different 
prediction algorithms based on PCR data sets of individual studies that are mathemati-
cally scaled to different scales of disease activity (9,11-13). Activity levels correlate with 
clinical status, e.g. stable or progressive disease. At present, this test is not routinely 
available and is only performed in a single laboratory. Until now, this test has only been 
studied in retrospective settings (14-16). Therefore, a prospective clinical controlled 
study is needed to further validate this test. 
Circulating Tumor Cells (CTCs)
Circulating Tumor Cells (CTCs) are potential biomarkers in different solid tumors 
including NETs. CTCs are cells that are grown into the vasculature or lymphatic system of 
a primary tumor and can be measured in the systemic circulation (17,18). Clinically vali-
dated are the United States Food and Drug Administration (FDA) approved CellSearch® 
CTC Test and CE-approved CellCollector® (19). The usefulness of CTCs as biomarker is 
currently under investigation in an ongoing phase IV CALM-NET study in patients with 
midgut NETs (NCT02075606). A potential problem for CTC tests in G1-2 GEP NETs is the 
relatively low proliferation rate of these tumors and only very low numbers of CTCs 
could be detected until now in blood samples of GEP NET patients.
Genomic and microRNA (miRNA) profiling
Genomic and microRNA (miRNA) profiling are other promising tumor markers for 
GEP NETs. The miRNAs are small non-coding RNAs that play a central role in diverse 
pathological processes. Large differences in miRNA expression profiles have been 
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demonstrated between different types of NETs (20-22). At the moment, the feasibility of 
genomic and miRNA profiling has to be demonstrated in clinical studies with GEP NET 
patients. Currently, a clinical study is ongoing to investigate molecular profiling in NETs 
(NCT02586844).
Epigenetic modifications
Epigenetic modifications have been demonstrated in GEP NETs, but it is still unclear 
whether NETs are driven by epigenetic changes (23-25).  
Biotherapy 
Biotherapy plays a significant role in the treatment of patients with GEP NETs when 
surgery or local therapies are no suitable options. Most patients with metastasized GEP 
NETs benefit from treatment with non-radiolabeled ‘cold’ somatostatin analogs (SSAs). 
These drugs can inhibit tumor growth and symptoms caused by hormonal secretion 
and, eventually improve quality of life (26-29). Radiolabeled ‘hot’ SSAs applied as PRRT 
for patients with inoperable or metastasized NETs has also shown significant tumor 
responses (30). Results of the randomized controlled phase III NETTER-trial may lead to 
formal worldwide registration of PRRT using 177Lu-DOTAtate in patients with metastatic 
midgut NETs (NCT02705313). The mammalian target of rapamycin (mTOR) inhibitor 
everolimus and multikinase inhibitor sunitinib have proven efficacy in patients with 
advanced progressive panNETs as well (31-34). 
Although clear progress in the treatment of patients with well- and moderately dif-
ferentiated metastatic GEP NETs has been made over the last 30 years, the therapeutic 
options are still limited. GEP NETs may escape from medical treatment by tachyphylaxis 
and/or the development of resistance and patients will eventually develop progressive 
disease (35,36). We have, therefore, investigated the use of biotherapeutical agents in 
panNET cells.
Combination biotherapy 
D2 expression has been demonstrated in vitro in GEP NET cell lines and tissues, however, 
this receptor is currently not used as therapeutical target (37-39). Dopamine-somatosta-
tin chimeric molecules or ‘dopastatins’ have shown strong inhibitory effects on hormonal 
hypersecretion in growth hormone secreting adenomas, and antiproliferative effects in 
other tumor cell types as compared to octreotide and cabergoline, and both sst2 and sst5 
monospecific analogs (40-42). 
We have shown favorable effects of the combination of SSAs and dopamine agonists 
(DAs), either or not as chimeric compound, on mainly IGF2-induced IR-A activation 
in panNET cells (Chapter 7). Our data suggested a role of targeting sst2/5 and D2 in 
modulating IGF2 production in GEP NETs. Our data support the necessity of more in 
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vivo research with dopastatins. Unfortunately, in a previous initial clinical trial, chronic 
administration of dopastatin BIM-23A760 produced a metabolite with dopaminergic 
activity that gradually accumulates and interferes with the activity of the parent com-
pound (43).
In another study described in Chapter 8, we have demonstrated that combination 
therapy of linsitinib plus low doses of the mTOR inhibitors everolimus or sirolimus could 
effectively influence both panNET cell migration and proliferation, which are important 
indicators of tumor progression. Modulation of cell migration as measure for disease 
progression was investigated in panNET cells and may be a new concept  for the treat-
ment of GEP NET patients. Our data indicate that more in vivo research is needed to 
investigate whether combined therapy of linsitinib plus low doses of an mTOR inhibitor 
would influence disease progression in GEP NET patients. In addition, we have shown 
significant inhibition on panNET cell proliferation and migration with the MEK1/2 in-
hibitor PD0325901 (PD). Therefore, this agent should be considered as a potential new 
target for TKI inhibition in GEP NETs as well. 
Future perspectives of biotherapy
Clinical trials are ongoing in the field of GEP NETs and will be expected in the future to 
result into new biotherapeutical agents. Some of these agents are already approved for 
other types of cancer and could therefore be of interest for GEP NETs as well. 
Dual mTOR inhibitors
The mTORC1 inhibitor everolimus has shown limited efficacy in patients with panNETs 
(34). Dual inhibition of both mTORC1 and mTORC2 might have stronger anti-proliferative 
properties. In an ongoing multicenter, open-label phase I-II study, safety and tolerability 
are assessed of the oral mTOR inhibitor CC-223, which is a competitive inhibitor of the 
mTOR kinase that targets mTORC1 and mTORC2 in patients with advanced non-pancre-
atic NETs (NCT01177397) (44).
Immunotherapy
New immunological agents, immune-checkpoint inhibitors, have shown to prolong 
survival in patients with inoperable or metastasized types of cancer (45-47). These FDA 
proven monoclonal antibodies target the cytotoxic T-lymphocyte-associated protein 4 
receptor (CTLA4, ipilimumab) and the programmed cell death protein 1 receptor (PD1, 
nivolumab) (48,49), which are both proteins that down regulate the immune system. 
After binding to the respective receptors, these monoclonal antibodies activate the 
immune system and result into antitumor responses leading to tumor cell apoptosis 
(48,49). Clinical trials with these drugs in gastroenteropancreatic neuroendocrine car-
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cinoma (GEP NEC) patients are in preparation (www.netrf.org/net-research-foundation-
launches-major-immunotherapy-initiative).
Multikinase inhibitors 
Besides sunitinib, registered multikinase inhibitors for other types of cancer and mul-
tikinase inhibitors in development are potential new therapies for patients with GEP 
NETs. Sorafenib tosylate, an inhibitor of vascular endothelial growth factor receptors 
(VEGFRs)1-3 and platelet-derived growth factor receptors (PDGFRs), and lenvatinib 
which targets mainly VEGFRs, PDGFRs and fibroblast growth factor receptors (FGFRs), 
have shown to inhibit tumor growth and progression and, increase PFS in other cancers 
(50-55). Results are expected of the phase II trial in which sorafenib tosylate was inves-
tigated in the treatment of patients with progressive metastatic NETs (NCT00131911). 
A prospective, multicenter phase II trial is ongoing in order to test lenvatinib efficacy in 
metastatic NETs (TALENT) (NCT02678780). 
Combination therapy
An increasing number of studies is focusing on combined treatments of SSAs, PRRT, 
everolimus, multikinase inhibitors and, chemotherapy in the field of NETs. 
With regard to studies on combined therapy with SSAs, there is a randomized double-
blinded phase II SUNLAND trial, in which patients are recruited with progressive ad-
vanced midgut NETs to study lanreotide acetate with sunitinib malate versus lanreotide 
acetate with placebo regarding PFS (NCT01731925). In addition, results of an ongoing 
randomized double-blind phase II trial are expected on octreotide LAR plus VEGFR1-3 
multikinase inhibitor axitinib versus placebo in patients with progressive advanced 
well-differentiated non-pancreatic NECs (NCT01744249).
A number of trials is ongoing on combination therapy with PRRT. Recently, results of 
the phase I NETTLE trial have been published in which acceptable safety profiles were 
investigated of PRRT and everolimus in GEP NET patients (56). These results should be 
further studied in a phase II-III trial. 
Moreover, studies are ongoing on the combined effects with everolimus as well. 
In a phase I trial with everolimus plus sorafenib, beneficial effects were shown in pa-
tients with advanced NETs. These data need to be further studied in a phase II-III trial. 
In an ongoing phase II study, the safety and efficacy of everolimus plus erlotinib, an 
epidermal growth factor receptor TKI, is under investigation in patients with G1-2 NETs 
(NCT00843531). The large ENETS randomized, open label phase II SEQTOR trial has been 
initiated in which the efficacy and safety are compared of everolimus followed by strep-
tozotocin and 5-fluorouracil (STZ-5FU), or the reverse sequence, upon progression in 
patients with advanced panNETs (NCT02246127). This trial is an important step forward 
in the search for the recommended sequence of treatments for GEP NETs with different 
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disease stages, since at present decisions with regards to therapy are mainly based on 
personal or expert opinions (57). 
Concluding remarks
In the reported studies, we have first investigated the use of sensitive and specific tumor 
markers in order to improve the diagnostic work-up and follow-up for patients with GEP 
NETs. We investigated existing serological and immunohistochemical markers (CgA, 
NSE; sst2a, Ki-67 proliferation index) and found new applications for clinical follow-up. 
Potential new markers (fasting plasma AG and UAG; IGF-related genes) appeared not 
to be of added diagnostic value for GEP NET patients. Primarily, our focus was on single 
or combined analytes. Since GEP NETs can behave very heterogeneously and secrete 
a variety of biologically active products, future diagnostic approaches might take into 
account more than one parameter to improve both the sensitivity and specificity of 
assays. Very recently, the multiple-analyte assay NETest®, in which more than 50 genes 
are investigated, has been introduced. Preliminary results show promising test metrics 
(7,8,15,16). The concept of multiple-analyte analyses might be a step forward to the 
further improvement of the diagnostic work-up and follow-up in GEP NET patients. 
Secondly, we examined new biotherapeutical options by influencing pathological 
pathways in panNET cells. In the last decades, treatment for GEP NET patients has 
evolved into targeted therapies which modulate receptors and deregulated pathways, 
in order to improve clinical symptoms, control tumor size and, improve quality of life 
and PFS. In our view, future research on the treatment of this patient group with me-
tastasized disease will focus more on multiple receptor targeting in order to tackle the 
multiple pathways that are involved in tumor-promoting processes and to overcome 
tachyphylaxis and/or resistance to treatment. Therefore, linsitinib (combined targeting 
of the IGF1R and IR), and combined SSAs and DAs (acting on both sst and D2), preferen-
tially using chimeric compounds, are potential novel therapeutical options for patients 
with GEP NETs (58). The importance of targeting other expressed receptor types, either 
or not in combination with IGF1R/IR receptors, could be of interest as well. Tumor 
heterogeneity characterizes, but also impedes the clinical success of novel therapies. 
Therefore, it will be a future challenge to develop new drugs with both antiproliferative 
and antisecretory effects with clinical feasibility for the whole GEP NET patient popula-
tion. Finally, future studies correlating drug responses to circulating tumor markers or 
molecular markers expressed in tumors might help to better select the appropriate drug 
to treat individual patients (e.g. tailored drug treatment). 
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SummARy
introduction
Neuroendocrine tumors (NETs) arise from the diffuse neuroendocrine (NE) cell system. 
These NETs are considered rare tumors and they generally show a very heterogeneous 
manifestation. The majority of NETs are gastroenteropancreatic NETs (GEP NETs) and 
lung NETs. NETs originating from the gastrointestinal tract and pancreas are considered 
as separate tumor entities. GEP NETs are historically subdivided according to their em-
bryologic origin into foregut, midgut or hindgut NETs. 
GEP NETs are characterized by tumoral production of metabolically active substances 
causing distinct clinical syndromes. Among these clinical syndromes, the carcinoid 
syndrome (CS) is the most well known. Besides presenting with a functional syndrome, 
these tumors, can also present as non-syndromic or non-functioning NETs.
NETs express somatostatin (sst) and dopamine (DA) receptors. Co-expression of these 
receptors may generate so-called chimeric receptors or hybrid receptors with altered 
functional properties. Sst receptors are used in the clinic as important therapeutic 
targets for the inhibition of hormonal secretion and cell proliferation in GEP NETs using 
somatostatin analogs (SSAs). 
Several pathways including the insulin-like growth factor (IGF) pathway, the phos-
phatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) 
pathway and the RAS/RAF/mitogen-activated protein kinase kinase/extracellular-
signal-regulated kinase (RAS/RAF/MEK/ERK) pathways are known to be involved in the 
pathophysiology of NETs. Under normal, non-pathological conditions, these signaling 
pathways are crucial for cell metabolism, proliferation, migration, differentiation and 
survival. How these different dysregulated pathways exactly are involved in the forma-
tion of NETs is presently unknown.
diagnosis
The diagnosis of a GEP NET is based on: pathology of tumor tissue, radiological and 
nuclear imaging and, circulating biomarkers. Pathological evaluation of tumor tissue is 
essential to establish or confirm the NE entity of the tumor, for ENETS TNM staging and, 
WHO grading, which are important for treatment decisions and prognosis. 
Besides general imaging techniques including computer tomography (CT), magnetic 
resonance imaging (MRI), ultrasound (US), and endoscopic ultrasound (EUS), somatosta-
tin receptor scintigraphy (SRS) using OctreoScan®, or 68Ga-DOTATATE-PET are used for 
staging in GEP NET patients. 
The most relevant immunohistochemical biomarkers are chromogranin (Cg) and 
synaptophysin. The most widely used serological biomarkers are chromogranin A (CgA) 
and neuron-specific enolase (NSE). The 24-hours urinary collection of the serotonin 
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breakdown metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is another established 
biomarker used in the diagnosis and follow-up of GEP and bronchial NET patients with 
the CS. However, these available single-analyte immunohistochemical and serological 
biomarkers have major limitations. 
in this thesis, the first main aim was to improve the diagnostic work-up and follow-up 
of GEP NET patients using sensitive and specific tumor markers. We have re-investigated 
the prognostic test properties of the two most frequently used single-analyte serologi-
cal biomarkers NSE and CgA. New insights on existing single-analyte tumor markers were 
presented. We have shown that the biomarker NSE is a predictive biomarker for overall 
survival independent of the primary tumor in GEP NET patients. Our data suggest that 
patients with non-CgA-secreting metastatic stage IV GEP NETs have a favorable progno-
sis as compared to those with CgA-secreting stage IV metastatic GEP NETs. 
No new sensitive and specific suitable single-analyte biomarkers were identified. Fasting 
plasma acylated and plasma unacylated ghrelin appeared not to be the expected 
suitable biomarkers. No significant association was found between the combined 
serological and immunohistochemical single-analyte biomarkers serum CgA, the Ki-67 
proliferation index in tumor specimens and, the expression of IGF-related genes in GEP 
NET tissues on one hand and patient survival on the other hand. The clinical relevance 
of the observed significant higher tumoral mRNA expression of insulin isoform-A (IR-
A) in GEP NET patients with elevated serum CgA, as compared to those patients with 
non-elevated serum CgA levels, might become an interesting topic for future clinical 
research. 
Finally, the expression of the somatostatin receptor sst2a on tumor samples had no 
significant additional value as compared to SRS using OctreoScan® in predicting the in 
vivo GEP NET response to peptide receptor radiotherapy (PRRT) with 177Lu-DOTAtate. 
However, this relatively cheap diagnostic tool might become helpful in those geographic 
areas of the world where there is no or very limited availability of SRS to select patients 
for PRRT with radiolabeled somatostatin analogs (SSAs).
Since GEP NETs can behave very heterogeneously and secrete a variety of biologically 
active products, future diagnostic approaches might take into account the concept of 
evaluating more than one parameter with multiple-analyte analyses to improve both 
the sensitivity and specificity of assays for the diagnostic work-up and follow-up in GEP 
NET patients.
treatment
Surgery with complete resection of the primary NET and if present its metastases, is the 
only curative option for patients with a NET. 
Medical therapy in advanced well- to moderately differentiated grade (G)1-2 NETs 
might include: 1) molecular targeted therapies with the synthetic SSAs, octreotide and 
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lanreotide, the new SSA pasireotide, and the serotonin synthesis inhibitor telotristat 
etiprate. 2) Protein kinase inhibitors including the mTOR inhibitor everolimus, the mul-
tikinase inhibitor sunitinib and potentially the dual insulin-like growth factor 1 receptor 
(IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor linsitinib. 3) PRRT with 177Lu-DOTA-
tate and 4) interferon. Dopamine-somatostatin chimeric molecules, or ‘dopastatins’, 
acting on both sst and D2 are not yet available for clinical use. Systemic chemotherapy 
is recommended in patients with poorly differentiated G3 NETs and neuroendocrine 
carcinomas of any site and, in progressive and/or extended panNETs. 
Progress had been made the last 30 years in the treatment of patients with advanced 
NETs. However, therapeutic options are still limited since NETs escape from medical 
treatment with SSAs by tachyphylaxis, which is the loss of response to chronic SSA 
administration, and/or develop resistance to the different drugs used, and patients will 
eventually develop progressive disease. We have, therefore, investigated the use of new 
potential biotherapeutical agents for the treatment of panNET cells.
in this thesis, the second aim was to identify new biotherapeutical options by 
modulating pathological pathways in panNET cells. We showed that especially combina-
tion therapy of  SSAs  and dopamine  agonists (DAs), either or not as chimeric compound, 
can have favorable effects on panNET cell function. We identified favorable effects on the 
combination of SSAs and DAs on IGF2-induced IR-A activation in panNET cells. In an-
other study, we demonstrated that combination therapy of linsitinib plus mTOR inhibi-
tors everolimus or sirolimus both in a low dose could effectively influence panNET cell 
migration and proliferation as important parameters of tumor progression. In addition, 
significant inhibition of both panNET cell proliferation and migration were observed 
with the MEK1/2 inhibitor PD0325901. These agents should therefore be considered as 
potential new therapies in patients with GEP NETs. 
We expect that future treatment for patients with GEP NETs will consist of combined 
therapies of SSAs, DAs, immunotherapy, protein and/or multikinase receptor inhibitors, 
either or not as a chimeric compound. These therapeutical approaches will focus on 
simultaneous multiple receptor targeting in order to target multiple pathways that are 
involved in tumor-promoting processes. A next step would be to find effective therapies 
that can overcome tachyphylaxis and/or drug resistance as well. Finally, future studies 
correlating drug responses to circulating tumor markers or molecular markers expressed 
in tumors might help to better select the appropriate drug to treat individual patients 
(e.g. tailored drug treatment).
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SAmenVAttinG
introductie
Neuroendocriene tumoren (NETs) zijn zeldzame tumoren die jaarlijks bij 5 op de 
100.000 personen worden vastgesteld. NETs ontstaan uit het diffuse neuroendocriene 
celsysteem. Ongeveer tweederde van de NETs bevindt zich in de maag, darmen en de 
alvleesklier (Gastro-Entero-Pancreas=GEP) en éénderde in de long. Darm en alvleesklier 
NETs maken deel uit van de groep GEP NETs, maar kunnen zich over het algemeen 
heel verschillend gedragen. Als vanouds wordt er een onderverdeling aangehouden, 
afhankelijk van hun embryologische oorsprong: voordarm, middendarm of achterdarm 
GEP NETs. 
GEP NETs worden gekenmerkt door productie van hormoonachtige stoffen welke ver-
schillende klachtenpatronen (syndromen) kunnen veroorzaken. Van deze syndromen is 
het carcinoïd syndroom het meest bekend. Bij dit syndroom produceert de NET grote 
hoeveelheden van het hormoon serotonine. Patiënten kunnen hierdoor last krijgen 
van opvliegers, kortademigheid, buikpijn en diarree. Wanneer door tumorproductie 
van deze hormoonachtige stoffen klachten worden veroorzaakt, spreekt men van een 
zogenaamde ‘functionele’ NET. Een NET die geen hormonaal syndroom veroorzaakt, kan 
in een later stadium door ingroei van omliggende structuren pas (pijn)klachten veroor-
zaken en dan spreken we van ‘niet-functionele’ NETs. 
Receptoren zijn eiwitten die het slot vormen waarop passende sleuteleiwitten kunnen 
binden. NETs hebben somatostatine (sst) en dopamine (DA) receptoren op hun celop-
pervlak. Deze, maar ook andere receptoren op het celoppervlak van NETs, kunnen door 
verbinding met elkaar ‘chimeer’ of ‘hybride’ receptoren vormen waardoor ze ook andere 
eigenschappen krijgen. 
Somatostatine receptoren worden als therapeutisch “doelwit” gebruikt. ‘Somatosta-
tine analoga’ (SSAs) binden aan deze somatostatine receptoren. Dit zijn medicijnen die 
de celgroei remmen van GEP NETs en ook de hormoonproductie. Uiteindelijk wordt dan 
verlichting van klachten bereikt. 
Van verschillende signaalpaden zoals het insuline-achtige groei factor (IGF) signaal-
pad, het PI3K/AKT/mTOR signaalpad en het RAS/RAF/MEK/ERK signaalpad, is bekend 
dat deze betrokken zijn bij de ontregelde groei van tumoren bij patiënten met GEP 
NETs. Onder normale, niet-zieke omstandigheden, spelen deze signaalpaden een 
onmisbare rol voor de cel en met name bij de groei en uitrijping ervan, maar ook bij 
de stofwisseling, celmigratie en celoverleving. Het is tot nu toe nog onbekend hoe de 
verschillende verstoorde signaalpaden precies betrokken zijn bij het ontstaan van NETs. 
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diagnose
De diagnose van een GEP NET is gebaseerd op: onderzoek van tumorweefsel, radio-
logische en nucleaire beeldvorming en circulerende biomerkers (tumorstoffen welke 
gemeten kunnen worden in het bloed van de patiënt). De beoordeling van tumorweef-
sel door een ervaren patholoog is essentieel om vast te stellen of te bevestigen dat 
het een NET betreft en geen andere soort tumor. Ook is tumorweefselonderzoek van 
belang om de tumorgroeisnelheid (Ki-67 proliferatie index) in kaart te brengen volgens 
de zogenaamde WHO gradering. Beeldvorming is nodig om de tumoruitbreiding vol-
gens de ENETS TNM stadiëring in beeld te brengen. Met deze gegevens kan een keuze 
gemaakt worden voor een bepaalde therapie. Ook worden deze gegevens gebruikt om 
een inschatting te kunnen maken van de prognose.
Naast algemene beeldvormende technieken zoals computer tomografie (CT), beeld-
vorming met magnetische resonantie (MRI), echo en endoscopische echografie is soma-
tostatine receptor scintigrafie (SRS) met OctreoScan® of een 68Ga-DOTATATE-PET scan 
belangrijk voor het in beeld brengen van de tumoruitbreiding bij GEP NET patiënten.
De meest relevante biomerkers op tumorweefsel zijn chromogranine (Cg) en synapto-
fysine. De meest gebruikte biomerkers gemeten in bloed zijn het chromogranine A (CgA) 
en het neuron-specifiek enolase (NSE). De 24-uurs urine verzameling van het serotonine 
afbraakproduct 5-hydroxyindolazijnzuur is een andere biomerker welke wordt gebruikt 
bij het stellen van de diagnose en voor het vervolgen van het succes van de therapie bij 
GEP en long NET patiënten met het carcinoïd syndroom. Momenteel hebben de meest 
gebruikte biomerkers die worden bepaald in bloed, maar ook in tumorweefsel, hun 
beperkingen. Zo kunnen de biomerkers ook verhoogd zijn bij andere omstandigheden 
en in andere gevallen kan de biomerker niet worden aangetoond terwijl een patient wel 
een NET heeft. 
in dit proefschrift was het eerste onderzoeksdoel om op een betere manier de diag-
nose te kunnen stellen en het succes van de therapie te vervolgen bij GEP NET patiënten 
gebruikmakend van bestaande biomerkers. We hebben de prognostische waarde van 
de twee meest gebruikte biomerkers in bloed, namelijk CgA en NSE, opnieuw bekeken. 
Er werden nieuwe inzichten gevonden bij bestaande tumormerkers. We hebben laten zien 
dat NSE een voorspellende biomerker is voor de overleving voor GEP NET patiënten 
en dit is onafhankelijk van de tumorlocatie in het lichaam. Onze onderzoeksresultaten 
tonen ook aan dat patiënten met uitgezaaide GEP NETs die geen CgA produceren een 
gunstigere prognose hebben vergeleken met patiënten met uitgezaaide GEP NETs 
die wel CgA produceren. Ons onderzoek leverde geen geschikte nieuwe biomerkers op. 
Het nuchter gemeten stofwisselingshormoon ghreline bleek in twee verschillende 
verschijningsvormen niet de geschikte biomerker te zijn welke we dachten te vinden. 
Er werd geen belangrijk verband gevonden tussen de combinatie van CgA bepaald in 
bloed, de Ki-67 proliferatie index onderzocht op tumorweefsel, en de aanwezigheid van 
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verschillende insuline-achtige genen in GEP NET weefsels. Wel werd een duidelijk ver-
hoogde hoeveelheid van de insuline receptor A (IR-A) aangetoond in tumoren van GEP 
NET patiënten met een verhoogd CgA gehalte in het bloed in vergelijking met tumoren 
van patiënten met niet-verhoogd CgA in het bloed. Deze bevinding is een interessant 
onderwerp voor toekomstige onderzoek.
Tenslotte had het vaststellen van de aanwezigheid van de somatostatine receptor sst2a 
op tumorweefsel geen belangrijk toegevoegde waarde, vergeleken met het aantonen 
van deze receptor met somatotatine receptor scintigrafie gebruik makend van de 
OctreoScan®, om het resultaat van peptide receptor radiotherapie met 177Lu-DOTAtaat 
(PRRT) te kunnen voorspellen. PRRT is behandeling met een SSA welke gekoppeld is, of 
‘gelabeld’ is, aan een radioactieve stof. Het aantonen van de somatostatine receptor sst2a 
op tumorweefsel is wel een relatief goedkopere methode die toepasbaar zou kunnen 
zijn in die gebieden waar geen of nauwelijks beschikbaarheid is van SRS om patiënten 
te selecteren voor PRRT met radioactief gelabelde SSAs. 
Zoals genoemd kunnen GEP NETs zich heel divers gedragen en veel verschillende 
soorten hormonen uitscheiden. Bij de ontwikkeling van toekomstige biomerkers waar-
mee we de diagnose kunnen stellen en behandelingseffecten kunnen vervolgen bij 
GEP NET patiënten, moeten we daarom rekening houden met de bepaling van niet één, 
maar meerdere geschikte biomerkers. 
therapie
De enige behandeloptie voor GEP NETs, met als doel genezing, is een operatie waarbij 
de tumor en ook alle eventueel aanwezige uitzaaiingen volledig worden verwijderd. 
NETs worden naar aanleiding van hun tumorgroeisnelheid (Ki-67 proliferatie index op 
tumorweefsel) in drie groepen ingedeeld: goed (=graad 1), matig (=graad 2) en slecht 
gedifferentieerde (=graad 3) NETs. Deze graad 3 tumoren worden tegenwoordig onder-
verdeeld in NETs en neuroendocriene carcinomen (NECs). 
Medicamenteuze therapie voor patiënten met graad 1-2 NETs kan bestaan uit: 1) 
gerichte therapieën met de SSAs octreotide en lanreotide, de nieuwe SSA pasireotide, 
en de serotonine aanmaakremmer telotristat etiprate. 2) Proteïne kinase remmers: de 
mTOR remmer everolimus, de multikinaseremmer sunitinib en mogelijk de insuline-
achtige groeifactor 1 receptor (IGF1R)/insuline receptor (IR) tyrosine kinase remmer 
linsitinib. 3) PRRT en 4) interferon alfa. Dopamine-somatostatine chimere moleculen of 
‘dopastatines’ binden aan zowel de sst als de D2 en worden momenteel nog niet gebruikt 
in de praktijk. Chemotherapie wordt aanbevolen bij patiënten met NECs. 
De laatste 30 jaar is er vooruitgang geboekt bij de behandeling van patiënten met 
uitgezaaide NETs. Hoewel er meerdere behandelopties zijn, zijn deze tumoren de be-
handeling soms te slim af waardoor deze therapieën niet langer meer effectief blijken. 
Eén van de processen waarmee tumoren dat voor elkaar krijgen heet ‘tachyfylaxie’. 
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Tachyfylaxie is het verschijnsel dat er bij langdurige SSA toediening geen remming meer 
van tumorgroei of hormoonproductie is. Ook treedt er onder sommige omstandigheden 
resistentie voor een bepaalde therapie op. Resistentie is het proces dat de tumor onge-
voelig wordt voor het medicijn. Als het medicijn geen effect meer heeft, zal de tumor 
ondanks behandeling verder groeien en zal er uitbreiding van ziekte ontstaan. Om deze 
reden hebben we de bruikbaarheid van nieuwe middelen onderzocht in pancreas NET 
cellen. 
in dit proefschrift was het tweede onderzoeksdoel om nieuwe middelen te onder-
zoeken die de verstoorde signaalpaden in pancreas NET cellen kunnen beïnvloeden. We 
hebben aangetoond dat in het bijzonder combinatietherapie van SSAs en dopamine ago-
nisten (DAs), al dan niet als chimeer (twee medicijnen in een toedieningsvorm), gunstige 
effecten kunnen hebben op de pancreas NET celfunctie. Met de combinatie van SSAs en 
DAs hebben we een duidelijke afname gezien van de door de pancreas NET cellen ge-
produceerde, tumorgroei stimulerende insuline-achtige stof IGF2. De effecten van IGF2 
kunnen deels worden uitgevoerd via de insuline receptor IR-A die aanwezig is op de 
pancreas NET cellen. In een andere studie hebben we aangetoond dat de combinatie 
van een lage dosis insuline receptor en IGF1 receptor remmer linsitinib en een lage dosis 
van de mTOR remmers everolimus of sirolimus een duidelijke remming geeft van de 
pancreas NET celgroei en –migratie. Deze twee eigenschappen vormen een belangrijke 
maat voor tumoruitbreiding. Bovendien werd er in deze studie een duidelijke remming 
gezien van zowel pancreas NET celgroei als -migratie met de MEK1/2 remmer (specifieke 
remmer van het RAS/RAF/MEK/ERK signaalpad) PD0325901. Bovengenoemde middelen 
kunnen daarom mogelijk in de toekomst als nieuwe therapieën worden ingezet voor 
patiënten met GEP NETs. 
In de toekomst verwachten we dat patiënten met GEP NETs behandeld zullen 
worden met combinatietherapieën met SSAs, DAs, immunotherapie, en eiwit en/of 
multi-eiwit receptor remmers. Deze medicamenten zullen dan, al dan niet als chimeer 
eiwit, worden toegepast. Nader onderzoek zal zich focussen op gelijktijdige activatie 
van meerdere receptoren met als doel meerdere signaalpaden, welke betrokken zijn bij 
tumor stimulerende processen, aan te pakken. De volgende stap zal als doel hebben om 
effectieve therapieën te vinden die ook tachyfylaxie en/of resistentie kunnen overwin-
nen. Toekomstig onderzoek waarbij de effectiviteit van geneesmiddelen bij patiënten 
met GEP NETs wordt gekoppeld aan circulerende tumor merkers of aan merkers die in 
tumorweefsel aanwezig zijn, kan leiden tot het selecteren van het juiste geneesmiddel 
voor de juiste patiënt. 
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dAnKwooRd
De bevalling ‘boekje’ is een feit! Na een ‘draagtijd’ van bijna vijf jaar is het dan eindelijk 
zover! Heerlijk om nu aan het slotstuk te schrijven dat niet meer door een reviewer kan 
worden afgeschoten.
Het was niet mogelijk geweest om tot dit eindresultaat te komen zonder de hulp en 
steun van een fantastisch team om me heen. Daarom wil ik graag een aantal personen 
in het bijzonder bedanken.
Allereerst mijn promotoren Prof.dr. W.W. de Herder en Prof.dr. L.J. Hofland. Wouter, ik 
weet nog goed dat je me een half jaar na mijn laatste keuze coschap op de afdeling 
Endocrinologie belde en zei: “Ik heb een baantje voor je, wat denk je ervan?” Nu vijf jaar 
later kan de “strik er om heen” en is het proefschrift een feit. Wouter, je bent ‘acromegaal’ 
met veel kennis op het gebied van neuroendocriene tumoren, je toon enorme inzet 
voor patiënten en onderzoek en je bent een bijzonder prettige collega om mee samen 
te werken. Het heeft me goed gedaan dat je me meerdere keren hebt gerustgesteld dat 
het wel goed komt. Voor mij was dit niet altijd vanzelfsprekend. Je typerende humor, ook 
tijdens de grote visites, heb ik altijd erg gewaardeerd. Leo, ik heb nooit durven denken 
dat mijn Master of Science project een onderdeel zou worden van mijn proefschrift. Ik 
bewonder je enorme interesse voor je vakgebied. Zo mocht ik je in het weekend een 
manuscript toesturen omdat je het heerlijk vond om het met een goed glas rode wijn 
te lezen. Resultaten waarin ik niet veel zag, wist je altijd op een positieve manier te 
benaderen. Hoewel ik het soms wel welletjes vond en meer tempo wilde maken met 
een project, is je kritische blik het eindresultaat alleen maar ten goede gekomen. Beide 
bedankt voor jullie fantastische hulp en steun in ook minder fijne periodes.
Mijn dank gaat uit naar de leden van de leescommissie. Prof.dr. G.D. Valk, Prof.dr. R.H.N. 
van Schaik en Dr. R.A. Feelders. Allen bedankt voor het kritisch lezen en positief beoor-
delen van het proefschrift en het plaatsnemen in de leescommissie. 
De leden van de grote commissie, Prof.dr. A.M. Pereira-Arias en Prof.dr. M. Peeters, wil 
ik graag bedanken voor het plaatsnemen hierin.
Lieve Bianca en Sylvana, dank dat jullie letterlijk achter me staan en me bij staan als 
paranimfen. Bianca, we kennen elkaar al vanaf dag één van de brugklas. Als onafschei-
delijk duo werden onze namen dan ook regelmatig door elkaar gehaald. Ik vind het 
buitengewoon speciaal dat we na al die jaren nog een vanzelfsprekende hechte vriend-
schap hebben. 
Sylvana, we zijn jaargenoten, vriendinnen en ook nog vijf jaar huisgenoten geweest. 
Daarnaast mocht ik getuige zijn op jullie huwelijk en ben je nu ook mijn paranimf. 
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Dankjewel voor het vervullen van deze bijzondere combinatie aan rollen, dat betekent 
veel voor me! Uiteraard waardeer ik ook erg de aanvulling van jullie aanhang, Malko en 
Laurens, thanks! 
Collega’s van het neuroendolab. Bijna tien jaar geleden kwam in direct vanuit de school-
banken onderzoek doen. Ik had nog nooit een pipet gezien, laat staan vastgehouden. 
Dank voor jullie hulp, de gemoedelijke sfeer en de prettige tijd! Ik zal nooit vergeten 
dat het trakteren van stroopwafels, of op het lab van ‘moederkoeken’, betekent dat je 
als jonge vrouw iets hebt op te biechten. In het bijzonder wil ik Fadime en Peter in het 
zonnetje zetten. Fadime, ik ken je als een harde nauwkeurige werker die geduldig zaken 
kan uitleggen. Voor allerlei vragen kon ik bij je terecht en direct was je beschikbaar om 
hulp te bieden. Je hebt me fantastisch geholpen bij het aanleren van technieken en de 
uitvoering van een aantal belangrijke experimenten waarvoor ik je erg dankbaar ben! 
Peter, ook jouw hulp was onmisbaar. Handige trucjes leren, meekijken of mijn cellen of 
platen er wel goed uitzien, meedenken over een experiment. Waar heb je eigenlijk geen 
rol in gespeeld? De nodige humor in de kweekkamer en ‘darkroom’ mocht zeker ook niet 
ontbreken. Ook daarvoor wil ik je graag bedanken. 
Neuro-endogekkies! Marije, Stephanie, Gerard, Sabine, Sara, Thomas, Timon, Matthias, 
Vincent, Federico, Mesut, Seyda, Giulia en Anneke ‘geadopteerd’ van het gonadenlab. 
Thanks voor de onvergetelijke tijd met jullie, zowel op als buiten het lab! Veel succes 
allemaal met jullie onderzoek en ik hoop jullie tegen te komen in de kliniek!
Collegae van de ‘5e verdieping’, bedankt voor de fijne werksfeer en gezelligheid, ook 
bij activiteiten als de lab- en wetenschapsdagen. Patric, Martin en Piet, dank voor jullie 
inzet tijdens ons interessante samenwerkingsproject! Fijn dat mijn laatste samples tus-
sen alle bedrijven door geanalyseerd mochten worden! 
Kliniek collega’s! Mijn fijne PhD tijd is ook mede mogelijk gemaakt door jullie! Sanne, 
moeder de Gans, labzus, sportchick, thanks voor je support op werkelijk alle gebieden 
en je aanstekelijke, vrolijke aanwezigheid! Meedenken over een niet-lopende zin, je op-
beurende woorden en me laten ratelen als een manuscript was afgewezen of bij andere 
mindere momenten, ontzettend ouwehoeren, met elkaar eten, noem maar op. Het was 
zo vanzelfsprekend en kon allemaal! Kimberly, NET buddy! Thanks voor de gezellige 
theemomentjes, memorabele werktripjes en fijne samenwerking tijdens databaseklus-
sen, soms tot diep in de nacht. Ook zal ik nooit vergeten dat je me fantastisch hebt 
opgevangen toen ik plots voor je deur stond te piepen met een allergische reactie. We 
zetten onze samenwerking en vriendschap voort in het IJsselland Ziekenhuis! Karin, 
dank voor je wijsheid als voorbeeldpromovendus en de leuke momenten die we met 
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elkaar hebben gedeeld. Uiteraard Mark en Ammar, jullie ook bedankt! Collega’s van de 
afdeling Epidemiologie en kamergenoten van Z-626, Nikki en Raymond, top dat we een 
tijd de kamer in het Z-gebouw met elkaar hebben mogen delen! 
Anneke en Karin, heel erg bedankt voor de gezellige kletspraatjes, jullie vrolijke aanwe-
zigheid en de uitvoering van allerlei regelklussen! Wanda en Judith, dank voor jullie hulp 
en prettige samenwerking! Sjaan, dankjewel voor de fijne samenwerking voor patiënt-
studies, je hulp bij bloedafnames en je aangename gezelschap tijdens het studietripje 
naar Sorrento en Pompeï! Trudie en Nancy, fijn dat jullie me hielpen als ik, uitgerust met 
mijn bakje ijs, met allerlei vragen en verzoeken de NET-poli bestormde. Carolien, Kees, 
Bruno, Elske, Marlies, Laura, Hans, Edward, Charlotte en Corina. Dank jullie wel voor de 
plezierige momenten op afdeling 5 Midden en tijdens de grote visite!
Dr. Carolien van Deurzen, bedankt voor de vele uren waarin we samen coupes hebben 
beoordeeld. Het was leerzaam om te doen en een boeiend samenwerkingsproject.
Uiteraard wil ik ook alle andere coauteurs bedanken voor hun bijdrage. Dames van de 
Pathologie Research en Trial Service van het Erasmus MC, bedankt voor jullie hulp bij 
verschillende uitzoekklussen als ik weer eens ‘blokjes’ nodig had. 
Collega’s van het IJsselland Ziekenhuis. Dank jullie wel allemaal voor jullie steun, begrip 
en medeleven in de periode naar de verdediging toe!
Onderzoek doen is hard werken. Zeker het laatste jaar in combinatie met de opleiding 
tot internist was het niet altijd een feest. Gelukkig heb ik fijne vrienden en vriendinnen 
die altijd klaar stonden, mijn verhalen aanhoorden, voor de nodige afleiding zorgden 
met gezellige avondjes, feestjes, etentjes en die al de andere dingen van het leven leuk 
maken. Dank jullie wel daarvoor!
‘Mastermeiden’ Els, Joyce, Sandra, Toke! Bedankt voor jullie al jaren durende gezelligheid 
en alle bijzondere momenten! De topvakantie die we na het volgen van het summer 
programme aan de Johns Hopkins University aan ons verblijf hebben vastgeplakt, is om 
nooit te vergeten! En Mariska, jij natuurlijk ook bedankt voor je enthousiaste en vrolijke 
aanvulling! 
Maaike, bijzonder dat we na al die jaren als collega’s ook nog steeds vriendinnen zijn. 
Ik weet zeker dat je dé huisarts gaat worden van Doornspijk!
Sanne Jongenelen-van Beek, dankjewel voor de vriendschap die is ontstaan uit onze 
gezamenlijke co-schappen in Vlissingen waarbij we later ook in Rotterdam huisgenoot-
jes zijn geworden in Huize Dubieus. 
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Stefanie, thanks ook voor de fijne tijd die we daar als huisgenootjes hebben gehad en 
de vriendschap die hieruit is ontstaan. 
Sietse, Stephanie, Elmy, Micheal, Floor en Zelda. Dank jullie wel voor al weer de bijna 
20 jaar dat we bevriend zijn sinds het GSG Leo Vroman tijdperk. Op naar de volgende 
20 jaar!
Sanne en Mariëtte, super dat ik met jullie in verpleeghuis Bloemendaal in Gouda heb 
samengewerkt en we na al die jaren nog steeds vriendinnen zijn. Thanks voor jullie 
steun! 
Desiree, lieve Deetje, op dag één van je bestaan vond ik je al “een droppie”, de dagen 
erna was ik niet bij je weg te krijgen en onze band is altijd bijzonder sterk gebleven. We 
denken hetzelfde, doen veel hetzelfde en je weet ook precies hoe je je zus onvoorwaar-
delijk steunt. Lief dat je dat elke keer en op de juiste momenten weet te doen. Woorden 
kunnen niet beschrijven wat je voor me betekent.
Lieve pa, Marcella, opa Wim, oma Ida, Daan, Betsie, Linda en Paula. Bedankt voor jullie 
interesse en onvoorwaardelijke steun die jullie mij altijd hebben gegeven. Ook al was 
het misschien niet altijd duidelijk waar ik mee bezig was. Sybren, ook bedankt voor je 
interesse, steun en het verhelpen van al m’n laptopproblemen! 
Lieve mam, kort nadat je ziek bent geworden, ben ik nog in de veronderstelling 
geweest dat je bij de verdediging zou kunnen zijn en heb ik als een dolle aan het proef-
schrift gewerkt. Echter, vanaf het moment dat “er iets in de buurt van je alvleesklier is 
gezien” heeft het geen twee maanden meer geduurd. Hoewel je er op mijn verdediging 
niet zichtbaar bij zal zijn, bedenk ik me dat je me stilletjes vanaf je wolkje weer bij zal 
staan. Je was altijd zo betrokken en stuurde voorafgaand aan elke presentatie een 
succes-sms’je. 
Kees, Marian, Marleen, John, Eddy, Madelief en Floor, ook wil ik jullie graag bedanken 
voor jullie oprechte interesse, betrokkenheid en mijn plekje in jullie fijne warme nest. 
Lieve Leendert, mijn Peentje, het is af! Jouw rol is onmisbaar geweest in dit alles. 
Dankjewel voor je geduld, begrip en vrijheid die je me hebt gegeven om tot dit resul-
taat te komen. Of je nu in Dallas bent of hier, je steunt me altijd en overal. Met jouw 
relativeringsvermogen weet je me altijd op de juiste momenten een zetje in de goede 
richting te geven. Het is niet in woorden uit te drukken hoe blij ik met je ben. Joe bin 
mijn Formule 1 en heb super veel zin in onze toekomst saemen!
Er is genoeg gekletst! Tijd voor een feestje! Zo is het maar NET! 

